0000899749-19-000092.txt : 20191104 0000899749-19-000092.hdr.sgml : 20191104 20191104170052 ACCESSION NUMBER: 0000899749-19-000092 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191104 DATE AS OF CHANGE: 20191104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHCARE REALTY TRUST INC CENTRAL INDEX KEY: 0000899749 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 621507028 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11852 FILM NUMBER: 191190588 BUSINESS ADDRESS: STREET 1: 3310 WEST END AVE STREET 2: FOURTH FL SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6152698175 MAIL ADDRESS: STREET 1: 3310 WEST END AVENUE, SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 10-Q 1 hr-2019930singlesource.htm 10-Q Document
false--12-31Q3201900008997494000000.300.900.300.900.010.013000000003000000001252790001313680001252790001313680000.0100P7Y0.010.0150000000500000000000 0000899749 2019-01-01 2019-09-30 0000899749 2019-10-31 0000899749 2019-09-30 0000899749 2018-12-31 0000899749 2018-01-01 2018-09-30 0000899749 2018-07-01 2018-09-30 0000899749 2019-07-01 2019-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0000899749 2018-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000899749 2018-06-30 0000899749 us-gaap:CommonStockMember 2017-12-31 0000899749 hr:CumulativeDividendsMember 2018-09-30 0000899749 us-gaap:CommonStockMember 2018-09-30 0000899749 hr:CumulativeNetIncomeMember 2017-12-31 0000899749 hr:CumulativeDividendsMember 2018-07-01 2018-09-30 0000899749 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000899749 hr:CumulativeNetIncomeMember 2018-06-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000899749 hr:CumulativeNetIncomeMember 2018-09-30 0000899749 hr:CumulativeDividendsMember 2018-06-30 0000899749 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000899749 hr:CumulativeNetIncomeMember 2018-01-01 2018-09-30 0000899749 hr:CumulativeDividendsMember 2018-01-01 2018-09-30 0000899749 hr:CumulativeNetIncomeMember 2018-07-01 2018-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000899749 hr:CumulativeDividendsMember 2017-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000899749 2017-12-31 0000899749 us-gaap:CommonStockMember 2018-06-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000899749 hr:CumulativeNetIncomeMember 2019-09-30 0000899749 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0000899749 hr:CumulativeNetIncomeMember 2018-12-31 0000899749 hr:CumulativeDividendsMember 2019-01-01 2019-09-30 0000899749 2019-06-30 0000899749 hr:CumulativeDividendsMember 2019-09-30 0000899749 us-gaap:CommonStockMember 2019-06-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0000899749 hr:CumulativeDividendsMember 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000899749 us-gaap:CommonStockMember 2019-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000899749 hr:CumulativeDividendsMember 2019-06-30 0000899749 hr:CumulativeNetIncomeMember 2019-07-01 2019-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000899749 hr:CumulativeNetIncomeMember 2019-06-30 0000899749 hr:CumulativeDividendsMember 2019-07-01 2019-09-30 0000899749 us-gaap:CommonStockMember 2018-12-31 0000899749 hr:CumulativeNetIncomeMember 2019-01-01 2019-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000899749 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000899749 us-gaap:OtherLiabilitiesMember 2019-01-01 2019-01-01 0000899749 srt:MaximumMember us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000899749 srt:MinimumMember us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000899749 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2019-01-01 2019-01-01 0000899749 us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000899749 srt:MinimumMember us-gaap:AccountingStandardsUpdate201602Member 2019-09-30 0000899749 srt:WeightedAverageMember us-gaap:AccountingStandardsUpdate201602Member 2019-09-30 0000899749 srt:MaximumMember us-gaap:AccountingStandardsUpdate201602Member 2019-09-30 0000899749 us-gaap:OtherAssetsMember 2019-01-01 2019-01-01 0000899749 hr:ParkingIncomeMember 2019-07-01 2019-09-30 0000899749 hr:MiscellaneousMember 2019-01-01 2019-09-30 0000899749 hr:ManagementFeeIncomeMember 2018-07-01 2018-09-30 0000899749 hr:MiscellaneousMember 2019-07-01 2019-09-30 0000899749 hr:ParkingIncomeMember 2018-07-01 2018-09-30 0000899749 hr:MiscellaneousMember 2018-01-01 2018-09-30 0000899749 hr:ManagementFeeIncomeMember 2019-07-01 2019-09-30 0000899749 hr:ManagementFeeIncomeMember 2018-01-01 2018-09-30 0000899749 hr:RentalLeaseGuarantyMember 2018-01-01 2018-09-30 0000899749 hr:ParkingIncomeMember 2018-01-01 2018-09-30 0000899749 hr:RentalLeaseGuarantyMember 2018-07-01 2018-09-30 0000899749 hr:ParkingIncomeMember 2019-01-01 2019-09-30 0000899749 hr:RentalLeaseGuarantyMember 2019-01-01 2019-09-30 0000899749 hr:RentalLeaseGuarantyMember 2019-07-01 2019-09-30 0000899749 hr:ManagementFeeIncomeMember 2019-01-01 2019-09-30 0000899749 hr:MiscellaneousMember 2018-07-01 2018-09-30 0000899749 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hr:InpatientRehabMember 2018-12-31 0000899749 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hr:InpatientRehabMember 2019-09-30 0000899749 hr:RealEstateDispositionsMember stpr:VA 2019-08-01 0000899749 hr:RealEstateDispositionsMember stpr:AZ 2019-04-09 2019-04-09 0000899749 hr:RealEstateDispositionsMember stpr:AZ 2019-04-09 0000899749 hr:RealEstateDispositionsMember hr:SanAntonioTexasMember 2019-08-28 2019-08-28 0000899749 hr:RealEstateDispositionsMember hr:SanAntonioTexasMember 2019-04-09 0000899749 hr:RealEstateDispositionsMember stpr:VA 2019-08-01 2019-08-01 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:DC 2019-03-28 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:DC 2019-09-30 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:NC us-gaap:SubsequentEventMember 2019-10-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:CA 2019-09-30 2019-09-30 0000899749 hr:RealEstateDispositionsMember stpr:PA 2019-09-30 0000899749 hr:RealEstateDispositionsMember stpr:PA us-gaap:SubsequentEventMember 2019-10-25 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:DC 2019-03-28 2019-03-28 0000899749 hr:RealEstateDispositionsMember stpr:VA 2019-04-01 2019-06-30 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:IN 2019-03-28 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember hr:DallasTexasMember us-gaap:SubsequentEventMember 2019-10-31 0000899749 stpr:PA 2019-05-01 2019-05-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:NC us-gaap:SubsequentEventMember 2019-10-31 2019-10-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember hr:DallasTexasMember us-gaap:SubsequentEventMember 2019-10-31 2019-10-31 0000899749 hr:RealEstateAcquisitionsMember 2019-09-30 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:OK 2019-09-26 2019-09-26 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:WA 2019-06-26 2019-06-26 0000899749 hr:RealEstateAcquisitionsMember 2019-01-01 2019-09-30 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember hr:DallasTexasMember 2019-06-10 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:WA 2019-06-11 2019-06-11 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:WA 2019-06-14 2019-06-14 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember hr:DallasTexasMember 2019-06-10 2019-06-10 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:OK 2019-09-26 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:GA 2019-04-02 2019-04-02 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:IN 2019-03-28 2019-03-28 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember hr:HoustonTexasMember 2019-08-01 2019-08-01 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:OK 2019-09-30 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember hr:HoustonTexasMember 2019-08-01 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:WA 2019-06-14 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:CA 2019-09-30 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:WA 2019-06-26 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:WA 2019-06-11 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:GA 2019-04-02 0000899749 srt:WeightedAverageMember 2018-12-31 0000899749 srt:MaximumMember 2018-01-01 2018-12-31 0000899749 2018-01-01 2018-12-31 0000899749 srt:MinimumMember 2018-12-31 0000899749 srt:MaximumMember 2018-12-31 0000899749 srt:MinimumMember 2018-01-01 2018-12-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2019-09-30 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2018-12-31 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2018-12-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2019-09-30 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2019-09-30 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2019-09-30 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-09-30 0000899749 hr:UnsecuredCreditFacilityMember us-gaap:LineOfCreditMember 2018-12-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:UnsecuredCreditFacilityMember us-gaap:LineOfCreditMember 2019-09-30 0000899749 srt:MinimumMember hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember 2019-05-31 2019-05-31 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-07-01 2019-09-30 0000899749 hr:TermLoanAgreementMember us-gaap:MediumTermNotesMember 2019-04-01 2019-06-30 0000899749 hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-07-01 2019-09-30 0000899749 srt:MinimumMember hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-05-31 2019-05-31 0000899749 srt:MaximumMember hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-05-31 2019-05-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2019-04-10 0000899749 hr:TermLoandue2024Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2019-09-30 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-05-31 2019-05-31 0000899749 hr:TermLoanAgreementMember us-gaap:MediumTermNotesMember 2019-05-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2019-01-01 2019-09-30 0000899749 hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember 2019-05-31 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-05-31 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-07-01 2019-09-30 0000899749 srt:MaximumMember hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-05-31 2019-05-31 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-09-30 0000899749 hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-11-04 2019-11-04 0000899749 srt:MaximumMember hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-05-31 2019-05-31 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2019-05-31 0000899749 srt:MinimumMember hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-05-31 2019-05-31 0000899749 srt:MaximumMember hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember 2019-05-31 2019-05-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2019-04-10 2019-04-10 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-05-31 0000899749 srt:MinimumMember hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-05-31 2019-05-31 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember 2018-07-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2018-07-01 2018-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2018-07-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateContractMember 2018-07-01 2018-09-30 0000899749 us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestExpenseMember 2018-07-01 2018-09-30 0000899749 us-gaap:InterestRateContractMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000899749 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000899749 hr:ActiveInterestRateSwapsMember 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-05-15 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-04-12 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateContractMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateContractMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:NC 2019-09-30 0000899749 hr:MedicalOfficeBuildingExpansionMember stpr:NC 2019-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:WA 2019-09-30 0000899749 hr:EquityOfferingMember 2019-03-19 2019-03-19 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-03-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember us-gaap:SubsequentEventMember 2019-10-01 2019-10-31 0000899749 hr:FormerExecutiveChairmanMember 2019-07-01 2019-09-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MaximumMember us-gaap:SubsequentEventMember 2019-10-01 2019-10-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember us-gaap:SubsequentEventMember 2019-01-01 2019-10-31 0000899749 hr:EquityOfferingMember 2019-03-19 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MaximumMember 2019-01-01 2019-03-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember us-gaap:SubsequentEventMember 2019-10-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MinimumMember 2019-01-01 2019-03-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MinimumMember us-gaap:SubsequentEventMember 2019-10-01 2019-10-31 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2019-01-01 2019-09-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2019-07-01 2019-09-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MaximumMember 2019-07-01 2019-09-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MinimumMember 2019-07-01 2019-09-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2019-04-01 2019-06-30 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2018-01-01 2018-09-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MinimumMember us-gaap:SubsequentEventMember 2019-01-01 2019-10-31 0000899749 us-gaap:SubsequentEventMember 2019-10-29 2019-10-29 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MaximumMember us-gaap:SubsequentEventMember 2019-01-01 2019-10-31 0000899749 hr:StockIncentivePlanMember 2018-09-30 0000899749 hr:StockIncentivePlanMember 2019-01-01 2019-09-30 0000899749 hr:StockIncentivePlanMember 2018-07-01 2018-09-30 0000899749 hr:StockIncentivePlanMember 2018-01-01 2018-09-30 0000899749 hr:StockIncentivePlanMember 2018-12-31 0000899749 hr:StockIncentivePlanMember 2019-07-01 2019-09-30 0000899749 hr:StockIncentivePlanMember 2017-12-31 0000899749 hr:StockIncentivePlanMember 2019-09-30 0000899749 hr:StockIncentivePlanMember 2018-06-30 0000899749 hr:StockIncentivePlanMember 2019-06-30 0000899749 us-gaap:EmployeeStockMember 2018-07-01 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2019-07-01 2019-09-30 0000899749 us-gaap:EmployeeStockMember 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2018-01-01 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2019-01-01 2019-09-30 0000899749 us-gaap:EmployeeStockMember 2019-09-30 0000899749 us-gaap:EmployeeStockMember 2017-12-31 0000899749 us-gaap:EmployeeStockMember 2018-12-31 0000899749 us-gaap:EmployeeStockMember 2018-06-30 0000899749 us-gaap:EmployeeStockMember 2019-06-30 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-09-30 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-09-30 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 xbrli:pure iso4217:USD xbrli:shares hr:revenue_type xbrli:shares hr:swap_agreement iso4217:USD utreg:sqft hr:state hr:property hr:Lease

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: September 30, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                     
Commission File Number: 001-11852
HEALTHCARE REALTY TRUST INCORPORATED
(Exact name of Registrant as specified in its charter) 
____________________________________________________________
Maryland
 
62-1507028
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
3310 West End Avenue, Suite 700
Nashville, Tennessee 37203
(Address of principal executive offices)
(615) 269-8175
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common stock, $0.01 par value per share
HR
New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:
Large accelerated filer
Accelerated filer
Non-accelerated filer  
Smaller reporting company
 
 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes      No  
 
As of October 31, 2019, the Registrant had 133,736,079 shares of Common Stock outstanding.
 



HEALTHCARE REALTY TRUST INCORPORATED
FORM 10-Q
September 30, 2019

TABLE OF CONTENTS
 



PART I. FINANCIAL INFORMATION

Item 1. Financial Statements
Healthcare Realty Trust Incorporated
Condensed Consolidated Balance Sheets
(Amounts in thousands, except per share data)
 
(Unaudited)
 
 
 
September 30,
2019
 
December 31,
2018
ASSETS
 
 
 
Real estate properties:
 
 
 
Land
$
267,803

 
$
230,206

Buildings, improvements and lease intangibles
3,915,308

 
3,675,415

Personal property
10,899

 
10,696

Construction in progress
44,041

 
33,107

Land held for development
24,647

 
24,647

 
4,262,698

 
3,974,071

Less accumulated depreciation and amortization
(1,106,387
)
 
(1,015,174
)
Total real estate properties, net
3,156,311

 
2,958,897

Cash and cash equivalents
11,809

 
8,381

Assets held for sale, net
5,289

 
9,272

Operating lease right-of-use assets
126,711

 

Financing lease right-of-use assets
9,063

 

Other assets, net
181,975

 
214,697

Total assets
$
3,491,158

 
$
3,191,247

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Liabilities:
 
 
 
Notes and bonds payable
$
1,443,919

 
$
1,345,984

Accounts payable and accrued liabilities
75,094

 
80,411

Liabilities of properties held for sale
300

 
587

Operating lease liabilities
91,356

 

Financing lease liabilities
14,305

 

Other liabilities
61,023

 
47,623

Total liabilities
1,685,997

 
1,474,605

Commitments and contingencies


 


Stockholders' equity:
 
 
 
Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding

 

Common stock, $.01 par value per share; 300,000 shares authorized; 131,368 and 125,279 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively
1,314

 
1,253

Additional paid-in capital
3,379,572

 
3,180,284

Accumulated other comprehensive loss
(8,470
)
 
(902
)
Cumulative net income attributable to common stockholders
1,100,094

 
1,088,119

Cumulative dividends
(2,667,349
)
 
(2,552,112
)
Total stockholders' equity
1,805,161

 
1,716,642

Total liabilities and stockholders' equity
$
3,491,158

 
$
3,191,247


The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are an integral part of these financial statements.

1


Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Income
For the Three and Nine Months Ended September 30, 2019 and 2018
(Amounts in thousands, except per share data)
(Unaudited)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
REVENUES
 
 
 
 
 
 
 
Rental income
$
117,740

 
$
111,452

 
$
342,787

 
$
331,247

Other operating
2,059

 
2,010

 
5,987

 
5,973

 
119,799

 
113,462

 
348,774

 
337,220

EXPENSES
 
 
 
 
 
 
 
Property operating
46,777

 
44,135

 
133,790

 
127,691

General and administrative
10,802

 
8,504

 
27,157

 
25,977

Acquisition and pursuit costs
501

 
141

 
1,227

 
538

Depreciation and amortization
45,137

 
42,061

 
131,725

 
121,764

Bad debts, net of recoveries

 
(62
)
 

 
42

 
103,217

 
94,779

 
293,899

 
276,012

OTHER INCOME (EXPENSE)
 
 
 
 
 
 
 
Gain on sales of real estate assets
200

 
1,288

 
5,065

 
30,879

Interest expense
(14,181
)
 
(13,464
)
 
(41,619
)
 
(39,202
)
Impairment of real estate assets

 

 
(5,610
)
 

Interest and other income (expense), net

 
41

 
(736
)
 
571

 
(13,981
)
 
(12,135
)
 
(42,900
)
 
(7,752
)
NET INCOME
$
2,601

 
$
6,548

 
$
11,975

 
$
53,456

Basic earnings per common share
$
0.02

 
$
0.05

 
$
0.08

 
$
0.42

Diluted earnings per common share
$
0.02

 
$
0.05

 
$
0.08

 
$
0.42

Weighted average common shares outstanding - basic
128,090

 
123,300

 
126,571

 
123,281

Weighted average common shares outstanding - diluted
128,169

 
123,352

 
126,657

 
123,336

Dividends declared, per common share, during the period
$
0.30

 
$
0.30

 
$
0.90

 
$
0.90

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are an integral part of these financial statements.

2


Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Comprehensive Income
For the Three and Nine Months Ended September 30, 2019 and 2018
(Dollars in thousands)
(Unaudited)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
NET INCOME
$
2,601

 
$
6,548

 
$
11,975

 
$
53,456

Other comprehensive income (loss):
 
 
 
 
 
 
 
Interest rate swaps:
 
 
 
 
 
 
 
Reclassification adjustments for losses included in net income (interest expense)
60

 
95

 
74

 
369

(Losses) gains arising during the period on interest rate swaps
(2,341
)
 
374

 
(7,642
)
 
1,403

Total other comprehensive income (loss)
(2,281
)
 
469

 
(7,568
)
 
1,772

COMPREHENSIVE INCOME
$
320

 
$
7,017

 
$
4,407

 
$
55,228


The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are an integral part of these financial statements.

3


Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Equity
For the Three and Nine Months Ended September 30, 2019
(Dollars in thousands, except per share data)
(Unaudited)
 
Common
Stock
 
Additional
Paid-In
Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Cumulative
Net
Income
 
Cumulative
Dividends
 
Total
Stockholders’
Equity
Balance at June 30, 2019
$
1,292

 
$
3,305,344

 
$
(6,189
)
 
$
1,097,493

 
$
(2,628,497
)
 
$
1,769,443

Issuance of common stock, net of issuance costs
22

 
71,792

 

 

 

 
71,814

Common stock redemptions

 
(2,695
)
 

 

 

 
(2,695
)
Share-based compensation

 
5,131

 

 

 

 
5,131

Net income

 

 

 
2,601

 

 
2,601

Reclassification adjustments for losses included in net income (interest expense)


 

 
60

 

 

 
60

Losses arising during the period on interest rate swaps


 

 
(2,341
)
 

 

 
(2,341
)
Dividends to common stockholders ($0.30 per share)

 

 

 

 
(38,852
)
 
(38,852
)
Balance at September 30, 2019
$
1,314

 
$
3,379,572

 
$
(8,470
)
 
$
1,100,094

 
$
(2,667,349
)
 
$
1,805,161

 
 
 
 
 
 
 
 
 
 
 
 
 
Common
Stock
 
Additional
Paid-In
Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Cumulative
Net
Income
 
Cumulative
Dividends
 
Total
Stockholders’
Equity
Balance at December 31, 2018
$
1,253

 
$
3,180,284

 
$
(902
)
 
$
1,088,119

 
$
(2,552,112
)
 
$
1,716,642

Issuance of common stock, net of issuance costs
61

 
192,414

 

 

 

 
192,475

Common stock redemptions
(1
)
 
(3,266
)
 

 

 

 
(3,267
)
Share-based compensation
1

 
10,140

 

 

 

 
10,141

Net income

 

 

 
11,975

 

 
11,975

Reclassification adjustments for losses included in net income (interest expense)


 

 
74

 

 

 
74

Losses arising during the period on interest rate swaps


 

 
(7,642
)
 

 

 
(7,642
)
Dividends to common stockholders ($0.90 per share)

 

 

 

 
(115,237
)
 
(115,237
)
Balance at September 30, 2019
$
1,314

 
$
3,379,572

 
$
(8,470
)
 
$
1,100,094

 
$
(2,667,349
)
 
$
1,805,161



The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are an integral part of these financial statements.


4


Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Equity
For the Three and Nine Months Ended September 30, 2018
(Dollars in thousands, except per share data)
(Unaudited)
 
Common
Stock
 
Additional
Paid-In
Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Cumulative
Net
Income
 
Cumulative
Dividends
 
Total
Stockholders’
Equity
Balance at June 30, 2018
$
1,252

 
$
3,178,514

 
$
4

 
$
1,065,256

 
$
(2,476,971
)
 
$
1,768,055

Issuance of common stock, net of issuance costs


 
113

 

 

 

 
113

Common stock redemptions

 
(39
)
 

 

 

 
(39
)
Share-based compensation

 
2,675

 

 

 

 
2,675

Net income

 

 

 
6,548

 

 
6,548

Reclassification adjustments for losses included in net income (interest expense)


 

 
95

 

 

 
95

Gains arising during the period on interest rate swaps


 

 
374

 

 

 
374

Dividends to common stockholders ($0.30 per share)

 

 

 

 
(37,569
)
 
(37,569
)
Balance at September 30, 2018
$
1,252

 
$
3,181,263

 
$
473

 
$
1,071,804

 
$
(2,514,540
)
 
$
1,740,252

 
 
 
 
 
 
 
 
 
 
 
 
 
Common
Stock
 
Additional
Paid-In
Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Cumulative
Net
Income
 
Cumulative
Dividends
 
Total
Stockholders’
Equity
Balance at December 31, 2017
$
1,251

 
$
3,173,429

 
$
(1,299
)
 
$
1,018,348

 
$
(2,401,846
)
 
$
1,789,883

Issuance of common stock, net of issuance costs

 
464

 

 

 

 
464

Common stock redemptions

 
(719
)
 

 

 

 
(719
)
Share-based compensation
1

 
8,089

 

 

 

 
8,090

Net income

 

 

 
53,456

 

 
53,456

Reclassification adjustments for losses included in net income (interest expense)

 

 
369

 

 

 
369

Gains arising during the period on interest rate swaps

 

 
1,403

 

 

 
1,403

Dividends to common stockholders ($0.90 per share)

 

 

 

 
(112,694
)
 
(112,694
)
Balance at September 30, 2018
$
1,252

 
$
3,181,263

 
$
473

 
$
1,071,804

 
$
(2,514,540
)
 
$
1,740,252


The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are an integral part of these financial statements.


5


Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Cash Flows
For the Nine Months Ended September 30, 2019 and 2018
(Dollars in thousands)
(Unaudited)
 
Nine Months Ended September 30,
 
2019
 
2018
OPERATING ACTIVITIES
 
 
 
Net income
$
11,975

 
$
53,456

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
131,725

 
121,764

Other amortization
2,279

 
2,113

Share-based compensation
10,141

 
8,090

Amortization of straight-line rent receivable (lessor)
(1,833
)
 
(3,599
)
Amortization of straight-line rent on operating leases (lessee)
1,159

 
1,147

Gain on sales of real estate assets
(5,065
)
 
(30,879
)
Impairment of real estate assets
5,610

 

Loss (income) from unconsolidated joint ventures
16

 
(15
)
Distributions from unconsolidated joint ventures
277

 
182

Provision for bad debts, net

 
42

Changes in operating assets and liabilities:
 
 
 
Other assets, including right-of-use-assets
(6,740
)
 
(6,891
)
Accounts payable and accrued liabilities
3,220

 
5,908

Other liabilities
5,709

 
(638
)
Net cash provided by operating activities
158,473

 
150,680

INVESTING ACTIVITIES
 
 
 
Acquisitions of real estate
(271,575
)
 
(67,445
)
Development of real estate
(19,152
)
 
(21,059
)
Additional long-lived assets
(45,902
)
 
(59,802
)
Proceeds from sales of real estate assets
14,151

 
64,271

Proceeds from notes receivable repayments

 
8

Net cash used in investing activities
(322,478
)
 
(84,027
)
FINANCING ACTIVITIES
 
 
 
Net borrowings on unsecured credit facility
60,000

 
56,000

Borrowings on term loan
50,000

 

Repayments of notes and bonds payable
(12,663
)
 
(3,808
)
Dividends paid
(115,237
)
 
(112,694
)
Net proceeds from issuance of common stock
192,514

 
459

Common stock redemptions
(2,343
)
 
(2,673
)
Debt issuance and assumption costs
(4,589
)
 
(125
)
Payments made on finance leases
(249
)
 

Net cash provided by (used in) financing activities
167,433

 
(62,841
)
Increase in cash and cash equivalents
3,428

 
3,812

Cash and cash equivalents at beginning of period
8,381

 
6,215

Cash and cash equivalents at end of period
$
11,809

 
$
10,027

 
 
 
 
Supplemental Cash Flow Information:
 
 
 
Interest paid
$
37,946

 
$
30,463

Invoices accrued for construction, tenant improvements and other capitalized costs
$
10,702

 
$
5,680

Mortgage notes payable assumed upon acquisition (adjusted to fair value)
$

 
$
7,995

Capitalized interest
$
999

 
$
684


The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are an integral part of these financial statements.

6

Healthcare Realty Trust Incorporated

Notes to the Condensed Consolidated Financial Statements
September 30, 2019
(Unaudited)

Note 1. Summary of Significant Accounting Policies
Business Overview
Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2019, the Company had gross investments of approximately $4.2 billion in 204 real estate properties located in 26 states totaling approximately 15.4 million square feet. The Company provided leasing and property management services to approximately 11.2 million square feet nationwide.

Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2018. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2019 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.

Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Revenue from Contracts with Customers (Topic 606)
The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance.

Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Type of Revenue
 
2019
 
2018
 
2019
 
2018
Parking income
 
$
1,935

 
$
1,752

 
$
5,538

 
$
5,197

Rental lease guaranty
 

 
168

 
128

 
488

Management fee income
 
69

 
68

 
201

 
205

Miscellaneous
 
55

 
22

 
120

 
83

 
 
$
2,059

 
$
2,010

 
$
5,987

 
$
5,973



The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.

7



New Accounting Pronouncements
Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11
In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, "Leases." In January 2018, FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," in July 2018, FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements," and in December 2018, FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These accounting standard updates are collectively referred to as "Topic 842."
Topic 842 provides several practical expedients that the Company elected. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, (b) the lessor practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately and (c) the lessee practical expedient not to separate certain non-lease components from the associated lease component.
For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. The Company's ground leases executed or assumed prior to the adoption of Topic 842 continue to be accounted for as operating leases and will not result in a materially different ground lease expense. However, each ground lease executed by the Company after the adoption of Topic 842 will be evaluated to determine if it is an operating or finance lease. If the lease is to be accounted for as a finance lease, ground lease expense would be accounted for using the effective interest method instead of the straight-line method over the term of the lease, which would result in higher ground lease expense in the earlier years of a ground lease when compared to the straight-line method. Leases in which the Company is the lessee are primarily ground leases, but also includes management office leases in third party buildings and certain copier and postage machine leases. The terms of the ground leases generally range from 40 to 99 years with a weighted average lease term remaining of 52.5 years, excluding renewal options. The Company's discount rates, which approximates the Company's incremental borrowing rate, ranged from 3.4% for leases expiring in 2019 to 6.2% for leases expiring in 2115. The Company utilized a third party to assist in determining the discount rates for its ground leases. The discount rates consider the general economic environment and factor in various financing and asset specific adjustments so that the discount rate is appropriate for the intended use of the underlying lease. As of January 1, 2019, the Company recognized the present value of its lease payments and a corresponding lease liability of $91.7 million. In addition, the Company reclassified $45.0 million of prepaid ground leases and below-market lease intangibles from the Other assets line item, $1.9 million of above-market lease intangibles from the Other liabilities line and $8.4 million of straight-line rent from the Accounts payable and accrued liabilities line item to the Operating lease right-of-use assets line item on the Condensed Consolidated Balance Sheets.
For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, are generally accounted for under Topic 606 and separated from the lease payments. However, the Company elected the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The combined component is accounted for under Topic 842. Lease related receivables, which include accounts receivable and accrued straight-line rent receivables, are reduced for revenue reserves and are recognized as a reduction to rental income. The adoption of Topic 842, where the Company is the lessor, did not have a material impact on the Company's Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2019.
The new standard was effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company elected to choose the prospective optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 was adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. See Note 3 to the Company's Condensed Consolidated Financial Statements for additional disclosures.

8


Accounting Standards Update No. 2016-13 and No. 2018-19
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of this topic. Instead, impairment of these receivables should be accounted for in accordance with Topic 842, Leases. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is evaluating the impact from the adoption of this new standard on the Condensed Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-04
In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Condensed Consolidated Financial Statements and related notes from the adoption of this standard.

Note 2. Real Estate Investments
2019 Acquisitions
The following table details the Company's acquisitions for the nine months ended September 30, 2019:
(Dollars in millions)
Type (1)
 
Date
Acquired
 
Purchase Price

 
Cash
Consideration
(2)

 
Real
Estate

 
Other (3)

 
Square
Footage
(Unaudited)

Washington, D.C. (4)
MOB
 
3/28/19
 
$
46.0

 
$
45.9

 
$
50.2

 
$
(4.3
)
 
158,338

Indianapolis, IN (5)
MOB
 
3/28/19
 
47.0

 
44.8

 
43.7

 
1.1

 
143,499

Atlanta, GA
MOB
 
4/2/19
 
28.0

 
28.0

 
28.0

 

 
47,963

Dallas, TX
MOB
 
6/10/19
 
17.0

 
16.7

 
17.0

 
(0.3
)
 
89,990

Seattle, WA
MOB
 
6/11/19
 
7.7

 
7.8

 
7.8

 

 
29,870

Seattle, WA
MOB
 
6/14/19
 
19.0

 
19.1

 
19.5

 
(0.4
)
 
47,255

Seattle, WA
MOB
 
6/28/19
 
30.5

 
30.4

 
30.6

 
(0.2
)
 
78,288

Houston, TX
MOB
 
8/1/19
 
13.5

 
13.5

 
13.5

 

 
29,903

Oklahoma City, OK
MOB
 
9/26/19
 
4.1

 
4.1

 
4.1

 

 
28,542

Los Angeles, CA (6)
MOB
 
9/30/19
 
61.1

 
60.9

 
61.8

 
(0.9
)
 
115,634

 
 
 
 
 
$
273.9

 
$
271.2

 
$
276.2

 
$
(5.0
)
 
769,282

______
(1)
MOB = medical office building.
(2)
Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
(3)
Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.
(4)
Includes two properties. The Company assumed two ground leases in connection with this acquisition that are classified as financing leases. The present value of future lease payments totaling $14.3 million was recorded on the Company's Condensed Consolidated Balance Sheets under the caption Finance lease liabilities. In addition, the right-of-use assets were partially offset by $5.2 million of above-market lease intangibles included in Other.
(5)
The Company assumed a prepaid ground lease totaling $0.8 million and recorded a below-market lease intangible totaling $0.9 million in connection with this acquisition that is classified as an operating lease that is included in Other.
(6)
Includes two properties.


9


Subsequent Acquisitions
On October 31, 2019, the Company acquired a 57,730 square foot medical office building in Raleigh, North Carolina for a purchase price of $21.6 million.

On October 31, 2019, the Company acquired a 48,192 square foot medical office building in Dallas, Texas for a purchase price of $20.1 million.

2019 Real Estate Asset Dispositions
The following table details the Company's dispositions for the nine months ended September 30, 2019:
(Dollars in millions)
Type (1)
 
Date
Disposed
 
Sales Price
 
Closing Adjustments
 
Net
Proceeds
 
Net Real
Estate
Investment
 
Other
(including
receivables)
 (2)
 
Gain/
(Impairment)
 
Square
Footage
(
Unaudited)
Tucson, AZ (3)
MOB
 
4/9/19
 
$
13.0

 
$
(0.9
)
 
$
12.1

 
$
6.9

 
$
0.4

 
$
4.8

 
67,345

Virginia Beach, VA (4)
MOB
 
8/1/19
 
1.3

 
(0.1
)
 
1.2

 
1.2

 

 

 
10,000

San Antonio, TX
MOB
 
8/28/19
 
0.9

 
(0.1
)
 
0.8

 
0.6

 

 
0.2

 
10,138

Total dispositions
 
$
15.2

 
$
(1.1
)
 
$
14.1

 
$
8.7

 
$
0.4

 
$
5.0

 
87,483

______
(1)
MOB = medical office building.
(2)
Includes straight-line rent receivables, leasing commissions and lease inducements.
(3)
Includes four properties sold to a single purchaser.
(4)
The Company reclassified this property to held for sale during the second quarter of 2019 and recorded an impairment charge of $0.4 million based on the sales price less estimated costs to sell.

Subsequent Disposition
On October 25, 2019, the Company disposed of a 90,123 square foot inpatient rehabilitation facility located in Erie, Pennsylvania following the ground lessor's exercise of a purchase option. The purchase price, determined by an appraisal process, was $14.0 million and the Company's net investment in the building as of September 30, 2019 was approximately $1.3 million.

Assets Held for Sale
As of September 30, 2019 and December 31, 2018, the Company had two properties and one property, respectively, classified as held for sale. The following is a description of the two properties held for sale as of September 30, 2019:

In March 2019, the Company reclassified an inpatient rehabilitation facility to held for sale upon notification that the ground lessor exercised a purchase option. The purchase price, determined by an appraisal process, was $14.0 million and the current net investment is approximately $1.3 million. This property was sold on October 25, 2019.

In May 2019, the Company accepted an offer from a third party to purchase a former long-term acute care facility located in Pittsburgh, Pennsylvania and recorded an impairment charge totaling $5.2 million based on the sales price less estimated costs to sell. This property was reclassified to held for sale in 2017.


10


The table below reflects the assets and liabilities of the properties classified as held for sale as of September 30, 2019 and December 31, 2018:
(Dollars in thousands)
September 30,
2019
 
December 31,
2018
Balance Sheet data:
 
 
 
Land
$
1,125

 
$
1,125

Buildings, improvements and lease intangibles
34,426

 
18,231

 
35,551

 
19,356

Accumulated depreciation
(30,706
)
 
(10,657
)
Real estate assets held for sale, net
4,845

 
8,699

Other assets, net
444

 
573

Assets held for sale, net
$
5,289

 
$
9,272

 
 
 
 
Accounts payable and accrued liabilities
$
93

 
$
450

Other liabilities
207

 
137

Liabilities of properties held for sale
$
300

 
$
587




Note 3. Leases
Lessor Accounting Under ASC 842
The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.

The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components such as reimbursement of operating expenses as additional rent or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. As of September 30, 2019, the Company had one ground lease that is associated with a property under construction where rent has not yet commenced. Lease income for the Company's operating leases recognized for the three and nine months ended September 30, 2019 was $117.7 million and $342.8 million, respectively.

Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of September 30, 2019 were as follows (in thousands):
2019
$
91,501

2020
340,549

2021
292,541

2022
252,315

2023
210,559

2024 and thereafter
572,767

 
$
1,760,232



Lessor Accounting Under ASC 840
The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases and financial arrangements provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease and for a short period thereafter, with an option or a right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.

11


Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 were as follows (in thousands):
2019
$
326,441

2020
279,211

2021
235,660

2022
201,072

2023
163,978

2024 and thereafter
476,673

 
$
1,683,035



Lessee Accounting Under ASC 842
As of September 30, 2019, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of September 30, 2019, the Company had 108 properties, excluding one property classified as held for sale, totaling 9.0 million square feet that were held under ground leases. Some of the ground leases renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index. The Company had 46 prepaid ground leases as of September 30, 2019. The amortization of the prepaid rent, included in the operating lease right-of-use asset represented approximately $0.2 million and $0.1 million of the Company’s rental expense for the three months ended September 30, 2019 and 2018, respectively and $0.4 million for the nine months ended September 30, 2019 and 2018, respectively.

The Company’s future lease payments (primarily for its 62 non-prepaid ground leases) as of September 30, 2019 were as follows (in thousands):

 
 
Operating

 
Financing

2019
$
999

 
$
107

2020
4,816

 
611

2021
4,846

 
619

2022
4,877

 
628

2023
4,915

 
637

2024 and thereafter
312,712

 
74,767

Total undiscounted lease payments
333,165

 
77,369

Discount
(241,809
)
 
(63,064
)
Lease liabilities
$
91,356

 
$
14,305




12


The following table provides details of the Company's total lease expense for the three and nine months ended September 30, 2019 (in thousands):
 
 
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2019
 
Operating lease cost
 
 
 
 
 
Operating lease expense
 
$
1,169

 
$
3,448

 
Variable lease expense
 
845

 
2,380

 
Finance lease cost
 
 
 
 
 
Amortization of right-of-use assets
 
51

 
101

 
Interest on lease liabilities
 
196

 
392

 
Total lease expense
 
$
2,261

 
$
6,321

 
 
 
 
 
 
 
Other information
 
 
 
 
 
Operating cash flows outflows related to operating leases
 
$
1,313

 
$
5,461

 
Financing cash flows outflows related to financing leases
 
$
107

 
$
249

 
Right-of-use assets obtained in exchange for new finance lease liabilities
 
$

 
$
14,294

 
 
 
 
 
 
 
Weighted-average remaining lease term (excluding renewal options) - operating leases
 
49.7
 
 
 
Weighted-average remaining lease term (excluding renewal options) -finance leases
 
70.1
 
 
 
Weighted-average discount rate - operating leases
 
5.7%
 
 
 
Weighted-average discount rate - finance leases
 
5.5%
 
 
 


Lessee Accounting Under ASC 840
As of December 31, 2018, the Company was obligated under operating lease agreements consisting primarily of the Company’s ground leases. At December 31, 2018, the Company had 107 properties totaling 8.8 million square feet that were held under ground leases with a remaining weighted average term of 53.9 years, excluding renewal options. These ground leases typically have initial terms of 50 to 75 years with one or more renewal options extending the terms to 75 to 100 years, with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index.

The Company’s future minimum lease payments (primarily for its 60 non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands):
 
2019
$
5,288

2020
5,260

2021
5,238

2022
5,207

2023
5,224

2024 and thereafter
323,533

 
$
349,750




13


Note 4. Notes and Bonds Payable
The table below details the Company’s notes and bonds payable. 
 
Maturity
Dates
 
Balance as of
 
Effective Interest Rate as of

(Dollars in thousands)
September 30, 2019

 
December 31, 2018

September 30, 2019

$700 million Unsecured Credit Facility
5/23
 
$
322,000

 
$
262,000

 
2.92
%
$200 million Unsecured Term Loan Facility, net of issuance costs (1)
5/24
 
198,957

 
149,183

 
3.29
%
$150 million Unsecured Term Loan due 2026 (2)
6/26
 

 

 
N/A

Senior Notes due 2023, net of discount and issuance costs
4/23
 
248,434

 
248,117

 
3.95
%
Senior Notes due 2025, net of discount and issuance costs (3)
5/25
 
248,460

 
248,278

 
4.08
%
Senior Notes due 2028, net of discount and issuance costs
1/28
 
295,536

 
295,198

 
3.84
%
Mortgage notes payable, net of discounts and issuance costs and including premiums
7/20-5/40
 
130,532

 
143,208

 
4.81
%
 
 
 
$
1,443,919

 
$
1,345,984

 
 

______
(1)
The effective interest rate includes the impact of interest rate swaps on $175.0 million at a weighted average rate of 2.29% (plus the applicable margin rate, currently 100 basis points).
(2)
As of September 30, 2019, there were no outstanding loans under the $150.0 million unsecured term loan due June 2026. This term loan has a delayed draw feature that allows the Company until February 2020 to draw against the commitments.
(3)
The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.

Changes in Debt Structure
On April 10, 2019, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.00% per annum with an outstanding principal of $8.9 million. The mortgage note encumbered a 52,813 square foot property in Washington.

On May 31, 2019, the Company amended and restated its $700.0 million unsecured credit facility due 2020 (the "Unsecured Credit Facility") to extend the maturity date from July 2020 to May 2023. Amounts outstanding under the Unsecured Credit Facility bear interest at LIBOR plus an applicable margin, which depends on the Company's credit ratings, ranging from 0.775% to 1.45% (currently 0.90%). In addition, the Company pays a facility fee per annum on the aggregate amount of commitments ranging from 0.125% to 0.30% (currently 0.20%). In connection with the amendment, the Company paid up front fees to the lenders and other costs of approximately $3.5 million, which were capitalized and are being amortized over the term of the Unsecured Credit Facility.

Also, on May 31, 2019, the Company amended and restated its term loan agreement (the "Term Loan") with a syndicate of lenders. The amended agreement extended the maturity date of the Company's unsecured term loan due 2022 to May 2024 (the "Term Loan due 2024") and increased the loan amount from $150.0 million to $200.0 million. In addition, the amended agreement added a $150.0 million seven-year term loan facility (the "Term Loan due 2026"). The Term Loan due 2024 bears interest at LIBOR plus an applicable margin ranging from 0.85% to 1.65% (1.00% at September 30, 2019) based upon the Company's unsecured debt ratings. The Term Loan due 2026 has a delayed draw feature that allows the Company up to nine months to draw against the commitments. As of September 30, 2019, no loans were outstanding under the Term Loan due 2026. Loans outstanding under the Term Loan due 2026 will bear interest at a rate equal to LIBOR plus a margin ranging from 1.45% to 2.40% (1.60% at September 30, 2019). Committed amounts that remain undrawn are subject to a ticking fee ranging from 0.125% to 0.30% per annum (0.20% at September 30, 2019). In connection with the amendment, the Company paid up front fees to the lenders of approximately $1.8 million, of which $1.0 million were capitalized and are being amortized over the respective term of the term loans and $0.8 million were expensed during the second quarter of 2019.

Note 5. Derivative Financial Instruments
Risk Management Objective of Using Derivatives
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the

14


amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the
receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.

For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) ("AOCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt.

On April 12, 2019, the Company entered into two interest rate swaps totaling $50.0 million to fix the one-month LIBOR portion of the cost of borrowing to a rate of 2.33%. These derivatives are being used to hedge variable cash flows associated with variable-rate debt.

On May 15, 2019, the Company entered into two interest rate swaps totaling $50.0 million to fix the one-month LIBOR portion of the cost of borrowing to a rate of 2.13%. These derivatives are being used to hedge variable cash flows associated with variable-rate debt.

As of September 30, 2019, the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Derivative Instrument
 
Number of Instruments

 
Notional Amount
(in millions)
Interest rate swaps
 
8

 
$175.0


Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of September 30, 2019.
 
Balance at September 30, 2019
(Dollars in thousands)
Balance Sheet Location
 
Fair Value

Derivatives designated as hedging instruments
 
 
 
Interest rate swaps
Other liabilities
 
$
7,533

Total derivatives designated as hedging instruments
 
 
$
7,533



Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)
The table below presents the effect of cash flow hedge accounting on AOCI during the three and nine months ended September 30, 2019 and 2018 related to the Company's outstanding interest rate swaps.
 
Gain (Loss) Recognized in AOCI on Derivative
 
Loss Reclassified from AOCI into Income
 
Three Months Ended September 30,
Three Months Ended September 30,
(Dollars in thousands)
2019

 
2018

2019

 
2018

Interest rate swaps
$
(2,341
)
 
$
374

Interest expense
$
18

 
$
53

Settled interest rate swaps

 

Interest expense
42

 
42

 
$
(2,341
)
 
$
374

Total interest expense
$
60

 
$
95


15


 
Gain (Loss) Recognized in AOCI on Derivative
 
(Gain) Loss Reclassified from AOCI into Income
 
Nine Months Ended September 30,
Nine Months Ended September 30,
(Dollars in thousands)
2019

 
2018

2019

 
2018

Interest rate swaps
$
(7,642
)
 
$
1,403

Interest expense
$
(52
)
 
$
243

Settled interest rate swaps

 

Interest expense
126

 
126

 
$
(7,642
)
 
$
1,403

Total interest expense
$
74


$
369


Credit-risk-related Contingent Features
The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.

The Company estimates that $1.3 million will be reclassified from AOCI to interest expense over the next 12 months.

Note 6. Commitments and Contingencies
Legal Proceedings
The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Redevelopment Activity
The Company redeveloped a medical office building in Charlotte, North Carolina, which includes a 40,278 square foot vertical expansion. As of September 30, 2019, the Company had funded approximately $9.8 million towards the redevelopment of this property. The Company expects to fund approximately $2.2 million for additional tenant improvements associated with this project. The first tenant took occupancy during the second quarter of 2019.

Development Activity
The Company began the development of a 151,000 square foot medical office building in Seattle, Washington during 2017. As of September 30, 2019, the Company had funded approximately $44.3 million towards the development. The Company expects to fund an additional amount of approximately $19.8 million to complete this project. The Company expects the first tenant to take occupancy in the first quarter of 2020.
Note 7. Stockholders' Equity

Common Stock    
The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2019 and the year ended December 31, 2018:
 
September 30, 2019
 
December 31, 2018
Balance, beginning of period
125,279,455

 
125,131,593

Issuance of common stock
6,099,012

 
26,203

Nonvested share-based awards, net of withheld shares (1)
(10,269
)
 
121,659

Balance, end of period
131,368,198

 
125,279,455


______
(1)
The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in $2.9 million of expenses associated with the acceleration of his outstanding nonvested share-based awards. In connection with the vesting, 80,490 shares were withheld to pay employee federal income taxes.

Equity Offering
On March 19, 2019, the Company issued 3,737,500 shares of common stock, par value $0.01 per share, at $31.40 per share in an underwritten public offering pursuant to the Company's existing effective registration statement. The net proceeds of the offering, after underwriting discounts and offering expenses, were approximately $115.8 million.

16



At-The-Market Equity Offering Program
The Company sold 4,694,624 shares under the Company's at-the-market equity offering program from January 1, 2019 through October 31, 2019. The sales generated $153.7 million in net proceeds at prices to the public ranging from $32.01 to $33.77 per share (weighted average of $33.31 per share). The sales occurred during the following time periods:

During the first quarter of 2019, the Company sold 135,265 shares generating $4.3 million in net proceeds at prices to the public ranging from $32.01 to $32.86 per share (weighted average of $32.36 per share).
No shares were sold in the second quarter of 2019.
During the third quarter of 2019, the Company sold 2,191,522 shares generating $71.6 million in net proceeds at prices to the public ranging from $32.62 to $33.77 per share (weighted average of $33.15 per share).
During October 2019, the Company sold 2,367,837 shares generating $78.2 million in net proceeds at prices to the public ranging from $33.17 to $33.74 per share (weighted average of $33.52 per share).

The Company had 1,174,073 authorized shares remaining available to be sold under the current sales agreements as of October 31, 2019.

Common Stock Dividends
During the nine months ended September 30, 2019, the Company declared and paid common stock dividends totaling $0.90 per share. On October 29, 2019, the Company declared a quarterly common stock dividend in the amount of $0.30 per share payable on November 29, 2019 to stockholders of record on November 14, 2019.

Earnings Per Common Share
The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2019 and 2018.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(Dollars in thousands, except per share data)
2019
 
2018
 
2019
 
2018
Weighted average Common Shares outstanding
 
 
 
 
 
 
 
Weighted average Common Shares outstanding
129,865,985

 
125,233,462

 
128,348,638

 
125,206,342

Nonvested shares
(1,775,911
)
 
(1,933,653
)
 
(1,777,743
)
 
(1,925,589
)
Weighted average Common Shares outstanding—Basic
128,090,074

 
123,299,809

 
126,570,895

 
123,280,753

Weighted average Common Shares outstanding—Basic
128,090,074

 
123,299,809

 
126,570,895

 
123,280,753

Dilutive effect of employee stock purchase plan
78,610

 
52,147

 
85,690

 
54,763

Weighted average Common Shares outstanding—Diluted
128,168,684

 
123,351,956

 
126,656,585

 
123,335,516

Net Income
$
2,601

 
$
6,548

 
$
11,975

 
$
53,456

Dividends paid on nonvested share-based awards
(534
)
 
(580
)
 
(1,603
)
 
(1,740
)
Net income applicable to common stockholders
$
2,067

 
$
5,968

 
$
10,372

 
$
51,716

Basic earnings per common share - Net income
$
0.02

 
$
0.05

 
$
0.08

 
$
0.42

Diluted earnings per common share - Net income
$
0.02

 
$
0.05

 
$
0.08

 
$
0.42




17


Incentive Plans
A summary of the activity under the Company's share-based incentive plans for the three and nine months ended September 30, 2019 and 2018 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Share-based awards, beginning of period
1,778,134

 
1,938,100

 
1,769,863

 
1,907,645

Granted

 

 
89,767

 
107,751

Vested (1)
(204,548
)
 
(5,051
)
 
(286,044
)
 
(82,347
)
Share-based awards, end of period
1,573,586

 
1,933,049

 
1,573,586

 
1,933,049


______
(1)
The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in the accelerated vesting of 204,548 outstanding nonvested share-based awards.

During the nine months ended September 30, 2019 and 2018, the Company withheld 100,036 and 22,555 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.

In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three and nine months ended September 30, 2019 and 2018 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Outstanding and exercisable, beginning of period
363,218

 
350,535

 
328,533

 
318,100

Granted

 

 
235,572

 
203,836

Exercised
(9,927
)
 
(2,531
)
 
(28,943
)
 
(13,236
)
Forfeited
(11,762
)
 
(9,583
)
 
(51,559
)
 
(34,489
)
Expired

 

 
(142,074
)
 
(135,790
)
Outstanding and exercisable, end of period
341,529

 
338,421

 
341,529

 
338,421



Note 8. Fair Value of Financial Instruments
The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.

Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments.

Borrowings under the Unsecured Credit Facility and the Term Loan Due 2024 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.
 
Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.

Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.


18


The table below details the fair values and carrying values for notes and bonds payable at September 30, 2019 and December 31, 2018.
 
September 30, 2019
 
December 31, 2018
(Dollars in millions)
Carrying Value
 
Fair Value
 
Carrying Value
 
Fair Value
Notes and bonds payable (1)
$
1,443.9

 
$
1,468.5

 
$
1,346.0

 
$
1,326.5


______
(1)
Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.



19


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Disclosure Regarding Forward-Looking Statements
This report and other materials the Company has filed or may file with the Securities and Exchange Commission, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, disclosures that are “forward-looking statements.” Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “target,” “intend,” “plan,” “estimate,” “project,” “continue,” “should,” “could," "budget" and other comparable terms. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of risks and uncertainties, including the risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, that could significantly affect the Company’s current plans and expectations and future financial condition and results.

The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Stockholders and investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in the Company’s filings and reports, including, without limitation, estimates and projections regarding the performance of development projects the Company is pursuing.

For a detailed discussion of the Company’s risk factors, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2018.

Liquidity and Capital Resources
Sources and Uses of Cash
The Company’s primary sources of cash include rent receipts from its real estate portfolio based on contractual arrangements with its tenants and sponsors, borrowings under the Company's Unsecured Credit Facility and Term Loan, proceeds from the sales of real estate properties and proceeds from public or private debt or equity offerings.

The Company expects to continue to meet its liquidity needs, including funding additional investments, paying dividends, and funding debt service, through cash on hand, cash flows from operations, and the cash flow sources described above. The Company had unencumbered real estate assets with a gross book value of approximately $3.9 billion at September 30, 2019, of which a portion could serve as collateral for secured mortgage financing. The Company believes that its liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.

Investing Activities
Cash flows used in investing activities for the nine months ended September 30, 2019 were approximately $322.5 million. Below is a summary of significant investing activities.
2019 Acquisitions
The following table details the Company's acquisitions for the nine months ended September 30, 2019:
(Dollars in millions)
 
Health System Affiliation
 
Date
Acquired
 
Purchase Price

 
Square
Footage

 
Cap Rate

 
Miles to Campus

Washington, D.C. (1)
 
Inova Health
 
3/28/19
 
$
46.0

 
158,338

 
5.2
%
 
0.00

Indianapolis, IN
 
Indiana University Health
 
3/28/19
 
47.0

 
143,499

 
5.1
%
 
0.00

Atlanta, GA
 
Piedmont Healthcare
 
4/2/19
 
28.0

 
47,963

 
5.7
%
 
0.14

Dallas, TX
 
Baylor Scott & White Health
 
6/10/19
 
17.0

 
89,990

 
6.2
%
 
0.01

Seattle, WA
 
MultiCare Health System
 
6/11/19
 
7.7

 
29,870

 
6.9
%
 
0.20

Seattle, WA
 
UW Medicine
 
6/14/19
 
19.0

 
47,255

 
5.8
%
 
0.27

Seattle, WA
 
UW Medicine
 
6/28/19
 
30.5

 
78,288

 
5.7
%
 
0.35

Houston, TX
 
Houston Methodist
 
8/1/19
 
13.5

 
29,903

 
5.7
%
 
0.00

Oklahoma City, OK
 
Integris Health
 
9/26/19
 
4.1

 
28,542

 
6.3
%
 
0.02

Los Angeles, CA (1)
 
Huntington Hospital
 
9/30/19
 
61.1

 
115,634

 
5.2
%
 
0.05

 
 
 
 
 
 
$
273.9

 
769,282

 
5.5
%
 
 
______
(1)
Includes two properties.


20


Subsequent Acquisitions
On October 31, 2019, the Company acquired a 57,730 square foot medical office building in Raleigh, North Carolina for a purchase price of $21.6 million.

On October 31, 2019, the Company acquired a 48,192 square foot medical office building in Dallas, Texas for a purchase price of $20.1 million.

Capital Funding
During the nine months ended September 30, 2019, the Company funded the following:
$21.6 million toward development and redevelopment of properties;
$10.9 million toward first generation tenant improvements and planned capital expenditures for acquisitions;
$16.6 million toward second generation tenant improvements; and
$12.0 million toward capital expenditures.

2019 Dispositions
The Company disposed of six properties during the nine months ended September 30, 2019 for a total sales price of $15.2 million, including cash proceeds of $14.1 million and $1.1 million of closing costs and related adjustments. The following table details these dispositions for the nine months ended September 30, 2019:
(Dollars in millions)
 
Date Disposed
 
Sales Price
 
Square Footage
 
3Q 2019 NOI
 
Disposition Cap Rate
 
Property Type (1)
Tucson, AZ (2)
 
4/9/2019
 
$
13.0

 
67,345

 
NA

 
6.2
%
 
MOB
Virginia Beach, VA
 
8/1/2019
 
1.3

 
10,000

 
$
0.0

 
12.2
%
 
MOB
San Antonio, TX
 
8/28/2019
 
0.9

 
10,138

 
0.0

 
3.0
%
 
MOB
Total dispositions
 
 
 
$
15.2

 
87,483

 
$
0.0

 
6.5
%
 
 
______
(1)
MOB = Medical office building
(2)
Includes three off-campus medical office buildings and one on-campus medical office building sold to a single purchaser.

Subsequent Disposition
On October 25, 2019, the Company disposed of a 90,123 square foot inpatient rehabilitation facility located in Erie, Pennsylvania following the ground lessor's exercise of a purchase option. The purchase price, determined by an appraisal process, was $14.0 million and the Company's net investment in the building as of September 30, 2019 was approximately $1.3 million.

Financing Activities
Cash flows provided by financing activities for the nine months ended September 30, 2019 were approximately $167.4 million. Inflows from equity related to the Company's common stock issuances and net borrowings totaled $302.5 million, net of issuance costs incurred. Aggregate cash outflows totaled approximately $135.1 million primarily associated with dividends paid to common stockholders. See Notes 4 and 7 to the Condensed Consolidated Financial Statements for more information about capital markets and financing activities.

Common Stock Issuances
The Company sold 4,694,624 shares under the Company's at-the-market equity offering program from January 1, 2019 through October 31, 2019. The sales generated $153.7 million in net proceeds at prices to the public ranging from $32.01 to $33.77 per share (weighted average of $33.31 per share). The sales occurred during the following time periods:

During the first quarter of 2019, the Company sold 135,265 shares generating $4.3 million in net proceeds at prices to the public ranging from $32.01 to $32.86 per share (weighted average of $32.36 per share).
No shares were sold in the second quarter.
During the third quarter of 2019, the Company sold 2,191,522 shares generating $71.6 million in net proceeds at prices to the public ranging from $32.62 to $33.77 per share (weighted average of $33.15 per share).
During October 2019, the Company sold 2,367,837 shares generating $78.2 million in net proceeds at prices to the public ranging from $33.17 to $33.74 per share (weighted average of $33.52 per share).


21


The Company had 1,174,073 authorized shares remaining available to be sold under the current sales agreements as of October 31, 2019.

On March 19, 2019, the Company issued 3,737,500 shares of common stock, par value $0.01 per share, at $31.40 per share in an underwritten public offering pursuant to the Company's existing effective registration statement. The net proceeds of the offering, after underwriting discounts and offering expenses, were approximately $115.8 million.

Debt Activity
On April 10, 2019, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.00% per annum with an outstanding principal of $8.9 million. The mortgage note encumbered a 52,813 square foot property in Washington.

On May 31, 2019, the Company amended and restated its Unsecured Credit Facility to extend the maturity date from July 2020 to May 2023. Amounts outstanding under the Unsecured Credit Facility bear interest at LIBOR plus an applicable margin, which depends on the Company's credit ratings ranging from 0.775% to 1.45% (currently 0.90%). In addition, the Company pays a facility fee per annum on the aggregate amount of commitments ranging from 0.125% to 0.30% (currently 0.20%). In connection with the amendment, the Company paid up front fees to the lenders and other costs of approximately $3.5 million, which were capitalized and will be amortized over the term of the Unsecured Credit Facility.

Also, on May 31, 2019, the Company amended and restated its Term Loan with a syndicate of lenders. The amended agreement extended the maturity date of the Company's unsecured term loan due 2022 to May 2024 and increased the loan amount from $150.0 million to $200.0 million. In addition, the amended agreement added a $150.0 million seven-year term loan facility due June 2026. The Term Loan due 2024 bears interest at LIBOR plus an applicable margin ranging from 0.85% to 1.65% (1.00% at September 30, 2019) based upon the Company's unsecured debt ratings. The Term Loan due 2026 has a delayed draw feature that allows the Company up to nine months to draw against the commitments. As of September 30, 2019, no loans were outstanding under the Term Loan due 2026. Loans outstanding under the Term Loan due 2026 will bear interest at a rate equal to LIBOR plus a margin ranging from 1.45% to 2.40% (1.60% at September 30, 2019). Committed amounts that remain undrawn are subject to a ticking fee ranging from 0.125% to 0.30% per annum (0.20% at September 30, 2019). In connection with the amendment, the Company paid up front fees to the lenders of approximately $1.8 million, of which $1.0 million were capitalized and will be amortized over the respective term of the Term Loans and $0.8 million were expensed during the second quarter of 2019.

The Company has outstanding interest rate swaps totaling $175.0 million to hedge one-month LIBOR. The following details the amount and rate of each swap (dollars in thousands):
Effective Date
 
Amount
 
Weighted Average Rate
 
Expiration Date
December 18, 2017
 
$
25,000

 
2.18
%
 
December 16, 2022
February 1, 2018
 
50,000

 
2.46
%
 
December 16, 2022
May 1, 2019
 
50,000

 
2.33
%
 
May 1, 2026
June 3, 2019
 
50,000

 
2.13
%
 
May 1, 2026
 
 
$
175,000

 
2.29
%
 
 

Operating Activities
Cash flows provided by operating activities increased from $150.7 million for the nine months ended September 30, 2018 to $158.5 million for the nine months ended September 30, 2019. Items impacting cash flows from operations include, but are not limited to, cash generated from property operations, interest payments and the timing related to the payment of invoices and other expenses.
The Company may, from time to time, sell properties and redeploy cash from property sales into new investments. To the extent revenues related to the properties being sold exceed income from these new investments, the Company's results of operations and cash flows could be adversely affected.

Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements that are reasonably likely to have a current or future material effect on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.


22


New Accounting Pronouncements
See Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report for information on new accounting standards.

Trends and Matters Impacting Operating Results
Management monitors factors and trends important to the Company and the REIT industry to gauge the potential impact on the operations of the Company. In addition to the matters discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, below are some of the factors and trends that management believes may impact future operations of the Company.

Expiring Leases
The Company expects that approximately 15% to 20% of the leases in its multi-tenanted portfolio will expire each year in the ordinary course of business. There are 204 leases totaling 0.7 million square feet in the Company's multi-tenant portfolio that will expire during the remainder of 2019. Approximately 95% of the leases expiring in 2019 are in buildings located on or adjacent to hospital campuses, are distributed throughout the portfolio, and are not concentrated with any one tenant, health system or market area. The Company typically expects to retain 75% to 90% of multi-tenant property tenants upon expiration, and the retention ratio for the first nine months of the year has been within this range.

Included in the 2019 lease expirations is a lease for a 111,000 square foot fitness center with Baylor Scott & White that has been extended for an additional 90 days to December 31, 2019. This fitness center is located in a 217,000 square foot on-campus medical office building. The Company is currently in lease negotiations with a fitness center operator for approximately half of the space and is exploring options to convert any remaining space to clinical use.

The Company had two single-tenant net leased, on-campus inpatient rehabilitation facilities with lease terms that expired in the third quarter of 2019.  The tenant exercised a five-year renewal for one of these facilities at a lease rate 7.6% greater than the previous lease rate. The other facility was sold to the ground lessor on October 25, 2019, as a result of its exercise of a purchase option, at a price of $14.0 million. Rent from this property represented 0.8% of total cash net operating income ("NOI") for the trailing twelve months ended September 30, 2019.
Property Operating Agreement Expirations
On February 28, 2019, the Company’s remaining property operating agreement between the Company and a sponsoring health system expired. This agreement contractually obligated the sponsoring health system to provide to the Company a minimum return on the Company’s investment in the property in exchange for the right to be involved in the operating decisions of the property, including tenancy. If the minimum return was not achieved through normal operations of the property, the Company calculated and accrued to property lease guaranty revenue, each quarter, any shortfalls due from the sponsor under the terms of the property operating agreement. The Company recognized $0.1 million in property lease guaranty revenue during the first quarter of 2019 related to this agreement.

Operating Expenses
The Company has historically experienced increases in property taxes throughout its portfolio as a result of increasing assessments and tax rates levied across the country. The Company continues its efforts to appeal property tax increases and manage the impact of the increases. In addition, the Company has historically incurred variability in portfolio utilities expense based on seasonality, with the first and third quarters usually reflecting greater amounts. The effects of these operating expense increases are mitigated in leases that have provisions for operating expense reimbursement. As of September 30, 2019, leases for 88% of the Company's multi-tenant leased square footage allow for some recovery of operating expenses, with 32% having modified gross lease structures and 56% having net lease structures.

23


Purchase Options
Information about the Company's unexercised purchase options and the amount and basis for determination of the purchase price is detailed in the table below (dollars in thousands):
 
 
Number of Properties
 
Gross Real Estate Investment as of September 30, 2019
Year Exercisable
 
MOB
 
Inpatient
 
Fair Market Value Method (1)

 
Non Fair Market Value Method (2)

 
Total

Current (3)
 
3

 
1

 
$
95,921

 
$

 
$
95,921

2020
 

 

 

 

 

2021
 
1

 

 

 
14,984

 
14,984

2022
 

 

 

 

 

2023
 

 

 

 

 

2024
 

 

 

 

 

2025
 
5

 
1

 
47,986

 
221,929

 
269,915

2026
 

 

 

 

 

2027
 

 

 

 

 

2028
 
1

 

 
43,904

 

 
43,904

2029 and thereafter
 
5

 

 
125,963

 

 
125,963

Total
 
15

 
2

 
$
313,774

 
$
236,913

 
$
550,687

_____
(1)
The purchase option price includes a fair market value component that is determined by an appraisal process.
(2)
Includes properties with stated purchase prices or prices based on fixed capitalization rates. These properties have purchase prices that are on average 17% greater than the Company's current gross investment.
(3)
These purchase options have been exercisable for an average of 11.1 years.
Non-GAAP Financial Measures and Key Performance Indicators
Management considers certain non-GAAP financial measures and key performance indicators to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of these measures to the most directly comparable GAAP financial measures.
The non-GAAP financial measures and key performance indicators presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.
Funds from Operations ("FFO"), Normalized FFO and Funds Available for Distribution ("FAD")
FFO and FFO per share are operating performance measures adopted by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT’s operating performance equal to “net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus depreciation and amortization, impairment, and after adjustments for unconsolidated partnerships and joint ventures.”
In addition to FFO, the Company presents Normalized FFO and FAD. Normalized FFO is presented by adding to FFO acquisition-related costs, acceleration of debt issuance costs, debt extinguishment costs and other Company-defined normalizing items to evaluate operating performance. FAD is presented by adding to Normalized FFO non-real estate depreciation and amortization, deferred financing fees amortization, stock-based compensation expense and provision for bad debts, net; and subtracting maintenance capital expenditures, including second generation tenant improvements and leasing commissions paid and straight-line rent income, net of expense. The Company's definition of these terms may not be comparable to that of other real estate companies as they may have different methodologies for computing these amounts. Normalized FFO and FAD should not be considered as an alternative to net income as an indicator of the Company's financial performance or to cash flow from operating activities as an indicator of the Company's liquidity. Normalized FFO and FAD should be reviewed in connection with GAAP financial measures.

24


Management believes FFO, Normalized FFO, FFO per share, Normalized FFO per share and FAD ("Non-GAAP Measures") provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, impairments and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, Non-GAAP Measures can facilitate comparisons of operating performance between periods. The Company reports Non-GAAP Measures because these measures are observed by management to also be the predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these Non-GAAP Measures. However, none of these measures represent cash generated from operating activities determined in accordance with GAAP and are not necessarily indicative of cash available to fund cash needs. Further, these measures should not be considered as an alternative to net income as an indicator of the Company’s operating performance or as an alternative to cash flow from operating activities as a measure of liquidity. The table below reconciles net income to FFO, Normalized FFO and FAD for the three and nine months ended September 30, 2019 and 2018:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(Amounts in thousands, except per share data)
2019
 
2018
 
2019
 
2018
Net Income
$
2,601

 
$
6,548

 
$
11,975

 
$
53,456

Gain on sales of real estate assets
(200
)
 
(1,288
)
 
(5,065
)
 
(30,879
)
Impairment of real estate assets

 

 
5,610

 

Real estate depreciation and amortization
45,926

 
42,723

 
133,993

 
123,475

Total adjustments
45,726

 
41,435

 
134,538

 
92,596

FFO Attributable to Common Stockholders
$
48,327

 
$
47,983

 
$
146,513

 
$
146,052

Acquisition and pursuit costs (1)
501

 
141

 
1,227

 
538

Lease intangible amortization (2)
5

 

 
143

 

Accelerated stock awards (3)
2,854

 
70

 
2,854

 
70

Forfeited earnest money received

 

 

 
(466
)
Debt financing costs

 

 
760

 

Normalized FFO Attributable to Common Stockholders
$
51,687

 
$
48,194

 
$
151,497

 
$
146,194

Non-real estate depreciation and amortization
838

 
845

 
2,430

 
2,494

Non-cash interest expense amortization (4)
727

 
661

 
2,136

 
1,959

Provision for bad debt, net
(32
)
 
(62
)
 
43

 
42

Straight-line rent, net
(379
)
 
(413
)
 
(650
)
 
(2,426
)
Stock-based compensation
2,375

 
2,605

 
7,386

 
8,020

Normalized FFO adjusted for non-cash items
$
55,216

 
$
51,830

 
$
162,842

 
$
156,283

2nd generation TI
(6,114
)
 
(6,950
)
 
(16,564
)
 
(20,572
)
Leasing commissions paid
(3,017
)
 
(1,139
)
 
(7,101
)
 
(4,937
)
Capital additions
(3,543
)
 
(6,229
)
 
(11,998
)
 
(17,530
)
FAD
$
42,542

 
$
37,512

 
$
127,179

 
$
113,244

FFO per Common Share—Diluted
$
0.37

 
$
0.39

 
$
1.15

 
$
1.18

Normalized FFO per Common Share—Diluted
$
0.40

 
$
0.39

 
$
1.19

 
$
1.18

FFO weighted average common shares outstanding - Diluted (5)
129,015

 
124,192

 
127,424

 
124,051

_____
(1)
Acquisition and pursuit costs include third party and travel costs related to the pursuit of acquisitions and developments.
(2)
The Company adopted the 2018 NAREIT FFO White Paper Restatement during the first quarter of 2019. This amended definition specifically includes the impact of acquisition related market lease intangible amortization in the calculation of NAREIT FFO.  The Company historically included this amortization in the real estate depreciation and amortization line item which is added back in the calculation of NAREIT FFO.  Prior periods were not restated for the adoption.
(3)
The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in a $2.9 million charge for the acceleration of his outstanding nonvested share-based awards and associated taxes. The third quarter of 2018 includes a revaluation adjustment recorded in connection with an officer retirement.
(4)
Includes the amortization of deferred financing costs, discounts and premiums.
(5)
The Company utilizes the treasury stock method which includes the dilutive effect of nonvested share-based awards outstanding of 846,327 and 839,883 and 767,479 and 715,491, respectively, for the three and nine months ended September 30, 2019 and 2018.

25


Cash NOI and Same Store Cash NOI
Cash NOI and Same Store Cash NOI are key performance indicators. Management considers these to be supplemental measures that allow investors, analysts and Company management to measure unlevered property-level operating results. The Company defines Cash NOI as rental income and property lease guaranty income less property operating expenses. Cash NOI excludes non-cash items such as above and below market lease intangibles, straight-line rent, lease inducements, tenant improvement amortization and leasing commission amortization. The Company also excludes cash lease termination fees. Cash NOI is historical and not necessarily indicative of future results.

Same Store Cash NOI compares Cash NOI for stabilized properties. Stabilized properties are properties that have been included in operations for the duration of the year-over-year comparison period presented and include redevelopment projects. Accordingly, stabilized properties exclude properties that were recently acquired or disposed of, properties classified as held for sale, reposition properties and newly developed properties. The Company utilizes the reposition classification for properties experiencing a shift in strategic direction. Such a shift can occur for a variety of reasons, including a substantial change in the use of the asset, a change in strategy or closure of a neighboring hospital, or significant property damage. Such properties may require enhanced management, leasing, capital needs or a disposition strategy that differs from the rest of the portfolio. To identify properties exhibiting these reposition characteristics, the Company applies the following Company-defined criteria:
Properties having less than 60% occupancy that is expected to last at least two quarters;
Properties that experience a loss of occupancy over 30% in a single quarter; or
Properties with negative net operating income that is expected to last at least two quarters.
Any recently acquired property will be included in the same store pool once the Company has owned the property for eight full quarters. Newly developed properties will be included in the same store pool eight full quarters after substantial completion. Any additional square footage created by redevelopment projects at a same store property is included in the same store pool immediately upon completion. Any property included in the reposition property group will be included in the same store analysis once occupancy has increased to 60% or greater with positive net operating income and has remained at that level for eight full quarters. The following table reflects the Company's same store cash NOI for the three months ended September 30, 2019 and 2018.
 
 
 
 
 
Same Store Cash NOI for the
 
 
 
 
 
Three Months Ended September 30,
(Dollars in thousands)
Number of Properties
 
Gross Investment at September 30, 2019
 
2019
 
2018
Multi-tenant Properties
149

 
$
3,004,110

 
$
54,128

 
$
52,898

Single-tenant Net Lease Properties
14

 
461,845

 
10,471

 
10,327

Total
163

 
$
3,465,955

 
$
64,599

 
$
63,225



26


The following tables reconcile net income to same store NOI and the same store property metrics to the total owned real estate portfolio for the three months ended September 30, 2019 and 2018:
Reconciliation of Same Store Cash NOI:
 
Three Months Ended September 30,
(Dollars in thousands)
2019
 
2018
Net income
$
2,601

 
$
6,548

Other income (expense)
13,981

 
12,135

General and administrative expense
10,802

 
8,504

Depreciation and amortization expense
45,137

 
42,061

Other expenses (1)
2,462

 
1,855

Straight-line rent revenue
(770
)
 
(802
)
Other revenue (2)
(1,608
)
 
(1,173
)
Cash NOI
72,605

 
69,128

Cash NOI not included in same store
(8,006
)
 
(5,903
)
Same store cash NOI
64,599

 
63,225

Reposition NOI
222

 
361

Same store and reposition cash NOI
$
64,821

 
$
63,586

_____
(1)
Includes acquisition and pursuit costs, bad debt, above and below market ground lease intangible amortization, leasing commission amortization and ground lease straight-line rent expense.
(2)
Includes management fee income, interest, above and below market lease intangible amortization, lease inducement amortization, lease terminations and tenant improvement overage amortization.
Reconciliation of Same Store Properties:
 
As of September 30, 2019
 
Property Count
 
Gross Investment
 
Square Feet
 
Occupancy
Same store properties
163

 
$
3,465,955

 
12,928,142

 
88.8
%
Acquisitions
30

 
637,827

 
1,935,189

 
90.1
%
Reposition
11

 
84,728

 
567,252

 
36.0
%
Total owned real estate properties
204

 
$
4,188,510

 
15,430,583

 
87.0
%


27


Results of Operations
Three Months Ended September 30, 2019 Compared to Three Months Ended September 30, 2018
The Company’s results of operations for the three months ended September 30, 2019 compared to the same period in 2018 were impacted by acquisitions, developments, dispositions, gains on sale, and capital markets transactions.

Revenues
Total revenues increased $6.3 million, or 5.6%, to approximately $119.8 million for the three months ended September 30, 2019 compared to $113.5 million in the prior year period. This increase is comprised of the following:
 
Three Months Ended September 30,
 
Change
(Dollars in thousands)
2019
 
2018
 
$
 
%
Property operating
$
105,805

 
$
99,367

 
$
6,438

 
6.5
 %
Single-tenant net lease
11,165

 
11,283

 
(118
)
 
(1.0
)%
Straight-line rent
770

 
802

 
(32
)
 
(4.0
)%
Rental income
117,740

 
111,452

 
6,288

 
5.6
 %
Other operating
2,059

 
2,010

 
49

 
2.4
 %
Total Revenues
$
119,799

 
$
113,462

 
$
6,337

 
5.6
 %

Property operating revenue increased $6.4 million, or 6.5%, from the prior year period primarily as a result of the following activity:

Acquisitions in 2018 and 2019 contributed $5.2 million.
Leasing activity, including contractual rent increases, contributed $2.5 million.
Dispositions in 2018 and 2019 resulted in a decrease of $1.3 million.

Single-tenant net lease revenue decreased $0.1 million, or 1.0%, from the prior year period primarily as a result of the following activity:

Dispositions in 2018 resulted in a decrease of $0.3 million.
Leasing activity, including contractual rent increases, contributed $0.2 million.

Straight-line rent revenue was consistent with the prior year period primarily as a result of the following activity:

Acquisitions in 2018 and 2019 contributed $0.3 million.
Leasing activity and contractual rent increases resulted in a decrease of $0.3 million.
    
Expenses
Property operating expenses increased $2.6 million, or 6.0%, for the three months ended September 30, 2019 compared to the prior year period primarily as a result of the following activity:

Acquisitions in 2018 and 2019 resulted in an increase of $2.3 million.
Maintenance and repair expense resulted in an increase of $0.4 million.
Portfolio property tax increased $0.4 million.
Portfolio insurance expense increased $0.2 million.
Dispositions in 2018 and 2019 resulted in a decrease of $0.7 million.


28


General and administrative expenses increased approximately $2.3 million, or 27.0%, for the three months ended September 30, 2019 compared to the prior year period primarily as a result of the following:
The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in a $2.9 million charge for the acceleration of his outstanding nonvested share-based awards and associated taxes.
Office rent decreased $0.3 million due to the acquisition of the Company's headquarters.
Compensation expense decreased $0.3 million.

Depreciation and amortization expense increased $3.1 million, or 7.3%, for the three months ended September 30, 2019 compared to the prior year period primarily as a result of the following activity:
Acquisitions in 2018 and 2019 resulted in an increase of $3.4 million.
Various building and tenant improvement expenditures resulted in an increase of $2.6 million.
Dispositions in 2018 and 2019 resulted in a decrease of $1.5 million.
Assets that became fully depreciated resulted in a decrease of $1.4 million.

Other income (expense)
In the third quarter of 2019, the Company recognized gains of approximately $0.2 million on the sale of two properties.

In the third quarter of 2018, the Company recorded gains of approximately $1.3 million on the sale of one property.

Interest expense increased $0.7 million, or 5.3%, for the three months ended September 30, 2019 compared to the prior year period. The components of interest expense are as follows:
 
Three Months Ended September 30,
 
Change
(Dollars in thousands)
2019
 
2018
 
$
 
%
Contractual interest
$
13,605

 
$
13,016

 
$
589

 
4.5
%
Net discount/premium accretion
72

 
8

 
64

 
800.0
%
Deferred financing costs amortization
613

 
611

 
2

 
0.3
%
Interest rate swap amortization
42

 
42

 

 
%
Interest cost capitalization
(347
)
 
(213
)
 
(134
)
 
62.9
%
Right-of-use assets financing amortization
196

 

 
196

 
%
Total interest expense
$
14,181

 
$
13,464

 
$
717

 
5.3
%

Contractual interest expense increased $0.6 million, or 4.5%, primarily due to the following activity:
The Unsecured Credit Facility balance increase accounted for an increase of approximately $0.5 million.
The Term Loan due 2024 balance and interest rate increase accounted for an increase of $0.5 million.
Mortgage notes repayments accounted for a decrease of approximately $0.4 million.


29


Results of Operations
Nine Months Ended September 30, 2019 Compared to Nine Months Ended September 30, 2018
The Company’s results of operations for the nine months ended September 30, 2019 compared to the same period in 2018 were impacted by acquisitions, developments, dispositions, gains on sale, impairments recorded and capital markets transactions.

Revenues
Total revenues increased $11.6 million, or 3.4%, to approximately $348.8 million for the nine months ended September 30, 2019 compared to $337.2 million in the prior year period. This increase is comprised of the following:
 
Nine Months Ended September 30,
 
Change
(Dollars in thousands)
2019
 
2018
 
$
 
%
Property operating
$
307,606

 
$
291,079

 
$
16,527

 
5.7
 %
Single-tenant net lease
33,348

 
36,569

 
(3,221
)
 
(8.8
)%
Straight-line rent
1,833

 
3,599

 
(1,766
)
 
(49.1
)%
Rental income
342,787

 
331,247

 
11,540

 
3.5
 %
Other operating
5,987

 
5,973

 
14

 
0.2
 %
Total Revenues
$
348,774

 
$
337,220

 
$
11,554

 
3.4
 %

Property operating revenue increased $16.5 million, or 5.7%, from the prior year period primarily as a result of the following activity:

Acquisitions in 2018 and 2019 contributed $12.3 million.
Leasing activity, including contractual rent increases, contributed $7.8 million.
Dispositions in 2018 and 2019 resulted in a decrease of $3.6 million.

Single-tenant net lease revenue decreased $3.2 million, or 8.8%, from the prior year period primarily as a result of the following activity:

Dispositions in 2018 resulted in a decrease of $4.0 million.
Leasing activity, including contractual rent increases, contributed $0.8 million.

Straight-line rent revenue decreased $1.8 million, or 49.1%, from the prior year period primarily as a result of the following activity:
Acquisitions in 2018 and 2019 contributed $0.6 million.
Dispositions in 2018 and 2019 resulted in a decrease of $0.1 million.
Leasing activity and contractual rent increases resulted in a decrease of $2.3 million.

Expenses
Property operating expenses increased $6.1 million, or 4.8%, for the nine months ended September 30, 2019 compared to the prior year period primarily as a result of the following activity:

Acquisitions in 2018 and 2019 resulted in an increase of $5.7 million.
Portfolio property tax increased $1.6 million.
Maintenance and repair expense increased $1.0 million.
Administration and legal expense increase $0.8 million.
Utilities expense decreased $0.9 million.
Dispositions in 2018 and 2019 resulted in a decrease of $2.1 million.


30


General and administrative expenses increased approximately $1.2 million, or 4.5%, for the nine months ended September 30, 2019 compared to the prior year period primarily as a result of the following:
The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in a $2.9 million charge for the acceleration of his outstanding nonvested share-based awards and associated taxes.
Compensation expense increased $0.2 million.
Performance-based compensation expense resulted in a decrease of $0.9 million.
Office rent decreased $0.7 million as a result of the acquisition of the Company's headquarters.
Other net decreases, including telecommunication lines, travel and other administrative, of $0.3 million.

Depreciation and amortization expense increased $10.0 million, or 8.2%, for the nine months ended September 30, 2019 compared to the prior year period primarily as a result of the following activity:
Acquisitions in 2018 and 2019 resulted in an increase of $9.1 million.
Various building and tenant improvement expenditures resulted in an increase of $8.2 million.
Dispositions in 2018 and 2019 resulted in a decrease of $3.5 million.
Assets that became fully depreciated resulted in a decrease of $3.8 million.

Other income (expense)
For the nine months ended September 30, 2019, the Company recorded gains of approximately $5.1 million on the sale of six properties. For the nine months ended September 30, 2018, the Company recorded gains of approximately $30.9 million on the sale of 13 properties including a gain recognized on the non-monetary exchange in the second quarter of 2018.

In the second quarter of 2019, the Company recorded $5.6 million of impairment charges related to two properties.

In the second quarter of 2019, the Company recorded approximately $0.8 million of debt issuance costs as a result of the Term Loan modifications. See Note 4 to the Company's Condensed Consolidated Financial Statements for additional information regarding the Term Loan modification.

In the first quarter of 2018, the Company recorded $0.5 million of other income related to the termination fee of a purchase and sale agreement.

Interest expense increased $2.4 million, or 6.2%, for the nine months ended September 30, 2019 compared to the prior year period. The components of interest expense are as follows:
 
Nine Months Ended September 30,
 
Change
(Dollars in thousands)
2019
 
2018
 
$
 
%
Contractual interest
$
40,091

 
$
37,927

 
2,164

 
5.7
%
Net discount/premium accretion
175

 
10

 
165

 
1,650.0
%
Deferred financing costs amortization
1,834

 
1,823

 
11

 
0.6
%
Interest rate swap amortization
126

 
126

 

 
%
Interest cost capitalization
(999
)
 
(684
)
 
(315
)
 
46.1
%
Right-of-use assets financing amortization
392

 

 
392

 
%
Total interest expense
$
41,619

 
$
39,202

 
$
2,417

 
6.2
%

Contractual interest expense increased $2.2 million, or 5.7%, primarily due to the following activity:
The Unsecured Credit Facility balance and interest rate increases accounted for an increase of approximately $2.2 million.
The Term Loan due 2024 balance and interest rate increases accounted for an increase of $0.9 million.
Mortgage notes repayments accounted for a decrease of approximately $0.9 million.


31


Item 3. Quantitative and Qualitative Disclosures about Market Risk
The Company is exposed to market risk in the form of changing interest rates on its debt and mortgage notes. Management uses regular monitoring of market conditions and analysis techniques to manage this risk. During the nine months ended September 30, 2019, there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

Item 4. Controls and Procedures
Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports it files or submits under the Exchange Act.
Changes in Internal Control over Financial Reporting
There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.


32


PART II—OTHER INFORMATION

Item 1. Legal Proceedings
The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Item 1A. Risk Factors
In addition to the other information set forth in this report, an investor should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, which could materially affect the Company’s business, financial condition or future results. The risks, as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, are not the only risks facing the Company. Additional risks and uncertainties not currently known to management or that management currently deems immaterial also may materially, adversely affect the Company’s business, financial condition, operating results or cash flows.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended September 30, 2019, the Company withheld shares of Company common stock to satisfy employee tax withholding obligations payable upon the vesting of nonvested stock, as follows:
Period
Total Number of Shares Purchased
Average Price Paid per Share
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
July 1 - July 31

$



August 1 - August 31




September 1 - September 30
80,490

33.50



Total
80,490

 
 
 


Authorized Repurchases of Equity Securities by the Issuer
On April 30, 2019, the Company’s Board of Directors authorized the repurchase of up to $50 million of outstanding shares of the Company’s common stock either in the open market or through privately negotiated transactions, subject to market conditions, regulatory constraints, and other customary conditions. The Company is not obligated under this authorization to repurchase any specific number of shares. This authorization supersedes all previous stock repurchase authorizations. As of the date of this report, the Company has not repurchased any shares of its common stock under this authorization.

33


Item 6. Exhibits
Exhibit
 
Description
 
 
 
 
 
 
 
 
 
 
 
Exhibit 4.1
 
Specimen Stock Certificate (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exhibit 101.INS
 
The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
 
 
 
Exhibit 101.SCH
 
XBRL Taxonomy Extension Schema Document (furnished electronically herewith)
 
 
 
Exhibit 101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document (furnished electronically herewith)
 
 
 
Exhibit 101.LAB
 
XBRL Taxonomy Extension Labels Linkbase Document (furnished electronically herewith)
 
 
 
Exhibit 101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document (furnished electronically herewith)
 
 
 
Exhibit 101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document (furnished electronically herewith)
_______________

(1)
Filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2018 filed February 13, 2019 and hereby incorporated by reference.
(2)
Filed as an exhibit to the Company’s Registration Statement on Form S-11 (Registration No. 33-60506) filed April 2, 1993 and hereby incorporated by reference.
(3)
Filed as an exhibit to the Company's Current Report on Form 8-K filed May 17, 2001 and hereby incorporated by reference.
(4)
Filed as an exhibit to the Company's Current Report on Form 8-K filed March 26, 2013 and hereby incorporated by reference.
(5)
Filed as an exhibit to the Company's Current Report on Form 8-K filed April 24, 2015 and hereby incorporated by reference.
(6)
Filed as an exhibit to the Company’s Current Report on Form 8-K filed December 11, 2017 and hereby incorporated by reference.





34



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
HEALTHCARE REALTY TRUST INCORPORATED
 
 
 
 
 
 
By:
/s/ J. CHRISTOPHER DOUGLAS
 
 
 
J. Christopher Douglas
Executive Vice President and Chief Financial Officer
 
 
 
 
Date:
November 4, 2019
 
 



35
EX-31.1 2 hr-2019930xex311.htm EXHIBIT 31.1 Exhibit


CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302

Exhibit 31.1
Healthcare Realty Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Todd J. Meredith, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:
November 4, 2019
 
 
 
/s/ TODD J. MEREDITH
 
 
Todd J. Meredith
 
 
President and Chief Executive Officer



EX-31.2 3 hr-2019930xex312.htm EXHIBIT 31.2 Exhibit


CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302
Exhibit 31.2
Healthcare Realty Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, J. Christopher Douglas, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


 

Date:
November 4, 2019
 
 
 
/s/ J. CHRISTOPHER DOUGLAS
 
 
J. Christopher Douglas
 
 
Executive Vice President and Chief Financial Officer



EX-32 4 hr-2019930xex32.htm EXHIBIT 32 Exhibit


CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350 SECTION 906
Exhibit 32
Healthcare Realty Trust Incorporated
Certification Pursuant to
18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Healthcare Realty Trust Incorporated (the “Company”) on Form 10-Q for the quarter ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Todd J. Meredith, President and Chief Executive Officer of the Company, and I, J. Christopher Douglas, Executive Vice President and Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:
November 4, 2019
 
 
 
/s/ TODD J. MEREDITH
 
 
Todd J. Meredith
 
 
President and Chief Executive Officer
 
 
 
 
 
/s/ J. CHRISTOPHER DOUGLAS
 
 
J. Christopher Douglas
 
 
Executive Vice President and Chief Financial Officer



EX-101.SCH 5 hr-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2106100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Commitments and Contingencies - Construction Activity (Details) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004001 - Statement - Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Statement link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Leases - Future Lease Payments Receivable under ASC 840 (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - Leases - Future Minimum Lease Payments under ASC 840 (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Leases - Ground Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Leases - Lease Income (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Leases - Lessor Accounting (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Notes and Bonds Payable link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Notes and Bonds Payable (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Notes and Bonds Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Real Estate Investments link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Real Estate Investments - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Real Estate Investments - Assets Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Real Estate Investments - Dispositions (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Real Estate Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2408406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2408408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2408407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 hr-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 hr-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 hr-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Employee Stock Purchase Plan Employee Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of the Employee Stock Purchase Plan activity Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding and exercisable, beginning of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding and exercisable, end of period (shares) Business Combinations [Abstract] Schedule of Long Lived Assets Held-for-sale [Table] Schedule of Long Lived Assets Held-for-sale [Table] Real Estate Dispositions and Mortgage Note Repayments [Axis] Real Estate Dispositions and Mortgage Note Repayments [Axis] Real Estate Dispositions and Mortgage Note Repayments [Axis] Real Estate Dispositions and Mortgage Note Repayments [Domain] Real Estate Dispositions and Mortgage Note Repayments [Domain] Real Estate Dispositions and Mortgage Note Repayments [Domain] Real Estate Dispositions Real Estate Dispositions [Member] Real Estate Dispositions [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Pennsylvania PENNSYLVANIA Long Lived Assets Held-for-sale [Line Items] Long Lived Assets Held-for-sale [Line Items] Number of properties held for sale Number of Properties Held for Sale Number of properties held for sale. Expected purchase price Real Estate Held for Sale, Sale Price Real Estate Held for Sale, Sale Price Net investment in property held for sale Real Estate Held-for-sale Impairment of assets held-for-sale Impairment of Long-Lived Assets to be Disposed of Summary of acquisitions Schedule of Business Acquisitions, by Acquisition [Table Text Block] Summary of dispositions Asset Dispositions [Table Text Block] Asset Dispositions. Assets held for sale Disposal Groups, Including Discontinued Operations [Table Text Block] Accounting Policies [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Parking Income Parking Income [Member] Parking Income [Member] Rental Lease Guaranty Rental Lease Guaranty [Member] Rental Lease Guaranty [Member] Management Fee Income Management Fee Income [Member] Management Fee Income [Member] Miscellaneous Miscellaneous [Member] Miscellaneous [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Number of major types of revenue Number of Major Types of Revenue Number of Major Types of Revenue Leases [Abstract] 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years 2024 and thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total Operating Leases, Future Minimum Payments Due Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Real estate properties: Real Estate Investment Property, Net [Abstract] Land Land Buildings, improvements and lease intangibles Investment Building and Building Improvements Personal property Personal Property Personal property. Construction in progress Development in Process Land held for development Land Available for Development Real estate properties, Total Real Estate Investment Property, at Cost Less accumulated depreciation and amortization Real Estate Investment Property, Accumulated Depreciation Total real estate properties, net Real Estate Investment Property, Net Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Assets held for sale, net Assets Held-for-sale and Discontinued Operations Net Assets held for sale and discontinued operations, net. Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Financing lease right-of-use assets Finance Lease, Right-of-Use Asset Other assets, net Other Assets Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Liabilities: Liabilities [Abstract] Notes and bonds payable Long-term Debt Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities Liabilities of properties held for sale Disposal Group, Including Discontinued Operation, Liabilities Operating lease liabilities Operating Lease, Liability Financing lease liabilities Finance Lease, Liability Other liabilities Other Liabilities Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders' equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Common stock, $.01 par value per share; 300,000 shares authorized; 131,368 and 125,279 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Cumulative net income attributable to common stockholders Cumulative Net Income Attributable to Common Stockholders Cumulative net income attributable to common stockholders. Cumulative dividends Cumulative Dividends Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Inpatient Rehabilitation Facility Inpatient Rehab [Member] Inpatient rehab. Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal Group, Held-for-sale, Not Discontinued Operations Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Asset Dispositions and Potential Dispositions Assets and Liabilities Related to Held for Sale and Discontinued Operations [Abstract] Assets and liabilities related to held for sale and discontinued operations. Balance Sheet data (as of the period ended): Buildings, improvements and lease intangibles Accumulated depreciation Other assets, net Disposal Group, Including Discontinued Operation, Other Assets Assets held for sale, net Disposal Group, Including Discontinued Operation, Assets Accounts payable and accrued liabilities Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities Liabilities of properties held for sale Restricted Stock Restricted Stock [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Stock Incentive Plan Stock Incentive Plan [Member] Stock Incentive Plan [Member] Summary of the activity under the incentive plans Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based awards, beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based awards, end of period Shares withheld to pay estimated withholding taxes Shares Paid for Tax Withholding for Share Based Compensation Leases Lessee, Finance Leases [Text Block] Leases Lessee, Operating Leases [Text Block] Operating lease cost Lease, Cost [Abstract] Operating lease expense Operating Lease, Cost Variable lease expense Variable Lease, Cost Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Interest on lease liabilities Finance Lease, Interest Expense Lease, Cost Lease, Cost Other information Leases, Operating [Abstract] Operating cash flows outflows related to operating leases Operating Lease, Payments Financing cash flows outflows related to financing leases Finance Lease, Principal Payments Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Weighted-average remaining lease term - operating leases Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term - finance leases Finance Lease, Weighted Average Remaining Lease Term Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - finance leases Finance Lease, Weighted Average Discount Rate, Percent 2019 Operating Leases, Future Minimum Payments Receivable, Current 2020 Operating Leases, Future Minimum Payments Receivable, in Two Years 2021 Operating Leases, Future Minimum Payments Receivable, in Three Years 2022 Operating Leases, Future Minimum Payments Receivable, in Four Years 2023 Operating Leases, Future Minimum Payments Receivable, in Five Years 2024 and thereafter Operating Leases, Future Minimum Payments Receivable, Thereafter Total Operating Leases, Future Minimum Payments Receivable Preferred stock, par value (dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, authorized shares Preferred Stock, Shares Authorized Preferred stock, issued shares Preferred Stock, Shares Issued Preferred stock, outstanding shares Preferred Stock, Shares Outstanding Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Common stock, authorized shares Common Stock, Shares Authorized Common stock, issued shares Common Stock, Shares, Issued Common stock, outstanding shares Common Stock, Shares, Outstanding Debt Disclosure [Abstract] Schedule of Debt Schedule of Debt [Table Text Block] Statement of Comprehensive Income [Abstract] NET INCOME Net Income (Loss) Attributable to Parent Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Interest rate swaps: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract] Reclassification adjustments for losses included in net income (interest expense) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (Losses) gains arising during the period on interest rate swaps Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax COMPREHENSIVE INCOME Comprehensive Income (Loss), Net of Tax, Attributable to Parent Operating Operating Lease Liabilities, Payments Due [Abstract] 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five 2024 and thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total undiscounted lease payments Lessee, Operating Lease, Liability, Payments, Due Discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lease liabilities Financing Finance Lease Liabilities, Payments, Due [Abstract] 2019 Finance Lease, Liability, Payments, Remainder of Fiscal Year 2020 Finance Lease, Liability, Payments, Due Year Two 2021 Finance Lease, Liability, Payments, Due Year Three 2022 Finance Lease, Liability, Payments, Due Year Four 2023 Finance Lease, Liability, Payments, Due Year Five 2024 and thereafter Finance Lease, Liability, Payments, Due after Year Five Total undiscounted lease payments Finance Lease, Liability, Payments, Due Discount Finance Lease, Liability, Undiscounted Excess Amount Lease liabilities Derivative Instruments and Hedging Activities Disclosure [Abstract] Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Derivative [Table] Derivative [Table] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Interest Rate Swap Interest Rate Swap [Member] Active Interest Rate Swap Active Interest Rate Swaps [Member] Active Interest Rate Swaps [Member] Derivative [Line Items] Derivative [Line Items] Number of instruments Number of Interest Rate Derivatives Held Notional amount Derivative, Notional Amount Fixed interest rate Derivative, Fixed Interest Rate Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Commitments and Contingencies Disclosure [Abstract] Other Commitments [Table] Other Commitments [Table] Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Real Estate [Domain] Real Estate [Domain] Medical Office Building Expansion Medical Office Building Expansion [Member] Medical Office Building Expansion [Member] Medical Office Building Medical Office Building [Member] Medical Office Building [Member] North Carolina NORTH CAROLINA Washington WASHINGTON Other Commitments [Line Items] Other Commitments [Line Items] Approximate Square Feet Area of Real Estate Property Total amount funded Construction Activity, Total Amount Funded Construction Activity, Total Amount Funded Estimated amount to complete project Construction Activity, Estimated Remaining Fundings Construction Activity, Estimated Remaining Fundings Future Minimum Lease Payments Receivable Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block] Future Minimum Lease Payments Receivable under ASC 840 Future Minimum Lease Payments Receivable under ASC 840 [Table Text Block] Future Minimum Lease Payments Receivable under ASC 840 [Table Text Block] Future Minimum Operating Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Future Minimum Financing Lease Payments Finance Lease, Liability, Maturity [Table Text Block] Lease Cost Lease, Cost [Table Text Block] Future Minimum Lease Payments under ASC 840 Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Former Executive Chairman Former Executive Chairman [Member] Former Executive Chairman [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Class of Stock [Line Items] Class of Stock [Line Items] Reconciliation of the beginning and ending common stock outstanding Reconciliation of Beginning and Ending Common Stock Outstanding [Roll Forward] Reconciliation of the beginning and ending common stock outstanding. Balance, beginning of period Issuance of common stock Stock Issued During Period, Shares, New Issues Nonvested share-based awards, net of withheld shares (1) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Balance, end of period Shares withheld to pay taxes Accelerated stock compensation expense Allocated Share-based Compensation Expense Ground leases not yet commenced Number of Ground Leases Not Yet Commenced Number of Ground Leases Not Yet Commenced Rental income Operating Leases, Income Statement, Lease Revenue Notes and Bonds Payable Debt Disclosure [Text Block] Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Reconciliation of beginning and ending common stock outstanding Reconciliation of Beginning and Ending Common Stock Outstanding [Table Text Block] Reconciliation of beginning and ending common stock outstanding. Earnings (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of the activity under the Incentive Plan Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Summary of employee stock purchase plan activity Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Income Statement [Abstract] REVENUES Revenues [Abstract] Other operating Revenues Revenues EXPENSES Operating Expenses [Abstract] Property operating Direct Costs of Leased and Rented Property or Equipment General and administrative General and Administrative Expense Acquisition and pursuit costs Acquisition Costs, Period Cost Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Bad debts, net of recoveries Provision for Loan and Lease Losses Total Expenses Operating Expenses OTHER INCOME (EXPENSE) Nonoperating Income (Expense) [Abstract] Gain on sales of real estate assets Gains (Losses) on Sales of Investment Real Estate Interest expense Interest Expense Impairment of real estate assets Impairment of Real Estate Interest and other income (expense), net Other Nonoperating Income (Expense) Total other income (expense) Nonoperating Income (Expense) NET INCOME Basic earnings per common share (in dollars per share) Earnings Per Share, Basic Diluted earnings per common share (in dollars per share) Earnings Per Share, Diluted Weighted average common shares outstanding - basic Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding - diluted Weighted Average Number of Shares Outstanding, Diluted Dividends declared, per common share, during the period (in dollars per share) Common Stock, Dividends, Per Share, Declared Fair Value Disclosures [Abstract] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying Value Reported Value Measurement [Member] Fair Value Estimate of Fair Value Measurement [Member] Notes and bonds payable Debt Instrument, Fair Value Disclosure Disaggreation of revenue Disaggregation of Revenue [Table Text Block] Business Overview: Business Overview [Abstract] Business Overview [Abstract] Gross investment amount, total Investment in Real Estate Properties and Mortgage Notes Investment in real estate properties and mortgage notes. Number of real estate properties Number of Real Estate Investments Number of real estate investments. Number of states that the Company owns real estate in, whole units Real Estate Investments Property Owned in Number of States Real estate investments property owned in number of states. Square footage of owned real estate properties Approximate square feet for which Nationwide property management services provided by company Approximate Square Feet Provided by Company Approximate square feet for which Nationwide property management services provided by company Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Weighted Average Remaining Term Weighted Average [Member] Minimum Minimum [Member] Maximum Maximum [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Number of properties subject to ground leases Number of Properties Subject to Ground Leases Number of properties held for sale, excluded from ground leases Number of Properties Held for Sale, Excluded from Ground Leases Number of Properties Held for Sale, Excluded from Ground Leases Square feet subject to ground leases Square Feet Subject to Ground Leases Square Feet Subject to Ground Leases Ground lease, initial term Lessee, Operating Lease, Term of Contract Term of lease, including renewals Lessee, Operating Lease, Term of Contract, Including Renewals Lessee, Operating Lease, Term of Contract, Including Renewals Number of prepaid ground leases Number of Ground Leases Prepaid Number of Ground Leases Prepaid Amortization of prepaid rent Amortization of Prepaid Rent Amortization of Prepaid Rent Number of non-prepaid ground leases Number of Ground Leases, Excluding Prepaid Leases Number of Ground Leases, Excluding Prepaid Leases Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable Fair Value, by Balance Sheet Grouping [Table Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Interest Expense Interest Expense [Member] Interest Rate Swaps Interest Rate Contract [Member] Settled Interest Rate Swaps Gain (Loss) Recognized in OCI on Derivative Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax (Gain) Loss Reclassified from Accumulated OCI into Income Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Business Overview Nature of Operations [Policy Text Block] Nature Of Operations Policy. Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates in the Condensed Consolidated Financial Statements Use of Estimates, Policy [Policy Text Block] Revenue from Contract with Customers (Topic 606) Revenue from Contract with Customer [Policy Text Block] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Weighted average Common Shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average Common Shares outstanding Weighted Average Number of Shares Issued, Basic Nonvested shares Weighted Average Number of Shares, Restricted Stock Weighted average Common Shares—Basic Dilutive effect of employee stock purchase plan Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan Incremental common shares attributable to dilutive effect of employee stock purchase plan. Weighted average Common Shares outstanding—Diluted Net Income Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Dividends paid on nonvested share-based awards Dividends, Share-based Compensation Net income applicable to common stockholders Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Statement of Stockholders' Equity [Abstract] Dividend per share to common Stockholders (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Equity Offering Equity Offering [Member] Equity Offering [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Stock Issuance Program [Axis] Stock Issuance Program [Axis] Stock Issuance Program [Axis] Stock Issuance Program [Domain] Stock Issuance Program [Domain] [Domain] for Stock Issuance Program [Axis] At The Market Equity Offering Program At The Market Equity Offering Program [Member] At The Market Equity Offering Program [Member] Issuance of common stock (shares) Shares issued, price per share Shares Issued, Price Per Share Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Shares issued during period, price per share Shares Issued During Period, Price Per Share Shares Issued During Period, Price Per Share Number of authorized shares remaining under offering program Number of Authorized Shares Remaining Under Offering Program Number of Authorized Shares Remaining Under Offering Program Dividends declared per common share, during the period (in dollars per share) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other liabilities Other Liabilities [Member] Liability derivatives Derivative Liability, Fair Value, Gross Liability Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Other amortization Amortization of Other Deferred Charges Share-based compensation Share-based Compensation Amortization of straight-line rent receivable (lessor) Straight-line Rent Receivable Straight-line rent receivable. Amortization of straight-line rent on operating leases (lessee) Straight-line Rent Liability Straight-line rent liability. Gain on sales of real estate assets Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation Impairment of real estate assets Impairment of Real Estate, Continuing and Discontinued Operations Impairment of Real Estate, Continuing and Discontinued Operations Loss (income) from unconsolidated joint ventures Income (Loss) from Equity Method Investments Distributions from unconsolidated joint ventures Proceeds from Equity Method Investment, Distribution Provision for bad debts, net Provision for Doubtful Accounts Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other assets, including right-of-use-assets Increase (Decrease) in Other Operating Assets Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Acquisitions of real estate Payments to Acquire Real Estate Development of real estate Payments to Develop Real Estate Assets Additional long-lived assets Payments for Capital Improvements Proceeds from sales of real estate assets Proceeds from Sale of Property Held-for-sale Proceeds from notes receivable repayments Proceeds from Sale and Collection of Notes Receivable Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Net borrowings on unsecured credit facility Proceeds from (Repayments of) Lines of Credit Borrowings on term loan Proceeds from Issuance of Other Long-term Debt Repayments on notes and bonds payable Repayments of Debt Dividends paid Payments of Ordinary Dividends, Common Stock Net proceeds from issuance of common stock Common stock redemptions Payments for Repurchase of Common Stock Debt issuance and assumption costs Payments of Debt Issuance Costs Payments made on finance leases Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Supplemental Cash Flow Information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Invoices accrued for construction, tenant improvements and other capitalized costs Capital Expenditures Incurred but Not yet Paid Mortgage notes payable assumed upon acquisition (adjusted to fair value) Notes Assumed Capitalized interest Interest Paid, Capitalized, Investing Activities Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of Real Estate Dispositions [Table] Schedule of Real Estate Dispositions [Table] Schedule of real estate dispositions. Erie, Pennsylvania Tucson, AZ (3) ARIZONA Virginia Beach, VA (4) VIRGINIA San Antonio, TX San Antonio, Texas [Member] San Antonio, Texas [Member] Real Estate Dispositions [Line Items] Real Estate Dispositions [Line Items] Real estate dispositions. Disposal Date Disposal Date Sales price Disposition Sales Price Disposition Sales Price Closing Adjustments Closing Adjustments Disposed Entity Closing Adjustments Disposed Entity, including closing costs and other adjustments to the sales price. Net Proceeds Proceeds from Sale of Real Estate Held-for-investment Net Real Estate Investment Real Estate Investment Net Disposed of During Period Real estate investment net disposed of during the Period. Real Estate Other Real Estate Other Real estate other. Gain/(Impairment) Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Square footage Area Covered Under Real Estate Investment Sold in Measurement Units Area covered under real estate investment sold in measurement units. Purchase price Net investment New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Other Assets Other Assets [Member] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Ground lease, discount rate Lessee, Operating Lease, Discount Rate Transfers to operating lease, right-of-use assets Transfers to Operating Lease, Right-of-use Assets Transfers to Operating Lease, Right-of-use Assets Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Washington, D.C. (4) DISTRICT OF COLUMBIA Indianapolis, IN (5) INDIANA Atlanta, GA GEORGIA Dallas, TX Dallas, Texas [Member] Dallas, Texas [Member] Seattle, WA Houston, TX Houston, Texas [Member] Houston, Texas [Member] Oklahoma City, OK OKLAHOMA Los Angeles, CA (6) CALIFORNIA Raleigh, North Carolina Real Estate Acquisitions and Mortgage Note Financing [Axis] Real Estate Acquisitions and Mortgage Note Financing [Axis] Real Estate Acquisitions and Mortgage Note Financing. Real Estate Acquisitions and Mortgage Note Financing [Domain] Real Estate Acquisitions and Mortgage Note Financing [Domain] Real Estate Acquisitions and Mortgage Note Financing. Real Estate Acquisition Real Estate Acquisitions [Member] Real estate acquisitions. Business Acquisition [Line Items] Business Acquisition [Line Items] Date Acquired Business Acquisition, Effective Date of Acquisition Purchase price Business Combination, Consideration Transferred Cash consideration Payments to Acquire Businesses, Gross Real Estate Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other Square footage Business Acquisition Purchase Price Allocation Square Footage Business Acquisition Purchase Price Allocation Square Footage. Number of properties acquired Number of Properties Acquired Number of Properties Acquired Above-market lease intangibles Finite-Lived Intangible Asset, Off-market Lease, Favorable, Gross Prepaid ground leases Ground Leases, Net Below-market lease intangible Below Market Lease, Net Statement [Table] Statement [Table] Additional Paid-In Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Cumulative Net Income Cumulative Net Income [Member] Cumulative Net Income [Member]. Cumulative Dividends Cumulative Dividends [Member] Cumulative Dividends [Member]. Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Stock Repurchased and Retired During Period, Shares Stock Repurchased and Retired During Period, Shares Common stock redemptions Stock Repurchased and Retired During Period, Value Share-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Reclassification adjustments for losses included in net income (interest expense) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Losses arising during the period on interest rate swaps Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax Dividends to common stockholders Dividends, Common Stock, Cash Ending balance Cover page. Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Real Estate Investments Acquisitions and Dispositions [Text Block] Acquisitions and dispositions. Future Lease Payments Receivable [Abstract] Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract] 2019 Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year 2020 Lessor, Operating Lease, Payments to be Received, Two Years 2021 Lessor, Operating Lease, Payments to be Received, Three Years 2022 Lessor, Operating Lease, Payments to be Received, Four Years 2023 Lessor, Operating Lease, Payments to be Received, Five Years 2024 and thereafter Lessor, Operating Lease, Payments to be Received, Thereafter Total Lessor, Operating Lease, Payments to be Received Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR London Interbank Offered Rate (LIBOR) [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of Credit Line of Credit [Member] Medium-term Notes Medium-term Notes [Member] Senior Notes Senior Notes [Member] Mortgages Mortgages [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] $700 million Unsecured Credit Facility Unsecured Credit Facility [Member] Unsecured Credit Facility [Member] $200 million Unsecured Term Loan Facility, net of issuance costs (1) Term Loan due 2024 [Member] Term Loan due 2024 [Member] Senior Notes due 2023, net of discount and issuance costs Senior Notes due 2023 [Member] Senior Notes due 2023 [Member] Senior Notes due 2025, net of discount and issuance costs (3) Senior Notes due 2025 [Member] Senior Notes due 2025 [Member] Senior Notes due 2028, net of discount and issuance costs Senior Notes due 2028 [Member] Senior Notes due 2028 [Member] Mortgage notes payable, net of discounts and issuance costs and including premiums Mortgage Notes Payable, Net [Member] Mortgage Notes Payable, Net [Member] Amended and Restated Unsecured Credit Facility Due 2023 Amended and Restated Unsecured Credit Facility Due 2023 [Member] Amended and Restated Unsecured Credit Facility Due 2023 [Member] Unsecured Term Loan due 2022 Term Loan due 2022 [Member] Term Loan due 2022 [Member] $150 million Unsecured Term Loan due 2026 Term Loan due 2026 [Member] Term Loan due 2026 [Member] Term Loan Agreement Term Loan Agreement [Member] Term Loan Agreement [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Notes and bonds payable Term-loan facility Debt Instrument, Face Amount Loss on forward starting interest rate swap agreement recognized in OCI Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Outstanding principal repaid Extinguishment of Debt, Amount Area of real estate property Maximum borrowing capacity on unsecured credit facility Line of Credit Facility, Maximum Borrowing Capacity Credit facility margin rate Line of Credit Facility Basis Spread on Variable Rate Line of credit facility basis spread on variable rate. Commitment fee Line of Credit Facility, Commitment Fee Percentage Debt issuance costs Debt Issuance Costs, Line of Credit Arrangements, Gross Term of loan facility Debt Instrument, Term Term loan margin rate Debt Instrument, Basis Spread on Variable Rate Delayed draw feature period Debt Instrument, Delayed Draw Feature Period Debt Instrument, Delayed Draw Feature Period Ticking fee Debt Instrument, Ticking Fee Percentage Debt Instrument, Ticking Fee Percentage Up front fees paid to lenders Debt Issuance Costs, Gross Up front fees to be amortized Debt Issuance Costs, Net Amortization of up front lender fees Amortization of Debt Issuance Costs EX-101.PRE 9 hr-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R29.htm IDEA: XBRL DOCUMENT v3.19.3
Real Estate Investments - Dispositions (Details)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 28, 2019
USD ($)
Aug. 01, 2019
USD ($)
ft²
Apr. 09, 2019
USD ($)
ft²
May 31, 2019
USD ($)
Jun. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
ft²
Oct. 25, 2019
USD ($)
ft²
Real Estate Dispositions [Line Items]              
Sales price           $ 15.2  
Closing Adjustments           (1.1)  
Net Proceeds           14.1  
Net Real Estate Investment           8.7  
Real Estate Other           0.4  
Gain/(Impairment)           $ 5.0  
Square footage | ft²           87,483  
Erie, Pennsylvania              
Real Estate Dispositions [Line Items]              
Impairment of assets held-for-sale       $ 5.2      
Real Estate Dispositions | Erie, Pennsylvania              
Real Estate Dispositions [Line Items]              
Purchase price           $ 1.3  
Net investment           $ 14.0  
Real Estate Dispositions | Tucson, AZ (3)              
Real Estate Dispositions [Line Items]              
Disposal Date     Apr. 09, 2019        
Sales price     $ 13.0        
Closing Adjustments     (0.9)        
Net Proceeds     12.1        
Net Real Estate Investment     6.9        
Real Estate Other     0.4        
Gain/(Impairment)     $ 4.8        
Square footage | ft²     67,345        
Real Estate Dispositions | Virginia Beach, VA (4)              
Real Estate Dispositions [Line Items]              
Impairment of assets held-for-sale         $ 0.4    
Disposal Date   Aug. 01, 2019          
Sales price   $ 1.3          
Closing Adjustments   (0.1)          
Net Proceeds   1.2          
Net Real Estate Investment   1.2          
Real Estate Other   0.0          
Gain/(Impairment)   $ 0.0          
Square footage | ft²   10,000          
Real Estate Dispositions | San Antonio, TX              
Real Estate Dispositions [Line Items]              
Disposal Date Aug. 28, 2019            
Sales price     $ 0.9        
Closing Adjustments     (0.1)        
Net Proceeds $ 0.8            
Net Real Estate Investment     0.6        
Real Estate Other     $ 0.0        
Gain/(Impairment) $ 0.2            
Square footage | ft²     10,138        
Subsequent Event | Real Estate Dispositions | Erie, Pennsylvania              
Real Estate Dispositions [Line Items]              
Sales price             $ 14.0
Net Real Estate Investment             $ 1.3
Square footage | ft²             90,123
XML 11 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies (Details)
ft² in Millions, $ in Billions
Sep. 30, 2019
USD ($)
ft²
state
property
Business Overview:  
Gross investment amount, total | $ $ 4.2
Number of real estate properties | property 204
Number of states that the Company owns real estate in, whole units | state 26
Square footage of owned real estate properties 15.4
Approximate square feet for which Nationwide property management services provided by company 11.2
XML 12 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Notes and Bonds Payable (Tables)
9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
Schedule of Debt
The table below details the Company’s notes and bonds payable. 
 
Maturity
Dates
 
Balance as of
 
Effective Interest Rate as of

(Dollars in thousands)
September 30, 2019

 
December 31, 2018

September 30, 2019

$700 million Unsecured Credit Facility
5/23
 
$
322,000

 
$
262,000

 
2.92
%
$200 million Unsecured Term Loan Facility, net of issuance costs (1)
5/24
 
198,957

 
149,183

 
3.29
%
$150 million Unsecured Term Loan due 2026 (2)
6/26
 

 

 
N/A

Senior Notes due 2023, net of discount and issuance costs
4/23
 
248,434

 
248,117

 
3.95
%
Senior Notes due 2025, net of discount and issuance costs (3)
5/25
 
248,460

 
248,278

 
4.08
%
Senior Notes due 2028, net of discount and issuance costs
1/28
 
295,536

 
295,198

 
3.84
%
Mortgage notes payable, net of discounts and issuance costs and including premiums
7/20-5/40
 
130,532

 
143,208

 
4.81
%
 
 
 
$
1,443,919

 
$
1,345,984

 
 

______
(1)
The effective interest rate includes the impact of interest rate swaps on $175.0 million at a weighted average rate of 2.29% (plus the applicable margin rate, currently 100 basis points).
(2)
As of September 30, 2019, there were no outstanding loans under the $150.0 million unsecured term loan due June 2026. This term loan has a delayed draw feature that allows the Company until February 2020 to draw against the commitments.
(3)
The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.

XML 13 R40.htm IDEA: XBRL DOCUMENT v3.19.3
Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)
Sep. 30, 2019
USD ($)
swap_agreement
May 15, 2019
USD ($)
swap_agreement
Apr. 12, 2019
USD ($)
swap_agreement
Active Interest Rate Swap      
Derivative [Line Items]      
Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months $ 1,300,000    
Cash Flow Hedging | Designated as Hedging Instrument | Interest Rate Swap      
Derivative [Line Items]      
Number of instruments | swap_agreement 8 2 2
Notional amount $ 175,000,000.0 $ 50,000,000.0 $ 50,000,000.0
Fixed interest rate   2.13% 2.33%
XML 14 R44.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2019
Sep. 30, 2018
Reconciliation of the beginning and ending common stock outstanding      
Balance, beginning of period   125,279,000  
Balance, end of period 131,368,000 131,368,000  
Common Stock      
Reconciliation of the beginning and ending common stock outstanding      
Balance, beginning of period   125,279,455 125,131,593
Issuance of common stock   6,099,012 26,203
Nonvested share-based awards, net of withheld shares (1)   (10,269) 121,659
Balance, end of period 131,368,198 131,368,198 125,279,455
Former Executive Chairman      
Reconciliation of the beginning and ending common stock outstanding      
Shares withheld to pay taxes 80,490    
Accelerated stock compensation expense $ 2.9    
XML 15 R48.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan - shares
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Summary of the Employee Stock Purchase Plan activity        
Outstanding and exercisable, beginning of period (shares) 363,218 350,535 328,533 318,100
Granted (shares) 0 0 235,572 203,836
Exercised (shares) (9,927) (2,531) (28,943) (13,236)
Forfeited (shares) (11,762) (9,583) (51,559) (34,489)
Expired (shares) 0 0 (142,074) (135,790)
Outstanding and exercisable, end of period (shares) 341,529 338,421 341,529 338,421
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
REVENUES        
Rental income $ 117,740,000 $ 111,452,000 $ 342,787,000 $ 331,247,000
Other operating 2,059,000 2,010,000 5,987,000 5,973,000
Revenues 119,799,000 113,462,000 348,774,000 337,220,000
EXPENSES        
Property operating 46,777,000 44,135,000 133,790,000 127,691,000
General and administrative 10,802,000 8,504,000 27,157,000 25,977,000
Acquisition and pursuit costs 501,000 141,000 1,227,000 538,000
Depreciation and amortization 45,137,000 42,061,000 131,725,000 121,764,000
Bad debts, net of recoveries   (62,000)   42,000
Total Expenses 103,217,000 94,779,000 293,899,000 276,012,000
OTHER INCOME (EXPENSE)        
Gain on sales of real estate assets 200,000 1,288,000 5,065,000 30,879,000
Interest expense (14,181,000) (13,464,000) (41,619,000) (39,202,000)
Impairment of real estate assets 0   (5,610,000)  
Interest and other income (expense), net 0 41,000 (736,000) 571,000
Total other income (expense) (13,981,000) (12,135,000) (42,900,000) (7,752,000)
NET INCOME $ 2,601,000 $ 6,548,000 $ 11,975,000 $ 53,456,000
Basic earnings per common share (in dollars per share) $ 0.02 $ 0.05 $ 0.08 $ 0.42
Diluted earnings per common share (in dollars per share) $ 0.02 $ 0.05 $ 0.08 $ 0.42
Weighted average common shares outstanding - basic 128,090,074 123,299,809 126,570,895 123,280,753
Weighted average common shares outstanding - diluted 128,168,684 123,351,956 126,656,585 123,335,516
Dividends declared, per common share, during the period (in dollars per share) $ 0.30 $ 0.30 $ 0.90 $ 0.90
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
OPERATING ACTIVITIES    
Net income $ 11,975 $ 53,456
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 131,725 121,764
Other amortization 2,279 2,113
Share-based compensation 10,141 8,090
Amortization of straight-line rent receivable (lessor) (1,833) (3,599)
Amortization of straight-line rent on operating leases (lessee) 1,159 1,147
Gain on sales of real estate assets (5,065) (30,879)
Impairment of real estate assets 5,610  
Loss (income) from unconsolidated joint ventures 16 (15)
Distributions from unconsolidated joint ventures 277 182
Provision for bad debts, net   42
Changes in operating assets and liabilities:    
Other assets, including right-of-use-assets (6,740) (6,891)
Accounts payable and accrued liabilities 3,220 5,908
Other liabilities 5,709 (638)
Net cash provided by operating activities 158,473 150,680
INVESTING ACTIVITIES    
Acquisitions of real estate (271,575) (67,445)
Development of real estate (19,152) (21,059)
Additional long-lived assets (45,902) (59,802)
Proceeds from sales of real estate assets 14,151 64,271
Proceeds from notes receivable repayments   8
Net cash used in investing activities (322,478) (84,027)
FINANCING ACTIVITIES    
Net borrowings on unsecured credit facility 60,000 56,000
Borrowings on term loan 50,000  
Repayments on notes and bonds payable (12,663) (3,808)
Dividends paid (115,237) (112,694)
Net proceeds from issuance of common stock 192,514 459
Common stock redemptions (2,343) (2,673)
Debt issuance and assumption costs (4,589) (125)
Payments made on finance leases (249)  
Net cash provided by (used in) financing activities 167,433 (62,841)
Increase in cash and cash equivalents 3,428 3,812
Cash and cash equivalents at beginning of period 8,381 6,215
Cash and cash equivalents at end of period 11,809 10,027
Supplemental Cash Flow Information:    
Interest paid 37,946 30,463
Invoices accrued for construction, tenant improvements and other capitalized costs 10,702 5,680
Mortgage notes payable assumed upon acquisition (adjusted to fair value)   7,995
Capitalized interest $ 999 $ 684
XML 18 R30.htm IDEA: XBRL DOCUMENT v3.19.3
Real Estate Investments - Assets Held for Sale (Details)
$ in Millions
1 Months Ended
May 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
property
Dec. 31, 2018
property
Long Lived Assets Held-for-sale [Line Items]      
Number of properties held for sale | property   2 1
Pennsylvania      
Long Lived Assets Held-for-sale [Line Items]      
Impairment of assets held-for-sale $ 5.2    
Real Estate Dispositions | Pennsylvania      
Long Lived Assets Held-for-sale [Line Items]      
Expected purchase price   $ 14.0  
Net investment in property held for sale   $ 1.3  
XML 19 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 242 372 1 false 65 0 false 10 false false R1.htm 0001000 - Document - Cover Page Sheet http://healthcarerealty.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Statement Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement Condensed Consolidated Statements of Equity (Unaudited) Statement Statements 6 false false R7.htm 1004001 - Statement - Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedParenthetical Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 2101100 - Disclosure - Summary of Significant Accounting Policies Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Real Estate Investments Sheet http://healthcarerealty.com/role/RealEstateInvestments Real Estate Investments Notes 10 false false R11.htm 2103100 - Disclosure - Leases Sheet http://healthcarerealty.com/role/Leases Leases Notes 11 false false R12.htm 2104100 - Disclosure - Notes and Bonds Payable Notes http://healthcarerealty.com/role/NotesAndBondsPayable Notes and Bonds Payable Notes 12 false false R13.htm 2105100 - Disclosure - Derivative Financial Instruments Sheet http://healthcarerealty.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 13 false false R14.htm 2106100 - Disclosure - Commitments and Contingencies Sheet http://healthcarerealty.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 2108100 - Disclosure - Stockholders' Equity Sheet http://healthcarerealty.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 2109100 - Disclosure - Fair Value of Financial Instruments Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 16 false false R17.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 2302301 - Disclosure - Real Estate Investments (Tables) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsTables Real Estate Investments (Tables) Tables http://healthcarerealty.com/role/RealEstateInvestments 19 false false R20.htm 2303301 - Disclosure - Leases (Tables) Sheet http://healthcarerealty.com/role/LeasesTables Leases (Tables) Tables http://healthcarerealty.com/role/Leases 20 false false R21.htm 2304301 - Disclosure - Notes and Bonds Payable (Tables) Notes http://healthcarerealty.com/role/NotesAndBondsPayableTables Notes and Bonds Payable (Tables) Tables http://healthcarerealty.com/role/NotesAndBondsPayable 21 false false R22.htm 2305301 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://healthcarerealty.com/role/DerivativeFinancialInstruments 22 false false R23.htm 2308301 - Disclosure - Stockholders' Equity (Tables) Sheet http://healthcarerealty.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://healthcarerealty.com/role/StockholdersEquity 23 false false R24.htm 2309301 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://healthcarerealty.com/role/FairValueOfFinancialInstruments 24 false false R25.htm 2401403 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies - Revenue Recognition (Details) Details 26 false false R27.htm 2401405 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) Details 27 false false R28.htm 2402402 - Disclosure - Real Estate Investments - Acquisitions (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails Real Estate Investments - Acquisitions (Details) Details 28 false false R29.htm 2402403 - Disclosure - Real Estate Investments - Dispositions (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails Real Estate Investments - Dispositions (Details) Details 29 false false R30.htm 2402404 - Disclosure - Real Estate Investments - Assets Held for Sale (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails Real Estate Investments - Assets Held for Sale (Details) Details 30 false false R31.htm 2402405 - Disclosure - Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) Details 31 false false R32.htm 2403402 - Disclosure - Leases - Lease Income (Details) Sheet http://healthcarerealty.com/role/LeasesLeaseIncomeDetails Leases - Lease Income (Details) Details 32 false false R33.htm 2403403 - Disclosure - Leases - Lessor Accounting (Details) Sheet http://healthcarerealty.com/role/LeasesLessorAccountingDetails Leases - Lessor Accounting (Details) Details 33 false false R34.htm 2403404 - Disclosure - Leases - Future Lease Payments Receivable under ASC 840 (Details) Sheet http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details Leases - Future Lease Payments Receivable under ASC 840 (Details) Details 34 false false R35.htm 2403405 - Disclosure - Leases - Ground Leases (Details) Sheet http://healthcarerealty.com/role/LeasesGroundLeasesDetails Leases - Ground Leases (Details) Details 35 false false R36.htm 2403406 - Disclosure - Leases - Future Minimum Lease Payments (Details) Sheet http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails Leases - Future Minimum Lease Payments (Details) Details 36 false false R37.htm 2403407 - Disclosure - Leases - Lease Cost (Details) Sheet http://healthcarerealty.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 37 false false R38.htm 2403408 - Disclosure - Leases - Future Minimum Lease Payments under ASC 840 (Details) Sheet http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details Leases - Future Minimum Lease Payments under ASC 840 (Details) Details 38 false false R39.htm 2404402 - Disclosure - Notes and Bonds Payable (Details) Notes http://healthcarerealty.com/role/NotesAndBondsPayableDetails Notes and Bonds Payable (Details) Details http://healthcarerealty.com/role/NotesAndBondsPayableTables 39 false false R40.htm 2405402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Details 40 false false R41.htm 2405403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Details 41 false false R42.htm 2405404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Details 42 false false R43.htm 2406401 - Disclosure - Commitments and Contingencies - Construction Activity (Details) Sheet http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails Commitments and Contingencies - Construction Activity (Details) Details 43 false false R44.htm 2408402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) Details 44 false false R45.htm 2408403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails Stockholders' Equity (Stock Transactions - Narrative) (Details) Details http://healthcarerealty.com/role/StockholdersEquityTables 45 false false R46.htm 2408406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) Details 46 false false R47.htm 2408407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) Sheet http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) Details 47 false false R48.htm 2408408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) Sheet http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) Details 48 false false R49.htm 2409402 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables 49 false false All Reports Book All Reports hr-2019930singlesource.htm hr-20190930.xsd hr-20190930_cal.xml hr-20190930_def.xml hr-20190930_lab.xml hr-20190930_pre.xml hr-2019930xex311.htm hr-2019930xex312.htm hr-2019930xex32.htm http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2018-01-31 true true XML 20 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Future Lease Payments Receivable under ASC 840 (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Leases [Abstract]  
2019 $ 326,441
2020 279,211
2021 235,660
2022 201,072
2023 163,978
2024 and thereafter 476,673
Total $ 1,683,035
XML 21 R38.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Future Minimum Lease Payments under ASC 840 (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Leases [Abstract]  
2019 $ 5,288
2020 5,260
2021 5,238
2022 5,207
2023 5,224
2024 and thereafter 323,533
Total $ 349,750
XML 22 R17.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Business Overview
Business Overview
Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2019, the Company had gross investments of approximately $4.2 billion in 204 real estate properties located in 26 states totaling approximately 15.4 million square feet. The Company provided leasing and property management services to approximately 11.2 million square feet nationwide.
Basis of Presentation
Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2018. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2019 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.
Use of Estimates in the Condensed Consolidated Financial Statements
Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Revenue from Contract with Customers (Topic 606)
Revenue from Contracts with Customers (Topic 606)
The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance.

Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Type of Revenue
 
2019
 
2018
 
2019
 
2018
Parking income
 
$
1,935

 
$
1,752

 
$
5,538

 
$
5,197

Rental lease guaranty
 

 
168

 
128

 
488

Management fee income
 
69

 
68

 
201

 
205

Miscellaneous
 
55

 
22

 
120

 
83

 
 
$
2,059

 
$
2,010

 
$
5,987

 
$
5,973



The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.
New Accounting Pronouncements

New Accounting Pronouncements
Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11
In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, "Leases." In January 2018, FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," in July 2018, FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements," and in December 2018, FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These accounting standard updates are collectively referred to as "Topic 842."
Topic 842 provides several practical expedients that the Company elected. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, (b) the lessor practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately and (c) the lessee practical expedient not to separate certain non-lease components from the associated lease component.
For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. The Company's ground leases executed or assumed prior to the adoption of Topic 842 continue to be accounted for as operating leases and will not result in a materially different ground lease expense. However, each ground lease executed by the Company after the adoption of Topic 842 will be evaluated to determine if it is an operating or finance lease. If the lease is to be accounted for as a finance lease, ground lease expense would be accounted for using the effective interest method instead of the straight-line method over the term of the lease, which would result in higher ground lease expense in the earlier years of a ground lease when compared to the straight-line method. Leases in which the Company is the lessee are primarily ground leases, but also includes management office leases in third party buildings and certain copier and postage machine leases. The terms of the ground leases generally range from 40 to 99 years with a weighted average lease term remaining of 52.5 years, excluding renewal options. The Company's discount rates, which approximates the Company's incremental borrowing rate, ranged from 3.4% for leases expiring in 2019 to 6.2% for leases expiring in 2115. The Company utilized a third party to assist in determining the discount rates for its ground leases. The discount rates consider the general economic environment and factor in various financing and asset specific adjustments so that the discount rate is appropriate for the intended use of the underlying lease. As of January 1, 2019, the Company recognized the present value of its lease payments and a corresponding lease liability of $91.7 million. In addition, the Company reclassified $45.0 million of prepaid ground leases and below-market lease intangibles from the Other assets line item, $1.9 million of above-market lease intangibles from the Other liabilities line and $8.4 million of straight-line rent from the Accounts payable and accrued liabilities line item to the Operating lease right-of-use assets line item on the Condensed Consolidated Balance Sheets.
For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, are generally accounted for under Topic 606 and separated from the lease payments. However, the Company elected the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The combined component is accounted for under Topic 842. Lease related receivables, which include accounts receivable and accrued straight-line rent receivables, are reduced for revenue reserves and are recognized as a reduction to rental income. The adoption of Topic 842, where the Company is the lessor, did not have a material impact on the Company's Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2019.
The new standard was effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company elected to choose the prospective optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 was adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. See Note 3 to the Company's Condensed Consolidated Financial Statements for additional disclosures.
Accounting Standards Update No. 2016-13 and No. 2018-19
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of this topic. Instead, impairment of these receivables should be accounted for in accordance with Topic 842, Leases. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is evaluating the impact from the adoption of this new standard on the Condensed Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-04
In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Condensed Consolidated Financial Statements and related notes from the adoption of this standard.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.19.3
Derivative Financial Instruments
9 Months Ended
Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial Instruments
Risk Management Objective of Using Derivatives
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the
amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the
receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.

For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) ("AOCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt.

On April 12, 2019, the Company entered into two interest rate swaps totaling $50.0 million to fix the one-month LIBOR portion of the cost of borrowing to a rate of 2.33%. These derivatives are being used to hedge variable cash flows associated with variable-rate debt.

On May 15, 2019, the Company entered into two interest rate swaps totaling $50.0 million to fix the one-month LIBOR portion of the cost of borrowing to a rate of 2.13%. These derivatives are being used to hedge variable cash flows associated with variable-rate debt.

As of September 30, 2019, the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Derivative Instrument
 
Number of Instruments

 
Notional Amount
(in millions)
Interest rate swaps
 
8

 
$175.0


Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of September 30, 2019.
 
Balance at September 30, 2019
(Dollars in thousands)
Balance Sheet Location
 
Fair Value

Derivatives designated as hedging instruments
 
 
 
Interest rate swaps
Other liabilities
 
$
7,533

Total derivatives designated as hedging instruments
 
 
$
7,533



Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)
The table below presents the effect of cash flow hedge accounting on AOCI during the three and nine months ended September 30, 2019 and 2018 related to the Company's outstanding interest rate swaps.
 
Gain (Loss) Recognized in AOCI on Derivative
 
Loss Reclassified from AOCI into Income
 
Three Months Ended September 30,
Three Months Ended September 30,
(Dollars in thousands)
2019

 
2018

2019

 
2018

Interest rate swaps
$
(2,341
)
 
$
374

Interest expense
$
18

 
$
53

Settled interest rate swaps

 

Interest expense
42

 
42

 
$
(2,341
)
 
$
374

Total interest expense
$
60

 
$
95

 
Gain (Loss) Recognized in AOCI on Derivative
 
(Gain) Loss Reclassified from AOCI into Income
 
Nine Months Ended September 30,
Nine Months Ended September 30,
(Dollars in thousands)
2019

 
2018

2019

 
2018

Interest rate swaps
$
(7,642
)
 
$
1,403

Interest expense
$
(52
)
 
$
243

Settled interest rate swaps

 

Interest expense
126

 
126

 
$
(7,642
)
 
$
1,403

Total interest expense
$
74


$
369


Credit-risk-related Contingent Features
The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.

The Company estimates that $1.3 million will be reclassified from AOCI to interest expense over the next 12 months.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Business Overview
Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2019, the Company had gross investments of approximately $4.2 billion in 204 real estate properties located in 26 states totaling approximately 15.4 million square feet. The Company provided leasing and property management services to approximately 11.2 million square feet nationwide.

Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2018. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2019 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.

Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Revenue from Contracts with Customers (Topic 606)
The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance.

Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Type of Revenue
 
2019
 
2018
 
2019
 
2018
Parking income
 
$
1,935

 
$
1,752

 
$
5,538

 
$
5,197

Rental lease guaranty
 

 
168

 
128

 
488

Management fee income
 
69

 
68

 
201

 
205

Miscellaneous
 
55

 
22

 
120

 
83

 
 
$
2,059

 
$
2,010

 
$
5,987

 
$
5,973



The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.

New Accounting Pronouncements
Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11
In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, "Leases." In January 2018, FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," in July 2018, FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements," and in December 2018, FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These accounting standard updates are collectively referred to as "Topic 842."
Topic 842 provides several practical expedients that the Company elected. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, (b) the lessor practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately and (c) the lessee practical expedient not to separate certain non-lease components from the associated lease component.
For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. The Company's ground leases executed or assumed prior to the adoption of Topic 842 continue to be accounted for as operating leases and will not result in a materially different ground lease expense. However, each ground lease executed by the Company after the adoption of Topic 842 will be evaluated to determine if it is an operating or finance lease. If the lease is to be accounted for as a finance lease, ground lease expense would be accounted for using the effective interest method instead of the straight-line method over the term of the lease, which would result in higher ground lease expense in the earlier years of a ground lease when compared to the straight-line method. Leases in which the Company is the lessee are primarily ground leases, but also includes management office leases in third party buildings and certain copier and postage machine leases. The terms of the ground leases generally range from 40 to 99 years with a weighted average lease term remaining of 52.5 years, excluding renewal options. The Company's discount rates, which approximates the Company's incremental borrowing rate, ranged from 3.4% for leases expiring in 2019 to 6.2% for leases expiring in 2115. The Company utilized a third party to assist in determining the discount rates for its ground leases. The discount rates consider the general economic environment and factor in various financing and asset specific adjustments so that the discount rate is appropriate for the intended use of the underlying lease. As of January 1, 2019, the Company recognized the present value of its lease payments and a corresponding lease liability of $91.7 million. In addition, the Company reclassified $45.0 million of prepaid ground leases and below-market lease intangibles from the Other assets line item, $1.9 million of above-market lease intangibles from the Other liabilities line and $8.4 million of straight-line rent from the Accounts payable and accrued liabilities line item to the Operating lease right-of-use assets line item on the Condensed Consolidated Balance Sheets.
For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, are generally accounted for under Topic 606 and separated from the lease payments. However, the Company elected the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The combined component is accounted for under Topic 842. Lease related receivables, which include accounts receivable and accrued straight-line rent receivables, are reduced for revenue reserves and are recognized as a reduction to rental income. The adoption of Topic 842, where the Company is the lessor, did not have a material impact on the Company's Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2019.
The new standard was effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company elected to choose the prospective optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 was adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. See Note 3 to the Company's Condensed Consolidated Financial Statements for additional disclosures.
Accounting Standards Update No. 2016-13 and No. 2018-19
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of this topic. Instead, impairment of these receivables should be accounted for in accordance with Topic 842, Leases. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is evaluating the impact from the adoption of this new standard on the Condensed Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-04
In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Condensed Consolidated Financial Statements and related notes from the adoption of this standard.
XML 25 R5.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Statement of Comprehensive Income [Abstract]        
NET INCOME $ 2,601 $ 6,548 $ 11,975 $ 53,456
Interest rate swaps:        
Reclassification adjustments for losses included in net income (interest expense) 60 95 74 369
(Losses) gains arising during the period on interest rate swaps (2,341) 374 (7,642) 1,403
Total other comprehensive income (loss) (2,281) 469 (7,568) 1,772
COMPREHENSIVE INCOME $ 320 $ 7,017 $ 4,407 $ 55,228
ZIP 26 0000899749-19-000092-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000899749-19-000092-xbrl.zip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end XML 27 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Cover Page - shares
9 Months Ended
Sep. 30, 2019
Oct. 31, 2019
Cover page.    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2019  
Document Transition Report false  
Entity File Number 001-11852  
Entity Registrant Name HEALTHCARE REALTY TRUST INCORPORATED  
Entity Incorporation, State or Country Code MD  
Entity Tax Identification Number 62-1507028  
Entity Address, Address Line One 3310 West End Avenue, Suite 700  
Entity Address, City or Town Nashville  
Entity Address, State or Province TN  
Entity Address, Postal Zip Code 37203  
City Area Code 615  
Local Phone Number 269-8175  
Title of 12(b) Security Common stock, $0.01 par value per share  
Trading Symbol HR  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   133,736,079
Entity Central Index Key 0000899749  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q3  
Amendment Flag false  

XML 28 R39.htm IDEA: XBRL DOCUMENT v3.19.3
Notes and Bonds Payable (Details)
3 Months Ended 9 Months Ended
Nov. 04, 2019
May 31, 2019
USD ($)
Apr. 10, 2019
USD ($)
ft²
Sep. 30, 2019
USD ($)
ft²
Jun. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
ft²
Dec. 31, 2018
USD ($)
Debt Instrument [Line Items]              
Notes and bonds payable       $ 1,443,919,000   $ 1,443,919,000 $ 1,345,984,000
Area of real estate property | ft²       15,400,000   15,400,000  
Line of Credit | $700 million Unsecured Credit Facility              
Debt Instrument [Line Items]              
Notes and bonds payable       $ 322,000,000   $ 322,000,000 262,000,000
Effective interest rate       2.92%   2.92%  
Line of Credit | Amended and Restated Unsecured Credit Facility Due 2023              
Debt Instrument [Line Items]              
Maximum borrowing capacity on unsecured credit facility   $ 700,000,000.0          
Debt issuance costs   3,500,000          
Medium-term Notes | $200 million Unsecured Term Loan Facility, net of issuance costs (1)              
Debt Instrument [Line Items]              
Notes and bonds payable       $ 198,957,000   $ 198,957,000 149,183,000
Term-loan facility   200,000,000.0          
Effective interest rate       3.29%   3.29%  
Term loan margin rate       1.00%   1.00%  
Medium-term Notes | Unsecured Term Loan due 2022              
Debt Instrument [Line Items]              
Term-loan facility   150,000,000.0          
Medium-term Notes | $150 million Unsecured Term Loan due 2026              
Debt Instrument [Line Items]              
Notes and bonds payable       $ 0   $ 0  
Term-loan facility   $ 150,000,000.0   $ 150,000,000.0   150,000,000.0  
Term of loan facility   7 years          
Term loan margin rate       1.60%      
Delayed draw feature period   9 months          
Ticking fee       0.20%      
Medium-term Notes | Term Loan Agreement              
Debt Instrument [Line Items]              
Up front fees paid to lenders   $ 1,800,000          
Up front fees to be amortized   $ 1,000,000.0          
Amortization of up front lender fees         $ 800,000    
Senior Notes | Senior Notes due 2023, net of discount and issuance costs              
Debt Instrument [Line Items]              
Notes and bonds payable       $ 248,434,000   $ 248,434,000 248,117,000
Effective interest rate       3.95%   3.95%  
Senior Notes | Senior Notes due 2025, net of discount and issuance costs (3)              
Debt Instrument [Line Items]              
Notes and bonds payable       $ 248,460,000   $ 248,460,000 248,278,000
Effective interest rate       4.08%   4.08%  
Senior Notes | Senior Notes due 2028, net of discount and issuance costs              
Debt Instrument [Line Items]              
Notes and bonds payable       $ 295,536,000   $ 295,536,000 295,198,000
Effective interest rate       3.84%   3.84%  
Mortgages | Mortgage notes payable, net of discounts and issuance costs and including premiums              
Debt Instrument [Line Items]              
Notes and bonds payable       $ 130,532,000   $ 130,532,000 $ 143,208,000
Effective interest rate     5.00% 4.81%   4.81%  
Outstanding principal repaid     $ 8,900,000        
Area of real estate property | ft²     52,813        
Interest Rate Swap | Medium-term Notes | $200 million Unsecured Term Loan Facility, net of issuance costs (1)              
Debt Instrument [Line Items]              
Notional amount       $ 175,000,000.0   $ 175,000,000.0  
Fixed interest rate       2.29%   2.29%  
Interest Rate Swap | Senior Notes | Senior Notes due 2025, net of discount and issuance costs (3)              
Debt Instrument [Line Items]              
Loss on forward starting interest rate swap agreement recognized in OCI           $ 1,700,000  
Minimum | Line of Credit | Amended and Restated Unsecured Credit Facility Due 2023              
Debt Instrument [Line Items]              
Commitment fee   0.125%          
Minimum | Medium-term Notes | $200 million Unsecured Term Loan Facility, net of issuance costs (1)              
Debt Instrument [Line Items]              
Term loan margin rate   0.85%          
Minimum | Medium-term Notes | $150 million Unsecured Term Loan due 2026              
Debt Instrument [Line Items]              
Term loan margin rate   1.45%          
Ticking fee   0.125%          
Maximum | Line of Credit | Amended and Restated Unsecured Credit Facility Due 2023              
Debt Instrument [Line Items]              
Commitment fee   0.30%          
Maximum | Medium-term Notes | $200 million Unsecured Term Loan Facility, net of issuance costs (1)              
Debt Instrument [Line Items]              
Term loan margin rate   1.65%          
Maximum | Medium-term Notes | $150 million Unsecured Term Loan due 2026              
Debt Instrument [Line Items]              
Term loan margin rate   2.40%          
Ticking fee   0.30%          
LIBOR | Line of Credit | Amended and Restated Unsecured Credit Facility Due 2023              
Debt Instrument [Line Items]              
Credit facility margin rate       0.90%      
LIBOR | Minimum | Line of Credit | Amended and Restated Unsecured Credit Facility Due 2023              
Debt Instrument [Line Items]              
Credit facility margin rate   0.775%          
LIBOR | Maximum | Line of Credit | Amended and Restated Unsecured Credit Facility Due 2023              
Debt Instrument [Line Items]              
Credit facility margin rate   1.45%          
Subsequent Event | Line of Credit | Amended and Restated Unsecured Credit Facility Due 2023              
Debt Instrument [Line Items]              
Commitment fee 0.20%            
XML 29 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Balance Sheet data (as of the period ended):    
Land $ 267,803 $ 230,206
Buildings, improvements and lease intangibles 3,915,308 3,675,415
Real estate properties, Total 4,262,698 3,974,071
Accumulated depreciation (1,106,387) (1,015,174)
Total real estate properties, net 3,156,311 2,958,897
Liabilities of properties held for sale 300 587
Inpatient Rehabilitation Facility | Disposal Group, Held-for-sale, Not Discontinued Operations    
Balance Sheet data (as of the period ended):    
Land 1,125 1,125
Buildings, improvements and lease intangibles 34,426 18,231
Real estate properties, Total 35,551 19,356
Accumulated depreciation (30,706) (10,657)
Total real estate properties, net 4,845 8,699
Other assets, net 444 573
Assets held for sale, net 5,289 9,272
Accounts payable and accrued liabilities 93 450
Other liabilities 207 137
Liabilities of properties held for sale $ 300 $ 587
XML 30 R35.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Ground Leases (Details)
ft² in Millions, $ in Millions
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2019
USD ($)
property
Lease
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
ft²
property
Lease
Sep. 30, 2018
USD ($)
Dec. 31, 2018
ft²
property
Lease
Lessee, Lease, Description [Line Items]          
Number of properties subject to ground leases | property 108   108   107
Number of properties held for sale, excluded from ground leases | property 1   1    
Square feet subject to ground leases | ft²     9.0   8.8
Number of prepaid ground leases | Lease     46    
Amortization of prepaid rent | $ $ 0.2 $ 0.1 $ 0.4 $ 0.4  
Number of non-prepaid ground leases | Lease 62   62   60
Weighted Average Remaining Term          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term         53 years 10 months 24 days
Minimum          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term         50 years
Term of lease, including renewals         75 years
Maximum          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term         75 years
Term of lease, including renewals         100 years
Accounting Standards Update 2016-02 | Weighted Average Remaining Term          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term 52 years 6 months   52 years 6 months    
Accounting Standards Update 2016-02 | Minimum          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term 40 years   40 years    
Accounting Standards Update 2016-02 | Maximum          
Lessee, Lease, Description [Line Items]          
Ground lease, initial term 99 years   99 years    
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value of Financial Instruments
9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.

Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments.

Borrowings under the Unsecured Credit Facility and the Term Loan Due 2024 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.
 
Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.

Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.

The table below details the fair values and carrying values for notes and bonds payable at September 30, 2019 and December 31, 2018.
 
September 30, 2019
 
December 31, 2018
(Dollars in millions)
Carrying Value
 
Fair Value
 
Carrying Value
 
Fair Value
Notes and bonds payable (1)
$
1,443.9

 
$
1,468.5

 
$
1,346.0

 
$
1,326.5


______
(1)
Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.
XML 32 R12.htm IDEA: XBRL DOCUMENT v3.19.3
Notes and Bonds Payable
9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
Notes and Bonds Payable Notes and Bonds Payable
The table below details the Company’s notes and bonds payable. 
 
Maturity
Dates
 
Balance as of
 
Effective Interest Rate as of

(Dollars in thousands)
September 30, 2019

 
December 31, 2018

September 30, 2019

$700 million Unsecured Credit Facility
5/23
 
$
322,000

 
$
262,000

 
2.92
%
$200 million Unsecured Term Loan Facility, net of issuance costs (1)
5/24
 
198,957

 
149,183

 
3.29
%
$150 million Unsecured Term Loan due 2026 (2)
6/26
 

 

 
N/A

Senior Notes due 2023, net of discount and issuance costs
4/23
 
248,434

 
248,117

 
3.95
%
Senior Notes due 2025, net of discount and issuance costs (3)
5/25
 
248,460

 
248,278

 
4.08
%
Senior Notes due 2028, net of discount and issuance costs
1/28
 
295,536

 
295,198

 
3.84
%
Mortgage notes payable, net of discounts and issuance costs and including premiums
7/20-5/40
 
130,532

 
143,208

 
4.81
%
 
 
 
$
1,443,919

 
$
1,345,984

 
 

______
(1)
The effective interest rate includes the impact of interest rate swaps on $175.0 million at a weighted average rate of 2.29% (plus the applicable margin rate, currently 100 basis points).
(2)
As of September 30, 2019, there were no outstanding loans under the $150.0 million unsecured term loan due June 2026. This term loan has a delayed draw feature that allows the Company until February 2020 to draw against the commitments.
(3)
The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.

Changes in Debt Structure
On April 10, 2019, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.00% per annum with an outstanding principal of $8.9 million. The mortgage note encumbered a 52,813 square foot property in Washington.

On May 31, 2019, the Company amended and restated its $700.0 million unsecured credit facility due 2020 (the "Unsecured Credit Facility") to extend the maturity date from July 2020 to May 2023. Amounts outstanding under the Unsecured Credit Facility bear interest at LIBOR plus an applicable margin, which depends on the Company's credit ratings, ranging from 0.775% to 1.45% (currently 0.90%). In addition, the Company pays a facility fee per annum on the aggregate amount of commitments ranging from 0.125% to 0.30% (currently 0.20%). In connection with the amendment, the Company paid up front fees to the lenders and other costs of approximately $3.5 million, which were capitalized and are being amortized over the term of the Unsecured Credit Facility.

Also, on May 31, 2019, the Company amended and restated its term loan agreement (the "Term Loan") with a syndicate of lenders. The amended agreement extended the maturity date of the Company's unsecured term loan due 2022 to May 2024 (the "Term Loan due 2024") and increased the loan amount from $150.0 million to $200.0 million. In addition, the amended agreement added a $150.0 million seven-year term loan facility (the "Term Loan due 2026"). The Term Loan due 2024 bears interest at LIBOR plus an applicable margin ranging from 0.85% to 1.65% (1.00% at September 30, 2019) based upon the Company's unsecured debt ratings. The Term Loan due 2026 has a delayed draw feature that allows the Company up to nine months to draw against the commitments. As of September 30, 2019, no loans were outstanding under the Term Loan due 2026. Loans outstanding under the Term Loan due 2026 will bear interest at a rate equal to LIBOR plus a margin ranging from 1.45% to 2.40% (1.60% at September 30, 2019). Committed amounts that remain undrawn are subject to a ticking fee ranging from 0.125% to 0.30% per annum (0.20% at September 30, 2019). In connection with the amendment, the Company paid up front fees to the lenders of approximately $1.8 million, of which $1.0 million were capitalized and are being amortized over the respective term of the term loans and $0.8 million were expensed during the second quarter of 2019.
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value of Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable
The table below details the fair values and carrying values for notes and bonds payable at September 30, 2019 and December 31, 2018.
 
September 30, 2019
 
December 31, 2018
(Dollars in millions)
Carrying Value
 
Fair Value
 
Carrying Value
 
Fair Value
Notes and bonds payable (1)
$
1,443.9

 
$
1,468.5

 
$
1,346.0

 
$
1,326.5


______
(1)
Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Leases (Tables)
9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Future Minimum Lease Payments Receivable
Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of September 30, 2019 were as follows (in thousands):
2019
$
91,501

2020
340,549

2021
292,541

2022
252,315

2023
210,559

2024 and thereafter
572,767

 
$
1,760,232


Future Minimum Lease Payments Receivable under ASC 840
Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 were as follows (in thousands):
2019
$
326,441

2020
279,211

2021
235,660

2022
201,072

2023
163,978

2024 and thereafter
476,673

 
$
1,683,035


Future Minimum Operating Lease Payments
The Company’s future lease payments (primarily for its 62 non-prepaid ground leases) as of September 30, 2019 were as follows (in thousands):

 
 
Operating

 
Financing

2019
$
999

 
$
107

2020
4,816

 
611

2021
4,846

 
619

2022
4,877

 
628

2023
4,915

 
637

2024 and thereafter
312,712

 
74,767

Total undiscounted lease payments
333,165

 
77,369

Discount
(241,809
)
 
(63,064
)
Lease liabilities
$
91,356

 
$
14,305



Future Minimum Financing Lease Payments
The Company’s future lease payments (primarily for its 62 non-prepaid ground leases) as of September 30, 2019 were as follows (in thousands):

 
 
Operating

 
Financing

2019
$
999

 
$
107

2020
4,816

 
611

2021
4,846

 
619

2022
4,877

 
628

2023
4,915

 
637

2024 and thereafter
312,712

 
74,767

Total undiscounted lease payments
333,165

 
77,369

Discount
(241,809
)
 
(63,064
)
Lease liabilities
$
91,356

 
$
14,305



Lease Cost
The following table provides details of the Company's total lease expense for the three and nine months ended September 30, 2019 (in thousands):
 
 
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2019
 
Operating lease cost
 
 
 
 
 
Operating lease expense
 
$
1,169

 
$
3,448

 
Variable lease expense
 
845

 
2,380

 
Finance lease cost
 
 
 
 
 
Amortization of right-of-use assets
 
51

 
101

 
Interest on lease liabilities
 
196

 
392

 
Total lease expense
 
$
2,261

 
$
6,321

 
 
 
 
 
 
 
Other information
 
 
 
 
 
Operating cash flows outflows related to operating leases
 
$
1,313

 
$
5,461

 
Financing cash flows outflows related to financing leases
 
$
107

 
$
249

 
Right-of-use assets obtained in exchange for new finance lease liabilities
 
$

 
$
14,294

 
 
 
 
 
 
 
Weighted-average remaining lease term (excluding renewal options) - operating leases
 
49.7
 
 
 
Weighted-average remaining lease term (excluding renewal options) -finance leases
 
70.1
 
 
 
Weighted-average discount rate - operating leases
 
5.7%
 
 
 
Weighted-average discount rate - finance leases
 
5.5%
 
 
 

Future Minimum Lease Payments under ASC 840
The Company’s future minimum lease payments (primarily for its 60 non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands):
 
2019
$
5,288

2020
5,260

2021
5,238

2022
5,207

2023
5,224

2024 and thereafter
323,533

 
$
349,750


XML 35 R28.htm IDEA: XBRL DOCUMENT v3.19.3
Real Estate Investments - Acquisitions (Details)
$ in Thousands
9 Months Ended
Oct. 31, 2019
USD ($)
ft²
Sep. 30, 2019
USD ($)
ft²
property
Sep. 26, 2019
USD ($)
Aug. 01, 2019
USD ($)
ft²
Jun. 26, 2019
USD ($)
ft²
Jun. 14, 2019
USD ($)
ft²
Jun. 11, 2019
USD ($)
ft²
Jun. 10, 2019
USD ($)
ft²
Apr. 02, 2019
USD ($)
ft²
Mar. 28, 2019
USD ($)
ft²
property
Lease
Sep. 30, 2019
USD ($)
ft²
property
Dec. 31, 2018
property
Business Acquisition [Line Items]                        
Number of properties subject to ground leases | property   108                 108 107
Financing lease liabilities   $ 14,305                 $ 14,305  
Real Estate Acquisition                        
Business Acquisition [Line Items]                        
Purchase price                     273,900  
Cash consideration                     271,200  
Real Estate   276,200                 276,200  
Other   $ (5,000)                 $ (5,000)  
Square footage | ft²   769,282                 769,282  
Medical Office Building | Washington, D.C. (4) | Real Estate Acquisition                        
Business Acquisition [Line Items]                        
Date Acquired                   Mar. 28, 2019    
Purchase price                   $ 46,000    
Cash consideration                   45,900    
Real Estate                   50,200    
Other                   $ (4,300)    
Square footage | ft²                   158,338    
Number of properties acquired | property                   2    
Number of properties subject to ground leases | Lease                   2    
Financing lease liabilities   $ 14,300                 $ 14,300  
Above-market lease intangibles   $ 5,200                 $ 5,200  
Medical Office Building | Indianapolis, IN (5) | Real Estate Acquisition                        
Business Acquisition [Line Items]                        
Date Acquired                   Mar. 28, 2019    
Purchase price                   $ 47,000    
Cash consideration                   44,800    
Real Estate                   43,700    
Other                   $ 1,100    
Square footage | ft²                   143,499    
Prepaid ground leases                   $ 800    
Below-market lease intangible                   $ 900    
Medical Office Building | Atlanta, GA | Real Estate Acquisition                        
Business Acquisition [Line Items]                        
Date Acquired                 Apr. 02, 2019      
Purchase price                 $ 28,000      
Cash consideration                 28,000      
Real Estate                 28,000      
Other                 $ 0      
Square footage | ft²                 47,963      
Medical Office Building | Dallas, TX | Real Estate Acquisition                        
Business Acquisition [Line Items]                        
Date Acquired               Jun. 10, 2019        
Purchase price               $ 17,000        
Cash consideration               16,700        
Real Estate               17,000        
Other               $ (300)        
Square footage | ft²               89,990        
Medical Office Building | Seattle, WA | Real Estate Acquisition                        
Business Acquisition [Line Items]                        
Date Acquired         Jun. 28, 2019 Jun. 14, 2019 Jun. 11, 2019          
Purchase price         $ 30,500 $ 19,000 $ 7,700          
Cash consideration         30,400 19,100 7,800          
Real Estate         30,600 19,500 7,800          
Other         $ (200) $ (400) $ 0          
Square footage | ft²         78,288 47,255 29,870          
Medical Office Building | Houston, TX | Real Estate Acquisition                        
Business Acquisition [Line Items]                        
Date Acquired       Aug. 01, 2019                
Purchase price       $ 13,500                
Cash consideration       13,500                
Real Estate       13,500                
Other       $ 0                
Square footage | ft²       29,903                
Medical Office Building | Oklahoma City, OK | Real Estate Acquisition                        
Business Acquisition [Line Items]                        
Date Acquired     Sep. 26, 2019                  
Purchase price     $ 4,100                  
Cash consideration     4,100                  
Real Estate     4,100                  
Other     $ 0                  
Square footage | ft²   28,542                 28,542  
Medical Office Building | Los Angeles, CA (6) | Real Estate Acquisition                        
Business Acquisition [Line Items]                        
Date Acquired   Sep. 30, 2019                    
Purchase price   $ 61,100                    
Cash consideration   60,900                    
Real Estate   61,800                 $ 61,800  
Other   $ (900)                 $ (900)  
Square footage | ft²   115,634                 115,634  
Number of properties acquired | property   2                    
Subsequent Event | Medical Office Building | Dallas, TX | Real Estate Acquisition                        
Business Acquisition [Line Items]                        
Purchase price $ 20,100                      
Square footage | ft² 48,192                      
Subsequent Event | Medical Office Building | Raleigh, North Carolina | Real Estate Acquisition                        
Business Acquisition [Line Items]                        
Purchase price $ 21,600                      
Square footage | ft² 57,730                      
EXCEL 36 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 37 R49.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value of Financial Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2019
Dec. 31, 2018
Carrying Value    
Derivative [Line Items]    
Notes and bonds payable $ 1,443.9 $ 1,346.0
Fair Value    
Derivative [Line Items]    
Notes and bonds payable $ 1,468.5 $ 1,326.5
XML 38 R41.htm IDEA: XBRL DOCUMENT v3.19.3
Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) - Designated as Hedging Instrument - Interest Rate Swap
$ in Thousands
Sep. 30, 2019
USD ($)
Derivative [Line Items]  
Liability derivatives $ 7,533
Other liabilities  
Derivative [Line Items]  
Liability derivatives $ 7,533
XML 39 R45.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity (Stock Transactions - Narrative) (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 10 Months Ended
Oct. 29, 2019
Mar. 19, 2019
Oct. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Oct. 31, 2019
Dec. 31, 2018
Class of Stock [Line Items]                      
Common stock, par value (dollars per share)       $ 0.01       $ 0.01     $ 0.01
Proceeds from issuance of common stock               $ 192,514,000 $ 459,000    
Dividends declared per common share, during the period (in dollars per share)       $ 0.30     $ 0.30 $ 0.90 $ 0.90    
At The Market Equity Offering Program                      
Class of Stock [Line Items]                      
Issuance of common stock (shares)       2,191,522 0 135,265          
Proceeds from issuance of common stock       $ 71,600,000   $ 4,300,000          
Shares issued during period, price per share       $ 33.15   $ 32.36          
Subsequent Event                      
Class of Stock [Line Items]                      
Dividends declared per common share, during the period (in dollars per share) $ 0.30                    
Subsequent Event | At The Market Equity Offering Program                      
Class of Stock [Line Items]                      
Issuance of common stock (shares)     2,367,837             4,694,624  
Proceeds from issuance of common stock     $ 78,200,000             $ 153,700,000  
Shares issued during period, price per share     $ 33.52             $ 33.31  
Number of authorized shares remaining under offering program     1,174,073             1,174,073  
Equity Offering                      
Class of Stock [Line Items]                      
Issuance of common stock (shares)   3,737,500                  
Common stock, par value (dollars per share)   $ 0.01                  
Shares issued, price per share   $ 31.40                  
Proceeds from issuance of common stock   $ 115,800,000                  
Minimum | At The Market Equity Offering Program                      
Class of Stock [Line Items]                      
Shares issued during period, price per share       32.62   32.01          
Minimum | Subsequent Event | At The Market Equity Offering Program                      
Class of Stock [Line Items]                      
Shares issued during period, price per share     $ 33.17             $ 32.01  
Maximum | At The Market Equity Offering Program                      
Class of Stock [Line Items]                      
Shares issued during period, price per share       $ 33.77   $ 32.86          
Maximum | Subsequent Event | At The Market Equity Offering Program                      
Class of Stock [Line Items]                      
Shares issued during period, price per share     $ 33.74             $ 33.77  
XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 R7.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) - $ / shares
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Statement of Stockholders' Equity [Abstract]        
Dividend per share to common Stockholders (in dollars per share) $ 0.30 $ 0.30 $ 0.90 $ 0.90
XML 42 R3.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Preferred stock, par value (dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized shares 50,000,000 50,000,000
Preferred stock, issued shares 0 0
Preferred stock, outstanding shares 0 0
Common stock, par value (dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares 300,000,000 300,000,000
Common stock, issued shares 131,368,000 125,279,000
Common stock, outstanding shares 131,368,000 125,279,000
XML 43 R18.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Disaggreation of revenue Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Type of Revenue
 
2019
 
2018
 
2019
 
2018
Parking income
 
$
1,935

 
$
1,752

 
$
5,538

 
$
5,197

Rental lease guaranty
 

 
168

 
128

 
488

Management fee income
 
69

 
68

 
201

 
205

Miscellaneous
 
55

 
22

 
120

 
83

 
 
$
2,059

 
$
2,010

 
$
5,987

 
$
5,973


XML 44 R14.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies
9 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Proceedings
The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Redevelopment Activity
The Company redeveloped a medical office building in Charlotte, North Carolina, which includes a 40,278 square foot vertical expansion. As of September 30, 2019, the Company had funded approximately $9.8 million towards the redevelopment of this property. The Company expects to fund approximately $2.2 million for additional tenant improvements associated with this project. The first tenant took occupancy during the second quarter of 2019.

Development Activity
The Company began the development of a 151,000 square foot medical office building in Seattle, Washington during 2017. As of September 30, 2019, the Company had funded approximately $44.3 million towards the development. The Company expects to fund an additional amount of approximately $19.8 million to complete this project. The Company expects the first tenant to take occupancy in the first quarter of 2020.
XML 45 R10.htm IDEA: XBRL DOCUMENT v3.19.3
Real Estate Investments
9 Months Ended
Sep. 30, 2019
Business Combinations [Abstract]  
Real Estate Investments Real Estate Investments
2019 Acquisitions
The following table details the Company's acquisitions for the nine months ended September 30, 2019:
(Dollars in millions)
Type (1)
 
Date
Acquired
 
Purchase Price

 
Cash
Consideration
(2)

 
Real
Estate

 
Other (3)

 
Square
Footage
(Unaudited)

Washington, D.C. (4)
MOB
 
3/28/19
 
$
46.0

 
$
45.9

 
$
50.2

 
$
(4.3
)
 
158,338

Indianapolis, IN (5)
MOB
 
3/28/19
 
47.0

 
44.8

 
43.7

 
1.1

 
143,499

Atlanta, GA
MOB
 
4/2/19
 
28.0

 
28.0

 
28.0

 

 
47,963

Dallas, TX
MOB
 
6/10/19
 
17.0

 
16.7

 
17.0

 
(0.3
)
 
89,990

Seattle, WA
MOB
 
6/11/19
 
7.7

 
7.8

 
7.8

 

 
29,870

Seattle, WA
MOB
 
6/14/19
 
19.0

 
19.1

 
19.5

 
(0.4
)
 
47,255

Seattle, WA
MOB
 
6/28/19
 
30.5

 
30.4

 
30.6

 
(0.2
)
 
78,288

Houston, TX
MOB
 
8/1/19
 
13.5

 
13.5

 
13.5

 

 
29,903

Oklahoma City, OK
MOB
 
9/26/19
 
4.1

 
4.1

 
4.1

 

 
28,542

Los Angeles, CA (6)
MOB
 
9/30/19
 
61.1

 
60.9

 
61.8

 
(0.9
)
 
115,634

 
 
 
 
 
$
273.9

 
$
271.2

 
$
276.2

 
$
(5.0
)
 
769,282

______
(1)
MOB = medical office building.
(2)
Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
(3)
Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.
(4)
Includes two properties. The Company assumed two ground leases in connection with this acquisition that are classified as financing leases. The present value of future lease payments totaling $14.3 million was recorded on the Company's Condensed Consolidated Balance Sheets under the caption Finance lease liabilities. In addition, the right-of-use assets were partially offset by $5.2 million of above-market lease intangibles included in Other.
(5)
The Company assumed a prepaid ground lease totaling $0.8 million and recorded a below-market lease intangible totaling $0.9 million in connection with this acquisition that is classified as an operating lease that is included in Other.
(6)
Includes two properties.

Subsequent Acquisitions
On October 31, 2019, the Company acquired a 57,730 square foot medical office building in Raleigh, North Carolina for a purchase price of $21.6 million.

On October 31, 2019, the Company acquired a 48,192 square foot medical office building in Dallas, Texas for a purchase price of $20.1 million.

2019 Real Estate Asset Dispositions
The following table details the Company's dispositions for the nine months ended September 30, 2019:
(Dollars in millions)
Type (1)
 
Date
Disposed
 
Sales Price
 
Closing Adjustments
 
Net
Proceeds
 
Net Real
Estate
Investment
 
Other
(including
receivables)
 (2)
 
Gain/
(Impairment)
 
Square
Footage
(
Unaudited)
Tucson, AZ (3)
MOB
 
4/9/19
 
$
13.0

 
$
(0.9
)
 
$
12.1

 
$
6.9

 
$
0.4

 
$
4.8

 
67,345

Virginia Beach, VA (4)
MOB
 
8/1/19
 
1.3

 
(0.1
)
 
1.2

 
1.2

 

 

 
10,000

San Antonio, TX
MOB
 
8/28/19
 
0.9

 
(0.1
)
 
0.8

 
0.6

 

 
0.2

 
10,138

Total dispositions
 
$
15.2

 
$
(1.1
)
 
$
14.1

 
$
8.7

 
$
0.4

 
$
5.0

 
87,483

______
(1)
MOB = medical office building.
(2)
Includes straight-line rent receivables, leasing commissions and lease inducements.
(3)
Includes four properties sold to a single purchaser.
(4)
The Company reclassified this property to held for sale during the second quarter of 2019 and recorded an impairment charge of $0.4 million based on the sales price less estimated costs to sell.

Subsequent Disposition
On October 25, 2019, the Company disposed of a 90,123 square foot inpatient rehabilitation facility located in Erie, Pennsylvania following the ground lessor's exercise of a purchase option. The purchase price, determined by an appraisal process, was $14.0 million and the Company's net investment in the building as of September 30, 2019 was approximately $1.3 million.

Assets Held for Sale
As of September 30, 2019 and December 31, 2018, the Company had two properties and one property, respectively, classified as held for sale. The following is a description of the two properties held for sale as of September 30, 2019:

In March 2019, the Company reclassified an inpatient rehabilitation facility to held for sale upon notification that the ground lessor exercised a purchase option. The purchase price, determined by an appraisal process, was $14.0 million and the current net investment is approximately $1.3 million. This property was sold on October 25, 2019.

In May 2019, the Company accepted an offer from a third party to purchase a former long-term acute care facility located in Pittsburgh, Pennsylvania and recorded an impairment charge totaling $5.2 million based on the sales price less estimated costs to sell. This property was reclassified to held for sale in 2017.

The table below reflects the assets and liabilities of the properties classified as held for sale as of September 30, 2019 and December 31, 2018:
(Dollars in thousands)
September 30,
2019
 
December 31,
2018
Balance Sheet data:
 
 
 
Land
$
1,125

 
$
1,125

Buildings, improvements and lease intangibles
34,426

 
18,231

 
35,551

 
19,356

Accumulated depreciation
(30,706
)
 
(10,657
)
Real estate assets held for sale, net
4,845

 
8,699

Other assets, net
444

 
573

Assets held for sale, net
$
5,289

 
$
9,272

 
 
 
 
Accounts payable and accrued liabilities
$
93

 
$
450

Other liabilities
207

 
137

Liabilities of properties held for sale
$
300

 
$
587


XML 46 R33.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Lessor Accounting (Details)
$ in Thousands
Sep. 30, 2019
USD ($)
Future Lease Payments Receivable [Abstract]  
2019 $ 91,501
2020 340,549
2021 292,541
2022 252,315
2023 210,559
2024 and thereafter 572,767
Total $ 1,760,232
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Lease Cost (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
Operating lease cost    
Operating lease expense $ 1,169 $ 3,448
Variable lease expense 845 2,380
Amortization of right-of-use assets 51 101
Interest on lease liabilities 196 392
Lease, Cost 2,261 6,321
Other information    
Operating cash flows outflows related to operating leases 1,313 5,461
Financing cash flows outflows related to financing leases 107 249
Right-of-use assets obtained in exchange for new operating lease liabilities $ 0  
Right-of-use assets obtained in exchange for new finance lease liabilities   $ 14,294
Weighted-average remaining lease term - operating leases 49 years 8 months 12 days 49 years 8 months 12 days
Weighted-average remaining lease term - finance leases 70 years 1 month 6 days 70 years 1 month 6 days
Weighted-average discount rate - operating leases 5.70% 5.70%
Weighted-average discount rate - finance leases 5.50% 5.50%
XML 48 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies - Revenue Recognition (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
revenue_type
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
revenue_type
Sep. 30, 2018
USD ($)
Disaggregation of Revenue [Line Items]        
Revenue $ 2,059 $ 2,010 $ 5,987 $ 5,973
Number of major types of revenue | revenue_type 3   3  
Parking Income        
Disaggregation of Revenue [Line Items]        
Revenue $ 1,935 1,752 $ 5,538 5,197
Rental Lease Guaranty        
Disaggregation of Revenue [Line Items]        
Revenue 0 168 128 488
Management Fee Income        
Disaggregation of Revenue [Line Items]        
Revenue 69 68 201 205
Miscellaneous        
Disaggregation of Revenue [Line Items]        
Revenue $ 55 $ 22 $ 120 $ 83
JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hr-2019930singlesource.htm": { "axisCustom": 3, "axisStandard": 22, "contextCount": 242, "dts": { "calculationLink": { "local": [ "hr-20190930_cal.xml" ] }, "definitionLink": { "local": [ "hr-20190930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "hr-2019930singlesource.htm" ] }, "labelLink": { "local": [ "hr-20190930_lab.xml" ], "remote": [ "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hr-20190930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hr-20190930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd" ] } }, "elementCount": 488, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 22, "http://healthcarerealty.com/20190930": 1, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 28 }, "keyCustom": 45, "keyStandard": 327, "memberCustom": 29, "memberStandard": 36, "nsprefix": "hr", "nsuri": "http://healthcarerealty.com/20190930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://healthcarerealty.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:AcquisitionsAndDispositionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Real Estate Investments", "role": "http://healthcarerealty.com/role/RealEstateInvestments", "shortName": "Real Estate Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:AcquisitionsAndDispositionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Leases", "role": "http://healthcarerealty.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Notes and Bonds Payable", "role": "http://healthcarerealty.com/role/NotesAndBondsPayable", "shortName": "Notes and Bonds Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Derivative Financial Instruments", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Commitments and Contingencies", "role": "http://healthcarerealty.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Stockholders' Equity", "role": "http://healthcarerealty.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Fair Value of Financial Instruments", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Real Estate Investments (Tables)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsTables", "shortName": "Real Estate Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-3", "lang": null, "name": "hr:PersonalProperty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Leases (Tables)", "role": "http://healthcarerealty.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Notes and Bonds Payable (Tables)", "role": "http://healthcarerealty.com/role/NotesAndBondsPayableTables", "shortName": "Notes and Bonds Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Derivative Financial Instruments (Tables)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables", "shortName": "Derivative Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Stockholders' Equity (Tables)", "role": "http://healthcarerealty.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "div", "hr:NatureOfOperationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-8", "first": true, "lang": null, "name": "hr:InvestmentInRealEstatePropertiesAndMortgageNotes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "hr:NatureOfOperationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-8", "first": true, "lang": null, "name": "hr:InvestmentInRealEstatePropertiesAndMortgageNotes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD_srt_ProductOrServiceAxis_hr_ParkingIncomeMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails", "shortName": "Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfPropertiesSubjectToGroundLeases", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Real Estate Investments - Acquisitions (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "shortName": "Real Estate Investments - Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD_hr_RealEstateAcquisitionsAndMortgageNoteFinancingAxis_hr_RealEstateAcquisitionsMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "hr:AssetDispositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-5", "first": true, "lang": null, "name": "hr:DispositionSalesPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Real Estate Investments - Dispositions (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails", "shortName": "Real Estate Investments - Dispositions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "hr:AssetDispositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-5", "first": true, "lang": null, "name": "hr:DispositionSalesPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "INF", "first": true, "lang": null, "name": "hr:NumberOfPropertiesHeldForSale", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - Real Estate Investments - Assets Held for Sale (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "shortName": "Real Estate Investments - Assets Held for Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "INF", "first": true, "lang": null, "name": "hr:NumberOfPropertiesHeldForSale", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails", "shortName": "Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_hr_InpatientRehabMember", "decimals": "-3", "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "INF", "first": true, "lang": null, "name": "hr:NumberofGroundLeasesNotYetCommenced", "reportCount": 1, "unitRef": "Lease", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Leases - Lease Income (Details)", "role": "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails", "shortName": "Leases - Lease Income (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Leases - Lessor Accounting (Details)", "role": "http://healthcarerealty.com/role/LeasesLessorAccountingDetails", "shortName": "Leases - Lessor Accounting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "hr:FutureMinimumLeasePaymentsReceivableunderASC840TableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - Leases - Future Lease Payments Receivable under ASC 840 (Details)", "role": "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details", "shortName": "Leases - Future Lease Payments Receivable under ASC 840 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "hr:FutureMinimumLeasePaymentsReceivableunderASC840TableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfPropertiesSubjectToGroundLeases", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - Leases - Ground Leases (Details)", "role": "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "shortName": "Leases - Ground Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": "-5", "lang": null, "name": "hr:SquareFeetSubjecttoGroundLeases", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403406 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "role": "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails", "shortName": "Leases - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403407 - Disclosure - Leases - Lease Cost (Details)", "role": "http://healthcarerealty.com/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403408 - Disclosure - Leases - Future Minimum Lease Payments under ASC 840 (Details)", "role": "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details", "shortName": "Leases - Future Minimum Lease Payments under ASC 840 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Notes and Bonds Payable (Details)", "role": "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "shortName": "Notes and Bonds Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2018Q4_us-gaap_DebtInstrumentAxis_hr_UnsecuredCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesIncomeStatementLeaseRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_hr_ActiveInterestRateSwapsMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "shortName": "Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_hr_ActiveInterestRateSwapsMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "shortName": "Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "shortName": "Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "hr:NatureOfOperationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unitRef": "sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - Commitments and Contingencies - Construction Activity (Details)", "role": "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "shortName": "Commitments and Contingencies - Construction Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_hr_MedicalOfficeBuildingExpansionMember_srt_StatementGeographicalAxis_stpr_NC", "decimals": "0", "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "shortName": "Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "shortName": "Stockholders' Equity (Stock Transactions - Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD_hr_StockIssuanceProgramAxis_hr_AtTheMarketEquityOfferingProgramMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails", "shortName": "Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "td", "tr", "table", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails", "shortName": "Stockholders' Equity - Summary of activity under stock-based incentive plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "td", "tr", "table", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "shortName": "Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Fair Value of Financial Instruments (Details)", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2019Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Statement", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement", "shortName": "Condensed Consolidated Statements of Equity (Unaudited) Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004001 - Statement - Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedParenthetical", "shortName": "Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hr-2019930singlesource.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 65, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hr_AcquisitionsAndDispositionsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquisitions and dispositions.", "label": "Acquisitions and Dispositions [Text Block]", "verboseLabel": "Real Estate Investments" } } }, "localname": "AcquisitionsAndDispositionsTextBlock", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestments" ], "xbrltype": "textBlockItemType" }, "hr_ActiveInterestRateSwapsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Active Interest Rate Swaps [Member]", "label": "Active Interest Rate Swaps [Member]", "terseLabel": "Active Interest Rate Swap" } } }, "localname": "ActiveInterestRateSwapsMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "hr_AmendedandRestatedUnsecuredCreditFacilityDue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amended and Restated Unsecured Credit Facility Due 2023 [Member]", "label": "Amended and Restated Unsecured Credit Facility Due 2023 [Member]", "terseLabel": "Amended and Restated Unsecured Credit Facility Due 2023" } } }, "localname": "AmendedandRestatedUnsecuredCreditFacilityDue2023Member", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_AmortizationofPrepaidRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of Prepaid Rent", "label": "Amortization of Prepaid Rent", "terseLabel": "Amortization of prepaid rent" } } }, "localname": "AmortizationofPrepaidRent", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "monetaryItemType" }, "hr_ApproximateSquareFeetProvidedByCompany": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Approximate square feet for which Nationwide property management services provided by company", "label": "Approximate Square Feet Provided by Company", "verboseLabel": "Approximate square feet for which Nationwide property management services provided by company" } } }, "localname": "ApproximateSquareFeetProvidedByCompany", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "areaItemType" }, "hr_AreaCoveredUnderRealEstateInvestmentSoldInMeasurementUnits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area covered under real estate investment sold in measurement units.", "label": "Area Covered Under Real Estate Investment Sold in Measurement Units", "terseLabel": "Square footage" } } }, "localname": "AreaCoveredUnderRealEstateInvestmentSoldInMeasurementUnits", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "areaItemType" }, "hr_AssetDispositionsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Dispositions.", "label": "Asset Dispositions [Table Text Block]", "terseLabel": "Summary of dispositions" } } }, "localname": "AssetDispositionsTableTextBlock", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "hr_AssetsAndLiabilitiesRelatedToHeldForSaleAndDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets and liabilities related to held for sale and discontinued operations.", "label": "Assets and Liabilities Related to Held for Sale and Discontinued Operations [Abstract]", "verboseLabel": "Asset Dispositions and Potential Dispositions" } } }, "localname": "AssetsAndLiabilitiesRelatedToHeldForSaleAndDiscontinuedOperationsAbstract", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Assets held for sale and discontinued operations, net.", "label": "Assets Held-for-sale and Discontinued Operations Net", "verboseLabel": "Assets held for sale, net" } } }, "localname": "AssetsHeldForSaleAndDiscontinuedOperationsNet", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_AtTheMarketEquityOfferingProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "At The Market Equity Offering Program [Member]", "label": "At The Market Equity Offering Program [Member]", "terseLabel": "At The Market Equity Offering Program" } } }, "localname": "AtTheMarketEquityOfferingProgramMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_BusinessAcquisitionPurchasePriceAllocationSquareFootage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition Purchase Price Allocation Square Footage.", "label": "Business Acquisition Purchase Price Allocation Square Footage", "verboseLabel": "Square footage" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationSquareFootage", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "areaItemType" }, "hr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealProperty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property", "terseLabel": "Real Estate" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealProperty", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValueAdjustmentsandOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other", "terseLabel": "Other" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValueAdjustmentsandOther", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_BusinessOverviewAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Overview [Abstract]", "label": "Business Overview [Abstract]", "terseLabel": "Business Overview:" } } }, "localname": "BusinessOverviewAbstract", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "hr_ClosingAdjustmentsDisposedEntity": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Closing Adjustments Disposed Entity, including closing costs and other adjustments to the sales price.", "label": "Closing Adjustments Disposed Entity", "negatedTerseLabel": "Closing Adjustments" } } }, "localname": "ClosingAdjustmentsDisposedEntity", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_ConstructionActivityEstimatedRemainingFundings": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Estimated Remaining Fundings", "label": "Construction Activity, Estimated Remaining Fundings", "terseLabel": "Estimated amount to complete project" } } }, "localname": "ConstructionActivityEstimatedRemainingFundings", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_ConstructionActivityTotalAmountFunded": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Total Amount Funded", "label": "Construction Activity, Total Amount Funded", "terseLabel": "Total amount funded" } } }, "localname": "ConstructionActivityTotalAmountFunded", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_CumulativeDividendsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Dividends [Member].", "label": "Cumulative Dividends [Member]", "terseLabel": "Cumulative Dividends" } } }, "localname": "CumulativeDividendsMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "hr_CumulativeNetIncomeAttributableToCommonStockholders": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cumulative net income attributable to common stockholders.", "label": "Cumulative Net Income Attributable to Common Stockholders", "verboseLabel": "Cumulative net income attributable to common stockholders" } } }, "localname": "CumulativeNetIncomeAttributableToCommonStockholders", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_CumulativeNetIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Net Income [Member].", "label": "Cumulative Net Income [Member]", "terseLabel": "Cumulative Net Income" } } }, "localname": "CumulativeNetIncomeMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "hr_DallasTexasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dallas, Texas [Member]", "label": "Dallas, Texas [Member]", "terseLabel": "Dallas, TX" } } }, "localname": "DallasTexasMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_DebtInstrumentDelayedDrawFeaturePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Delayed Draw Feature Period", "label": "Debt Instrument, Delayed Draw Feature Period", "terseLabel": "Delayed draw feature period" } } }, "localname": "DebtInstrumentDelayedDrawFeaturePeriod", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "durationItemType" }, "hr_DebtInstrumentTickingFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Ticking Fee Percentage", "label": "Debt Instrument, Ticking Fee Percentage", "terseLabel": "Ticking fee" } } }, "localname": "DebtInstrumentTickingFeePercentage", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "hr_DispositionSalesPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposition Sales Price", "label": "Disposition Sales Price", "terseLabel": "Sales price" } } }, "localname": "DispositionSalesPrice", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_EquityOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Offering [Member]", "label": "Equity Offering [Member]", "terseLabel": "Equity Offering" } } }, "localname": "EquityOfferingMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_FormerExecutiveChairmanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Former Executive Chairman [Member]", "label": "Former Executive Chairman [Member]", "terseLabel": "Former Executive Chairman" } } }, "localname": "FormerExecutiveChairmanMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "domainItemType" }, "hr_FutureMinimumLeasePaymentsReceivableunderASC840TableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Future Minimum Lease Payments Receivable under ASC 840 [Table Text Block]", "label": "Future Minimum Lease Payments Receivable under ASC 840 [Table Text Block]", "terseLabel": "Future Minimum Lease Payments Receivable under ASC 840" } } }, "localname": "FutureMinimumLeasePaymentsReceivableunderASC840TableTextBlock", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "hr_GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation", "label": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation", "negatedLabel": "Gain on sales of real estate assets" } } }, "localname": "GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_HoustonTexasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Houston, Texas [Member]", "label": "Houston, Texas [Member]", "terseLabel": "Houston, TX" } } }, "localname": "HoustonTexasMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_ImpairmentOfRealEstateContinuingAndDiscontinuedOperations": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Impairment of Real Estate, Continuing and Discontinued Operations", "label": "Impairment of Real Estate, Continuing and Discontinued Operations", "terseLabel": "Impairment of real estate assets" } } }, "localname": "ImpairmentOfRealEstateContinuingAndDiscontinuedOperations", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to dilutive effect of employee stock purchase plan.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan", "verboseLabel": "Dilutive effect of employee stock purchase plan" } } }, "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "hr_InpatientRehabMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inpatient rehab.", "label": "Inpatient Rehab [Member]", "terseLabel": "Inpatient Rehabilitation Facility" } } }, "localname": "InpatientRehabMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "hr_InvestmentInRealEstatePropertiesAndMortgageNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment in real estate properties and mortgage notes.", "label": "Investment in Real Estate Properties and Mortgage Notes", "terseLabel": "Gross investment amount, total" } } }, "localname": "InvestmentInRealEstatePropertiesAndMortgageNotes", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hr_LesseeOperatingLeaseTermofContractIncludingRenewals": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Term of Contract, Including Renewals", "label": "Lessee, Operating Lease, Term of Contract, Including Renewals", "terseLabel": "Term of lease, including renewals" } } }, "localname": "LesseeOperatingLeaseTermofContractIncludingRenewals", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "durationItemType" }, "hr_LineOfCreditFacilityBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line of credit facility basis spread on variable rate.", "label": "Line of Credit Facility Basis Spread on Variable Rate", "terseLabel": "Credit facility margin rate" } } }, "localname": "LineOfCreditFacilityBasisSpreadOnVariableRate", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "hr_ManagementFeeIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Management Fee Income [Member]", "label": "Management Fee Income [Member]", "terseLabel": "Management Fee Income" } } }, "localname": "ManagementFeeIncomeMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_MedicalOfficeBuildingExpansionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Office Building Expansion [Member]", "label": "Medical Office Building Expansion [Member]", "terseLabel": "Medical Office Building Expansion" } } }, "localname": "MedicalOfficeBuildingExpansionMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "hr_MedicalOfficeBuildingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Office Building [Member]", "label": "Medical Office Building [Member]", "terseLabel": "Medical Office Building" } } }, "localname": "MedicalOfficeBuildingMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_MiscellaneousMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Miscellaneous [Member]", "label": "Miscellaneous [Member]", "terseLabel": "Miscellaneous" } } }, "localname": "MiscellaneousMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_MortgageNotesPayableNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mortgage Notes Payable, Net [Member]", "label": "Mortgage Notes Payable, Net [Member]", "terseLabel": "Mortgage notes payable, net of discounts and issuance costs and including premiums" } } }, "localname": "MortgageNotesPayableNetMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_NatureOfOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nature Of Operations Policy.", "label": "Nature of Operations [Policy Text Block]", "terseLabel": "Business Overview" } } }, "localname": "NatureOfOperationsPolicyTextBlock", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic", "label": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic", "totalLabel": "Net income applicable to common stockholders" } } }, "localname": "NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "hr_NumberOfPropertiesHeldForSale": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of properties held for sale.", "label": "Number of Properties Held for Sale", "terseLabel": "Number of properties held for sale" } } }, "localname": "NumberOfPropertiesHeldForSale", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails" ], "xbrltype": "integerItemType" }, "hr_NumberOfRealEstateInvestments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of real estate investments.", "label": "Number of Real Estate Investments", "terseLabel": "Number of real estate properties" } } }, "localname": "NumberOfRealEstateInvestments", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofAuthorizedSharesRemainingUnderOfferingProgram": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Authorized Shares Remaining Under Offering Program", "label": "Number of Authorized Shares Remaining Under Offering Program", "terseLabel": "Number of authorized shares remaining under offering program" } } }, "localname": "NumberofAuthorizedSharesRemainingUnderOfferingProgram", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "hr_NumberofGroundLeasesExcludingPrepaidLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Ground Leases, Excluding Prepaid Leases", "label": "Number of Ground Leases, Excluding Prepaid Leases", "terseLabel": "Number of non-prepaid ground leases" } } }, "localname": "NumberofGroundLeasesExcludingPrepaidLeases", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofGroundLeasesNotYetCommenced": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Ground Leases Not Yet Commenced", "label": "Number of Ground Leases Not Yet Commenced", "terseLabel": "Ground leases not yet commenced" } } }, "localname": "NumberofGroundLeasesNotYetCommenced", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofGroundLeasesPrepaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Ground Leases Prepaid", "label": "Number of Ground Leases Prepaid", "terseLabel": "Number of prepaid ground leases" } } }, "localname": "NumberofGroundLeasesPrepaid", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofMajorTypesofRevenue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Major Types of Revenue", "label": "Number of Major Types of Revenue", "terseLabel": "Number of major types of revenue" } } }, "localname": "NumberofMajorTypesofRevenue", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofPropertiesAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Properties Acquired", "label": "Number of Properties Acquired", "terseLabel": "Number of properties acquired" } } }, "localname": "NumberofPropertiesAcquired", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofPropertiesHeldforSaleExcludedfromGroundLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Properties Held for Sale, Excluded from Ground Leases", "label": "Number of Properties Held for Sale, Excluded from Ground Leases", "terseLabel": "Number of properties held for sale, excluded from ground leases" } } }, "localname": "NumberofPropertiesHeldforSaleExcludedfromGroundLeases", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "hr_ParkingIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Parking Income [Member]", "label": "Parking Income [Member]", "terseLabel": "Parking Income" } } }, "localname": "ParkingIncomeMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_PersonalProperty": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Personal property.", "label": "Personal Property", "terseLabel": "Personal property" } } }, "localname": "PersonalProperty", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_RealEstateAcquisitionsAndMortgageNoteFinancingAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Acquisitions and Mortgage Note Financing.", "label": "Real Estate Acquisitions and Mortgage Note Financing [Axis]", "terseLabel": "Real Estate Acquisitions and Mortgage Note Financing [Axis]" } } }, "localname": "RealEstateAcquisitionsAndMortgageNoteFinancingAxis", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "hr_RealEstateAcquisitionsAndMortgageNoteFinancingDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Acquisitions and Mortgage Note Financing.", "label": "Real Estate Acquisitions and Mortgage Note Financing [Domain]", "terseLabel": "Real Estate Acquisitions and Mortgage Note Financing [Domain]" } } }, "localname": "RealEstateAcquisitionsAndMortgageNoteFinancingDomain", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateAcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate acquisitions.", "label": "Real Estate Acquisitions [Member]", "terseLabel": "Real Estate Acquisition" } } }, "localname": "RealEstateAcquisitionsMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateDispositionsAndMortgageNoteRepaymentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Dispositions and Mortgage Note Repayments [Axis]", "label": "Real Estate Dispositions and Mortgage Note Repayments [Axis]", "terseLabel": "Real Estate Dispositions and Mortgage Note Repayments [Axis]" } } }, "localname": "RealEstateDispositionsAndMortgageNoteRepaymentsAxis", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "hr_RealEstateDispositionsAndMortgageNoteRepaymentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Dispositions and Mortgage Note Repayments [Domain]", "label": "Real Estate Dispositions and Mortgage Note Repayments [Domain]", "terseLabel": "Real Estate Dispositions and Mortgage Note Repayments [Domain]" } } }, "localname": "RealEstateDispositionsAndMortgageNoteRepaymentsDomain", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateDispositionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate dispositions.", "label": "Real Estate Dispositions [Line Items]", "terseLabel": "Real Estate Dispositions [Line Items]" } } }, "localname": "RealEstateDispositionsLineItems", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "hr_RealEstateDispositionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Dispositions [Member]", "label": "Real Estate Dispositions [Member]", "terseLabel": "Real Estate Dispositions" } } }, "localname": "RealEstateDispositionsMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateHeldforSaleSalePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Real Estate Held for Sale, Sale Price", "label": "Real Estate Held for Sale, Sale Price", "terseLabel": "Expected purchase price", "verboseLabel": "Net investment" } } }, "localname": "RealEstateHeldforSaleSalePrice", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_RealEstateInvestmentNetDisposedOfDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Real estate investment net disposed of during the Period.", "label": "Real Estate Investment Net Disposed of During Period", "verboseLabel": "Net Real Estate Investment" } } }, "localname": "RealEstateInvestmentNetDisposedOfDuringPeriod", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_RealEstateInvestmentsPropertyOwnedInNumberOfStates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate investments property owned in number of states.", "label": "Real Estate Investments Property Owned in Number of States", "verboseLabel": "Number of states that the Company owns real estate in, whole units" } } }, "localname": "RealEstateInvestmentsPropertyOwnedInNumberOfStates", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "hr_RealEstateOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Real estate other.", "label": "Real Estate Other", "terseLabel": "Real Estate Other" } } }, "localname": "RealEstateOther", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of the beginning and ending common stock outstanding.", "label": "Reconciliation of Beginning and Ending Common Stock Outstanding [Roll Forward]", "verboseLabel": "Reconciliation of the beginning and ending common stock outstanding" } } }, "localname": "ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "stringItemType" }, "hr_ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of beginning and ending common stock outstanding.", "label": "Reconciliation of Beginning and Ending Common Stock Outstanding [Table Text Block]", "terseLabel": "Reconciliation of beginning and ending common stock outstanding" } } }, "localname": "ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "hr_RentalLeaseGuarantyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rental Lease Guaranty [Member]", "label": "Rental Lease Guaranty [Member]", "terseLabel": "Rental Lease Guaranty" } } }, "localname": "RentalLeaseGuarantyMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_SanAntonioTexasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "San Antonio, Texas [Member]", "label": "San Antonio, Texas [Member]", "terseLabel": "San Antonio, TX" } } }, "localname": "SanAntonioTexasMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_ScheduleOfRealEstateDispositionsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of real estate dispositions.", "label": "Schedule of Real Estate Dispositions [Table]", "terseLabel": "Schedule of Real Estate Dispositions [Table]" } } }, "localname": "ScheduleOfRealEstateDispositionsTable", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "hr_SeniorNotesdue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2023 [Member]", "label": "Senior Notes due 2023 [Member]", "terseLabel": "Senior Notes due 2023, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2023Member", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2025 [Member]", "label": "Senior Notes due 2025 [Member]", "terseLabel": "Senior Notes due 2025, net of discount and issuance costs (3)" } } }, "localname": "SeniorNotesdue2025Member", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2028 [Member]", "label": "Senior Notes due 2028 [Member]", "terseLabel": "Senior Notes due 2028, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2028Member", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SharesIssuedDuringPeriodPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares Issued During Period, Price Per Share", "label": "Shares Issued During Period, Price Per Share", "terseLabel": "Shares issued during period, price per share" } } }, "localname": "SharesIssuedDuringPeriodPricePerShare", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "hr_SquareFeetSubjecttoGroundLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Square Feet Subject to Ground Leases", "label": "Square Feet Subject to Ground Leases", "terseLabel": "Square feet subject to ground leases" } } }, "localname": "SquareFeetSubjecttoGroundLeases", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "areaItemType" }, "hr_StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Incentive Plan [Member]", "label": "Stock Incentive Plan [Member]", "terseLabel": "Stock Incentive Plan" } } }, "localname": "StockIncentivePlanMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "hr_StockIssuanceProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issuance Program [Axis]", "label": "Stock Issuance Program [Axis]", "terseLabel": "Stock Issuance Program [Axis]" } } }, "localname": "StockIssuanceProgramAxis", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "hr_StockIssuanceProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Stock Issuance Program [Axis]", "label": "Stock Issuance Program [Domain]", "terseLabel": "Stock Issuance Program [Domain]" } } }, "localname": "StockIssuanceProgramDomain", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_StraightLineRentReceivable": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Straight-line rent receivable.", "label": "Straight-line Rent Receivable", "negatedLabel": "Amortization of straight-line rent receivable (lessor)" } } }, "localname": "StraightLineRentReceivable", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_StraightlineRentLiability": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Straight-line rent liability.", "label": "Straight-line Rent Liability", "terseLabel": "Amortization of straight-line rent on operating leases (lessee)" } } }, "localname": "StraightlineRentLiability", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_TermLoanAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan Agreement [Member]", "label": "Term Loan Agreement [Member]", "terseLabel": "Term Loan Agreement" } } }, "localname": "TermLoanAgreementMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_TermLoandue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan due 2022 [Member]", "label": "Term Loan due 2022 [Member]", "terseLabel": "Unsecured Term Loan due 2022" } } }, "localname": "TermLoandue2022Member", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_TermLoandue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan due 2024 [Member]", "label": "Term Loan due 2024 [Member]", "terseLabel": "$200 million Unsecured Term Loan Facility, net of issuance costs (1)" } } }, "localname": "TermLoandue2024Member", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_TermLoandue2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan due 2026 [Member]", "label": "Term Loan due 2026 [Member]", "terseLabel": "$150 million Unsecured Term Loan due 2026" } } }, "localname": "TermLoandue2026Member", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_TransferstoOperatingLeaseRightofuseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Transfers to Operating Lease, Right-of-use Assets", "label": "Transfers to Operating Lease, Right-of-use Assets", "terseLabel": "Transfers to operating lease, right-of-use assets" } } }, "localname": "TransferstoOperatingLeaseRightofuseAssets", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "hr_UnsecuredCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Unsecured Credit Facility [Member]", "label": "Unsecured Credit Facility [Member]", "terseLabel": "$700 million Unsecured Credit Facility" } } }, "localname": "UnsecuredCreditFacilityMember", "nsuri": "http://healthcarerealty.com/20190930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r304", "r305" ], "lang": { "en-US": { "role": { "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Real Estate [Domain]", "terseLabel": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r127", "r164", "r165", "r303" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r128", "r164", "r166", "r304", "r305" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average [Member]", "verboseLabel": "Weighted Average Remaining Term" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "stpr_AZ": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ARIZONA", "terseLabel": "Tucson, AZ (3)" } } }, "localname": "AZ", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CALIFORNIA", "terseLabel": "Los Angeles, CA (6)" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_DC": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "DISTRICT OF COLUMBIA", "terseLabel": "Washington, D.C. (4)" } } }, "localname": "DC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_GA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "GEORGIA", "terseLabel": "Atlanta, GA" } } }, "localname": "GA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_IN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "INDIANA", "terseLabel": "Indianapolis, IN (5)" } } }, "localname": "IN", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_NC": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NORTH CAROLINA", "terseLabel": "North Carolina", "verboseLabel": "Raleigh, North Carolina" } } }, "localname": "NC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_OK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "OKLAHOMA", "terseLabel": "Oklahoma City, OK" } } }, "localname": "OK", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_PA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "PENNSYLVANIA", "terseLabel": "Pennsylvania", "verboseLabel": "Erie, Pennsylvania" } } }, "localname": "PA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_VA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "VIRGINIA", "terseLabel": "Virginia Beach, VA (4)" } } }, "localname": "VA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_WA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "WASHINGTON", "terseLabel": "Washington", "verboseLabel": "Seattle, WA" } } }, "localname": "WA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r277", "r298" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r41", "r44" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r42", "r44", "r47", "r197" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AcquisitionCosts": { "auth_ref": [ "r270", "r271" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.", "label": "Acquisition Costs, Period Cost", "terseLabel": "Acquisition and pursuit costs" } } }, "localname": "AcquisitionCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r22" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r169", "r171", "r185", "r186" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r171", "r182", "r184" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Accelerated stock compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r59", "r85", "r239" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of up front lender fees" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "netLabel": "Approximate Square Feet", "terseLabel": "Area of real estate property", "verboseLabel": "Square footage of owned real estate properties" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r125", "r273", "r289" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r8", "r10", "r139" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Assets held for sale, net" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r172", "r183" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r206", "r211" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BelowMarketLeaseNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life.", "label": "Below Market Lease, Net", "terseLabel": "Below-market lease intangible" } } }, "localname": "BelowMarketLeaseNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": { "auth_ref": [ "r187", "r188", "r189" ], "lang": { "en-US": { "role": { "documentation": "Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.", "label": "Business Acquisition, Effective Date of Acquisition", "terseLabel": "Date Acquired" } } }, "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r192", "r193", "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "verboseLabel": "Purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r89", "r90", "r91" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "verboseLabel": "Invoices accrued for construction, tenant improvements and other capitalized costs" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r233", "r234" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r14", "r26", "r87" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r81", "r87", "r92" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r81", "r235" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r34", "r143", "r279", "r293" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r142", "r144" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "verboseLabel": "Dividend per share to common Stockholders (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per common share, during the period (in dollars per share)", "verboseLabel": "Dividends declared, per common share, during the period (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, authorized shares" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, issued shares" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r152" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "verboseLabel": "Common stock, outstanding shares" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $.01 par value per share; 300,000 shares authorized; 131,368 and 125,279 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r50", "r52", "r53" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE INCOME" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CumulativeDividends": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative cash dividends distributed to shareholders.", "label": "Cumulative Dividends", "negatedLabel": "Cumulative dividends" } } }, "localname": "CumulativeDividends", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Notes and Bonds Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r274", "r275", "r287" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Term loan margin rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r238", "r240" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Term-loan facility" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r232" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "verboseLabel": "Notes and bonds payable" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r32", "r147", "r238" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r33", "r95", "r153", "r156", "r157", "r158", "r237", "r238", "r240", "r286" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Term of loan facility" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": { "auth_ref": [ "r241" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r239" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Up front fees paid to lenders" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r29", "r239" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Up front fees to be amortized" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r85", "r135" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r85", "r123" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r37", "r38", "r209", "r269" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Liability derivatives" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Fixed interest rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r207", "r210", "r216", "r219" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r203", "r207", "r216" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r96", "r198", "r200", "r201", "r203", "r205", "r212", "r216", "r221", "r222", "r225" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopmentInProcess": { "auth_ref": [ "r297" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current amount of expenditures for a real estate project that has not yet been completed.", "label": "Development in Process", "terseLabel": "Construction in progress" } } }, "localname": "DevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment": { "auth_ref": [ "r64" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense incurred and directly related to generating revenue from leased and rented property or equipment.", "label": "Direct Costs of Leased and Rented Property or Equipment", "verboseLabel": "Property operating" } } }, "localname": "DirectCostsOfLeasedAndRentedPropertyOrEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggreation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r172", "r183" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summary of the activity under the Incentive Plan" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalDate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date the entity disposed of a business or a group of assets, in CCYY-MM-DD format.", "label": "Disposal Date", "terseLabel": "Disposal Date" } } }, "localname": "DisposalDate1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r10", "r132", "r140" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r0", "r1", "r8", "r139" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "auth_ref": [ "r0", "r1", "r8", "r139" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "terseLabel": "Other assets, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "auth_ref": [ "r0", "r1", "r8", "r139" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r159" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends to common stockholders" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsShareBasedCompensation": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared and applicable to holders of share-based compensation, for example, but not limited to, non-vested shares, stock options, or restricted stock units.", "label": "Dividends, Share-based Compensation", "negatedTerseLabel": "Dividends paid on nonvested share-based awards" } } }, "localname": "DividendsShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r58", "r100", "r106", "r107", "r108", "r109", "r112", "r283", "r301" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r58", "r100", "r106", "r107", "r108", "r109", "r112", "r283", "r301" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per common share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "verboseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r56", "r80", "r85", "r299" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Distributions from unconsolidated joint ventures" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Outstanding principal repaid" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r228", "r233" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r228", "r229" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r250", "r256", "r265" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease Liabilities, Payments, Due [Abstract]", "terseLabel": "Financing" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r249", "r264" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Financing lease liabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future Minimum Financing Lease Payments" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r264" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payments, Due", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "2024 and thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r264" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Discount" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r251", "r259" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments made on finance leases", "terseLabel": "Financing cash flows outflows related to financing leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r248" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Financing lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r250", "r256", "r265" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r262", "r265" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r261", "r265" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetOffMarketLeaseFavorableGross": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease at the acquisition date.", "label": "Finite-Lived Intangible Asset, Off-market Lease, Favorable, Gross", "terseLabel": "Above-market lease intangibles" } } }, "localname": "FiniteLivedIntangibleAssetOffMarketLeaseFavorableGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r85", "r134", "r137" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "netLabel": "Gain/(Impairment)" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "auth_ref": [ "r60", "r61", "r85", "r281", "r302" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes.", "label": "Gains (Losses) on Sales of Investment Real Estate", "terseLabel": "Gain on sales of real estate assets" } } }, "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r66" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GroundLeasesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Net long-term land leases which are capitalized as part of real property.", "label": "Ground Leases, Net", "terseLabel": "Prepaid ground leases" } } }, "localname": "GroundLeasesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r203", "r220" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r85", "r133" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Impairment of assets held-for-sale" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfRealEstate": { "auth_ref": [ "r85", "r136" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value.", "label": "Impairment of Real Estate", "negatedLabel": "Impairment of real estate assets" } } }, "localname": "ImpairmentOfRealEstate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r63", "r86", "r109", "r196" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net Income" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r56", "r85", "r124", "r131", "r280", "r299" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Loss (income) from unconsolidated joint ventures" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r9", "r11", "r12", "r13", "r140", "r141" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r84" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r84" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets, including right-of-use-assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r84" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r55", "r122", "r236", "r239", "r285" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidCapitalized": { "auth_ref": [ "r73", "r88" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest capitalized, classified as investing activity.", "label": "Interest Paid, Capitalized, Investing Activities", "terseLabel": "Capitalized interest" } } }, "localname": "InterestPaidCapitalized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r79", "r82", "r88" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r226" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r168", "r217" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Swaps" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap", "verboseLabel": "Settled Interest Rate Swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "auth_ref": [ "r295" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.", "label": "Investment Building and Building Improvements", "terseLabel": "Buildings, improvements and lease intangibles", "verboseLabel": "Buildings, improvements and lease intangibles" } } }, "localname": "InvestmentBuildingAndBuildingImprovements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r15", "r27" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "verboseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandAvailableForDevelopment": { "auth_ref": [ "r292" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of land available for development.", "label": "Land Available for Development", "terseLabel": "Land held for development" } } }, "localname": "LandAvailableForDevelopment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r263", "r265" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Lease, Cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Operating lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOperatingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases, Operating [Abstract]", "terseLabel": "Other information" } } }, "localname": "LeasesOperatingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Ground lease, discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future Minimum Operating Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r264" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "2024 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r264" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Ground lease, initial term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]", "terseLabel": "Future Lease Payments Receivable [Abstract]" } } }, "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r267" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r267" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in fifth fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Five Years", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r267" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in fourth year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Four Years", "terseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block]", "terseLabel": "Future Minimum Lease Payments Receivable" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r267" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in remainder of fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r267" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor after fifth fiscal year following latest statement of financial position date for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Thereafter", "terseLabel": "2024 and thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r267" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in third fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Three Years", "terseLabel": "2021" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r267" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in second fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Two Years", "terseLabel": "2020" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "verboseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r276", "r291" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r8", "r10", "r139" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Liabilities of properties held for sale", "verboseLabel": "Liabilities of properties held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity on unsecured credit facility" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsHeldForSaleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long Lived Assets Held-for-sale [Line Items]", "terseLabel": "Long Lived Assets Held-for-sale [Line Items]" } } }, "localname": "LongLivedAssetsHeldForSaleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r146", "r275", "r290" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Notes and bonds payable", "verboseLabel": "Notes and bonds payable" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r33", "r145" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MediumTermNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instruments with maturities ranging from five to ten years.", "label": "Medium-term Notes [Member]", "terseLabel": "Medium-term Notes" } } }, "localname": "MediumTermNotesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgages" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r81", "r83", "r86" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r48", "r51", "r57", "r86", "r111", "r282", "r300" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "NET INCOME", "totalLabel": "NET INCOME", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r99", "r101", "r102" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAssumed1": { "auth_ref": [ "r89", "r90", "r91" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of notes assumed in noncash investing or financing activities.", "label": "Notes Assumed", "terseLabel": "Mortgage notes payable assumed upon acquisition (adjusted to fair value)" } } }, "localname": "NotesAssumed1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r199", "r201" ], "lang": { "en-US": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number of Interest Rate Derivatives Held", "terseLabel": "Number of instruments" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfPropertiesSubjectToGroundLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of separate real estate development properties located on land subject to ground leases.", "label": "Number of Properties Subject to Ground Leases", "terseLabel": "Number of properties subject to ground leases" } } }, "localname": "NumberOfPropertiesSubjectToGroundLeases", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r257", "r265" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r249" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r252", "r259" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows outflows related to operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r248" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r262", "r265" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r261", "r265" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r242", "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r242", "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r242", "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r242", "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r242", "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r242", "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r242", "r244" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "2024 and thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable": { "auth_ref": [ "r246" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future minimum rental payments in aggregate as of the balance sheet date under operating leases.", "label": "Operating Leases, Future Minimum Payments Receivable", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent": { "auth_ref": [ "r246" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within one year of the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, Current", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears": { "auth_ref": [ "r246" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the fifth year from the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFourYears": { "auth_ref": [ "r246" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the fourth year from the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears": { "auth_ref": [ "r246" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the third year from the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears": { "auth_ref": [ "r246" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the second year from the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableThereafter": { "auth_ref": [ "r246" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future minimum lease payments receivable under operating leases for periods greater than five years following the balance sheet date.", "label": "Operating Leases, Future Minimum Payments Receivable, Thereafter", "terseLabel": "2024 and thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureLeasePaymentsReceivableUnderAsc840Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesIncomeStatementLeaseRevenue": { "auth_ref": [ "r243" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue.", "label": "Operating Leases, Income Statement, Lease Revenue", "terseLabel": "Rental income" } } }, "localname": "OperatingLeasesIncomeStatementLeaseRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAmortizationOfDeferredCharges": { "auth_ref": [ "r65", "r85" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization of other deferred costs recognized in the income statement.", "label": "Amortization of Other Deferred Charges", "terseLabel": "Other amortization" } } }, "localname": "OtherAmortizationOfDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r16", "r272", "r288" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "verboseLabel": "Other assets, net" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r206", "r223" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]", "terseLabel": "Interest rate swaps:" } } }, "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r39", "r43" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "(Losses) gains arising during the period on interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r39", "r43", "r208", "r213", "r224" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gain (Loss) Recognized in OCI on Derivative" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r43", "r45" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedLabel": "Reclassification adjustments for losses included in net income (interest expense)", "terseLabel": "(Gain) Loss Reclassified from Accumulated OCI into Income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": { "auth_ref": [ "r40", "r214" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax", "terseLabel": "Losses arising during the period on interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax", "negatedTerseLabel": "Loss on forward starting interest rate swap agreement recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r49", "r52", "r54", "r152" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax": { "auth_ref": [ "r43", "r45", "r46", "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax", "negatedTerseLabel": "Reclassification adjustments for losses included in net income (interest expense)" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r278" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r206", "r223" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Interest and other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForCapitalImprovements": { "auth_ref": [ "r73" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.", "label": "Payments for Capital Improvements", "negatedTerseLabel": "Additional long-lived assets" } } }, "localname": "PaymentsForCapitalImprovements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r76" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Common stock redemptions" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r78" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance and assumption costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r76" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r72", "r195" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRealEstate": { "auth_ref": [ "r73" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.", "label": "Payments to Acquire Real Estate", "negatedTerseLabel": "Acquisitions of real estate" } } }, "localname": "PaymentsToAcquireRealEstate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopRealEstateAssets": { "auth_ref": [ "r73" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments to develop real estate assets is the process of adding improvements on or to a parcel of land. Such improvements may include drainage, utilities, subdividing, access, buildings, and any combination of these elements; and are generally classified as cash flow from investing activities.", "label": "Payments to Develop Real Estate Assets", "negatedLabel": "Development of real estate" } } }, "localname": "PaymentsToDevelopRealEstateAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r172", "r183" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, authorized shares" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, issued shares" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, outstanding shares" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r20" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r74" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "auth_ref": [ "r75" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.", "label": "Proceeds from Issuance of Other Long-term Debt", "terseLabel": "Borrowings on term loan" } } }, "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r97" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net borrowings on unsecured credit facility" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndCollectionOfNotesReceivable": { "auth_ref": [ "r70" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the proceeds from sale of notes receivable, as well as principal collections from a borrowing supported by a written promise to pay an obligation (note receivable).", "label": "Proceeds from Sale and Collection of Notes Receivable", "verboseLabel": "Proceeds from notes receivable repayments" } } }, "localname": "ProceedsFromSaleAndCollectionOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": { "auth_ref": [ "r71" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.", "label": "Proceeds from Sale of Property Held-for-sale", "terseLabel": "Proceeds from sales of real estate assets" } } }, "localname": "ProceedsFromSaleOfPropertyHeldForSale", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period.", "label": "Proceeds from Sale of Real Estate Held-for-investment", "terseLabel": "Net Proceeds" } } }, "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r67", "r161" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.", "label": "Provision for Doubtful Accounts", "terseLabel": "Provision for bad debts, net" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForLoanAndLeaseLosses": { "auth_ref": [ "r84", "r129", "r284" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to estimated loss from loan and lease transactions.", "label": "Provision for Loan and Lease Losses", "terseLabel": "Bad debts, net of recoveries" } } }, "localname": "ProvisionForLoanAndLeaseLosses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateHeldforsale": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of investments in land and buildings held for sale, excluding real estate considered to be inventory of the entity.", "label": "Real Estate Held-for-sale", "terseLabel": "Net investment in property held for sale", "verboseLabel": "Purchase price" } } }, "localname": "RealEstateHeldforsale", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r294" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property, Accumulated Depreciation", "negatedLabel": "Less accumulated depreciation and amortization", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r295" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, at Cost", "totalLabel": "Real estate properties, Total" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r295" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, Net", "totalLabel": "Total real estate properties, net" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Real Estate Investment Property, Net [Abstract]", "verboseLabel": "Real estate properties:" } } }, "localname": "RealEstateInvestmentPropertyNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r77" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Repayments on notes and bonds payable" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r162", "r163", "r164" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Other operating" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r93", "r167" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue from Contract with Customers (Topic 606)" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r62", "r120", "r121", "r126" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "REVENUES" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r260", "r265" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r260", "r265" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r190", "r191" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r190", "r191" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Summary of acquisitions" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.", "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r9", "r11", "r12", "r13", "r140", "r141" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Assets held for sale" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Earnings (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Future Minimum Lease Payments under ASC 840" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable": { "auth_ref": [ "r2", "r140" ], "lang": { "en-US": { "role": { "documentation": "Description and amounts of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).", "label": "Schedule of Long Lived Assets Held-for-sale [Table]", "terseLabel": "Schedule of Long Lived Assets Held-for-sale [Table]" } } }, "localname": "ScheduleOfLongLivedAssetsHeldForSaleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r172", "r183" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of employee stock purchase plan activity.", "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "Summary of employee stock purchase plan activity" } } }, "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r35", "r94", "r149", "r150", "r151", "r153", "r154", "r155", "r156", "r157", "r158", "r159" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r84" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Share-based awards, end of period", "periodStartLabel": "Share-based awards, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "verboseLabel": "Summary of the activity under the incentive plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r174", "r183" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding and exercisable, end of period (shares)", "periodStartLabel": "Outstanding and exercisable, beginning of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Summary of the Employee Stock Purchase Plan activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r170", "r173" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.", "label": "Shares Paid for Tax Withholding for Share Based Compensation", "terseLabel": "Shares withheld to pay estimated withholding taxes", "verboseLabel": "Shares withheld to pay taxes" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r36", "r152" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Balance Sheet data (as of the period ended):" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r20", "r21", "r152", "r159" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (shares)", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r20", "r21", "r152", "r159" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Nonvested share-based awards, net of withheld shares (1)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r152", "r159", "r175" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r20", "r21", "r152", "r159" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r20", "r21", "r152", "r159" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "negatedTerseLabel": "Stock Repurchased and Retired During Period, Shares" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r20", "r21", "r152", "r159" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Common stock redemptions" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r23", "r24", "r130" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "verboseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Relationship to Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r113", "r114", "r115", "r116", "r117", "r118", "r119" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates in the Condensed Consolidated Financial Statements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r258", "r265" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease expense" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r105", "r109" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average Common Shares outstanding\u2014Diluted", "verboseLabel": "Weighted average common shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r103", "r104", "r111" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number of Shares Issued, Basic", "verboseLabel": "Weighted average Common Shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted average Common Shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r103", "r109" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted average Common Shares\u2014Basic", "verboseLabel": "Weighted average common shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r104" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "negatedTerseLabel": "Nonvested shares" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e2646-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130534-203044" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e845-128460" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e848-128460" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109975725&loc=SL5629052-113961" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL6742756-110258" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13476-108611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39896-112707" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888428&loc=SL77919396-209981" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(14)(d))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.11)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r306": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r307": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r308": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r309": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r311": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r312": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e689-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724391-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.5)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=SL94080555-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" } }, "version": "2.1" } XML 50 R22.htm IDEA: XBRL DOCUMENT v3.19.3
Derivative Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)
As of September 30, 2019, the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Derivative Instrument
 
Number of Instruments

 
Notional Amount
(in millions)
Interest rate swaps
 
8

 
$175.0

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value
The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of September 30, 2019.
 
Balance at September 30, 2019
(Dollars in thousands)
Balance Sheet Location
 
Fair Value

Derivatives designated as hedging instruments
 
 
 
Interest rate swaps
Other liabilities
 
$
7,533

Total derivatives designated as hedging instruments
 
 
$
7,533


Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)
The table below presents the effect of cash flow hedge accounting on AOCI during the three and nine months ended September 30, 2019 and 2018 related to the Company's outstanding interest rate swaps.
 
Gain (Loss) Recognized in AOCI on Derivative
 
Loss Reclassified from AOCI into Income
 
Three Months Ended September 30,
Three Months Ended September 30,
(Dollars in thousands)
2019

 
2018

2019

 
2018

Interest rate swaps
$
(2,341
)
 
$
374

Interest expense
$
18

 
$
53

Settled interest rate swaps

 

Interest expense
42

 
42

 
$
(2,341
)
 
$
374

Total interest expense
$
60

 
$
95

 
Gain (Loss) Recognized in AOCI on Derivative
 
(Gain) Loss Reclassified from AOCI into Income
 
Nine Months Ended September 30,
Nine Months Ended September 30,
(Dollars in thousands)
2019

 
2018

2019

 
2018

Interest rate swaps
$
(7,642
)
 
$
1,403

Interest expense
$
(52
)
 
$
243

Settled interest rate swaps

 

Interest expense
126

 
126

 
$
(7,642
)
 
$
1,403

Total interest expense
$
74


$
369


XML 51 R43.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies - Construction Activity (Details)
$ in Millions
Sep. 30, 2019
USD ($)
ft²
Other Commitments [Line Items]  
Approximate Square Feet | ft² 15,400,000
Medical Office Building Expansion | North Carolina  
Other Commitments [Line Items]  
Approximate Square Feet | ft² 40,278
Medical Office Building | North Carolina  
Other Commitments [Line Items]  
Total amount funded $ 9.8
Estimated amount to complete project $ 2.2
Medical Office Building | Washington  
Other Commitments [Line Items]  
Approximate Square Feet | ft² 151,000
Total amount funded $ 44.3
Estimated amount to complete project $ 19.8
XML 52 R47.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Summary of the activity under the incentive plans        
Vested (shares) (204,548)      
Stock Incentive Plan        
Summary of the activity under the incentive plans        
Share-based awards, beginning of period 1,778,134 1,938,100 1,769,863 1,907,645
Granted (shares) 0 0 89,767 107,751
Vested (shares) (204,548) (5,051) (286,044) (82,347)
Share-based awards, end of period 1,573,586 1,933,049 1,573,586 1,933,049
Restricted Stock | Stock Incentive Plan        
Summary of the activity under the incentive plans        
Shares withheld to pay estimated withholding taxes     100,036 22,555
XML 53 hr-2019930singlesource_htm.xml IDEA: XBRL DOCUMENT 0000899749 2019-01-01 2019-09-30 0000899749 2019-10-31 0000899749 2019-09-30 0000899749 2018-12-31 0000899749 2018-01-01 2018-09-30 0000899749 2018-07-01 2018-09-30 0000899749 2019-07-01 2019-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0000899749 2018-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000899749 2018-06-30 0000899749 us-gaap:CommonStockMember 2017-12-31 0000899749 hr:CumulativeDividendsMember 2018-09-30 0000899749 us-gaap:CommonStockMember 2018-09-30 0000899749 hr:CumulativeNetIncomeMember 2017-12-31 0000899749 hr:CumulativeDividendsMember 2018-07-01 2018-09-30 0000899749 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000899749 hr:CumulativeNetIncomeMember 2018-06-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000899749 hr:CumulativeNetIncomeMember 2018-09-30 0000899749 hr:CumulativeDividendsMember 2018-06-30 0000899749 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000899749 hr:CumulativeNetIncomeMember 2018-01-01 2018-09-30 0000899749 hr:CumulativeDividendsMember 2018-01-01 2018-09-30 0000899749 hr:CumulativeNetIncomeMember 2018-07-01 2018-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000899749 hr:CumulativeDividendsMember 2017-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000899749 2017-12-31 0000899749 us-gaap:CommonStockMember 2018-06-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000899749 hr:CumulativeNetIncomeMember 2019-09-30 0000899749 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0000899749 hr:CumulativeNetIncomeMember 2018-12-31 0000899749 hr:CumulativeDividendsMember 2019-01-01 2019-09-30 0000899749 2019-06-30 0000899749 hr:CumulativeDividendsMember 2019-09-30 0000899749 us-gaap:CommonStockMember 2019-06-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0000899749 hr:CumulativeDividendsMember 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000899749 us-gaap:CommonStockMember 2019-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000899749 hr:CumulativeDividendsMember 2019-06-30 0000899749 hr:CumulativeNetIncomeMember 2019-07-01 2019-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000899749 hr:CumulativeNetIncomeMember 2019-06-30 0000899749 hr:CumulativeDividendsMember 2019-07-01 2019-09-30 0000899749 us-gaap:CommonStockMember 2018-12-31 0000899749 hr:CumulativeNetIncomeMember 2019-01-01 2019-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000899749 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000899749 us-gaap:OtherLiabilitiesMember 2019-01-01 2019-01-01 0000899749 srt:MaximumMember us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000899749 srt:MinimumMember us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000899749 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2019-01-01 2019-01-01 0000899749 us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000899749 srt:MinimumMember us-gaap:AccountingStandardsUpdate201602Member 2019-09-30 0000899749 srt:WeightedAverageMember us-gaap:AccountingStandardsUpdate201602Member 2019-09-30 0000899749 srt:MaximumMember us-gaap:AccountingStandardsUpdate201602Member 2019-09-30 0000899749 us-gaap:OtherAssetsMember 2019-01-01 2019-01-01 0000899749 hr:ParkingIncomeMember 2019-07-01 2019-09-30 0000899749 hr:MiscellaneousMember 2019-01-01 2019-09-30 0000899749 hr:ManagementFeeIncomeMember 2018-07-01 2018-09-30 0000899749 hr:MiscellaneousMember 2019-07-01 2019-09-30 0000899749 hr:ParkingIncomeMember 2018-07-01 2018-09-30 0000899749 hr:MiscellaneousMember 2018-01-01 2018-09-30 0000899749 hr:ManagementFeeIncomeMember 2019-07-01 2019-09-30 0000899749 hr:ManagementFeeIncomeMember 2018-01-01 2018-09-30 0000899749 hr:RentalLeaseGuarantyMember 2018-01-01 2018-09-30 0000899749 hr:ParkingIncomeMember 2018-01-01 2018-09-30 0000899749 hr:RentalLeaseGuarantyMember 2018-07-01 2018-09-30 0000899749 hr:ParkingIncomeMember 2019-01-01 2019-09-30 0000899749 hr:RentalLeaseGuarantyMember 2019-01-01 2019-09-30 0000899749 hr:RentalLeaseGuarantyMember 2019-07-01 2019-09-30 0000899749 hr:ManagementFeeIncomeMember 2019-01-01 2019-09-30 0000899749 hr:MiscellaneousMember 2018-07-01 2018-09-30 0000899749 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hr:InpatientRehabMember 2018-12-31 0000899749 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hr:InpatientRehabMember 2019-09-30 0000899749 stpr:VA hr:RealEstateDispositionsMember 2019-08-01 0000899749 stpr:AZ hr:RealEstateDispositionsMember 2019-04-09 2019-04-09 0000899749 stpr:AZ hr:RealEstateDispositionsMember 2019-04-09 0000899749 hr:SanAntonioTexasMember hr:RealEstateDispositionsMember 2019-08-28 2019-08-28 0000899749 hr:SanAntonioTexasMember hr:RealEstateDispositionsMember 2019-04-09 0000899749 stpr:VA hr:RealEstateDispositionsMember 2019-08-01 2019-08-01 0000899749 hr:MedicalOfficeBuildingMember stpr:DC hr:RealEstateAcquisitionsMember 2019-03-28 0000899749 hr:MedicalOfficeBuildingMember stpr:DC hr:RealEstateAcquisitionsMember 2019-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:NC us-gaap:SubsequentEventMember hr:RealEstateAcquisitionsMember 2019-10-31 0000899749 hr:MedicalOfficeBuildingMember stpr:CA hr:RealEstateAcquisitionsMember 2019-09-30 2019-09-30 0000899749 stpr:PA hr:RealEstateDispositionsMember 2019-09-30 0000899749 stpr:PA us-gaap:SubsequentEventMember hr:RealEstateDispositionsMember 2019-10-25 0000899749 hr:MedicalOfficeBuildingMember stpr:DC hr:RealEstateAcquisitionsMember 2019-03-28 2019-03-28 0000899749 stpr:VA hr:RealEstateDispositionsMember 2019-04-01 2019-06-30 0000899749 hr:MedicalOfficeBuildingMember stpr:IN hr:RealEstateAcquisitionsMember 2019-03-28 0000899749 hr:MedicalOfficeBuildingMember hr:DallasTexasMember us-gaap:SubsequentEventMember hr:RealEstateAcquisitionsMember 2019-10-31 0000899749 stpr:PA 2019-05-01 2019-05-31 0000899749 hr:MedicalOfficeBuildingMember stpr:NC us-gaap:SubsequentEventMember hr:RealEstateAcquisitionsMember 2019-10-31 2019-10-31 0000899749 hr:MedicalOfficeBuildingMember hr:DallasTexasMember us-gaap:SubsequentEventMember hr:RealEstateAcquisitionsMember 2019-10-31 2019-10-31 0000899749 hr:RealEstateAcquisitionsMember 2019-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:OK hr:RealEstateAcquisitionsMember 2019-09-26 2019-09-26 0000899749 hr:MedicalOfficeBuildingMember stpr:WA hr:RealEstateAcquisitionsMember 2019-06-26 2019-06-26 0000899749 hr:RealEstateAcquisitionsMember 2019-01-01 2019-09-30 0000899749 hr:MedicalOfficeBuildingMember hr:DallasTexasMember hr:RealEstateAcquisitionsMember 2019-06-10 0000899749 hr:MedicalOfficeBuildingMember stpr:WA hr:RealEstateAcquisitionsMember 2019-06-11 2019-06-11 0000899749 hr:MedicalOfficeBuildingMember stpr:WA hr:RealEstateAcquisitionsMember 2019-06-14 2019-06-14 0000899749 hr:MedicalOfficeBuildingMember hr:DallasTexasMember hr:RealEstateAcquisitionsMember 2019-06-10 2019-06-10 0000899749 hr:MedicalOfficeBuildingMember stpr:OK hr:RealEstateAcquisitionsMember 2019-09-26 0000899749 hr:MedicalOfficeBuildingMember stpr:GA hr:RealEstateAcquisitionsMember 2019-04-02 2019-04-02 0000899749 hr:MedicalOfficeBuildingMember stpr:IN hr:RealEstateAcquisitionsMember 2019-03-28 2019-03-28 0000899749 hr:MedicalOfficeBuildingMember hr:HoustonTexasMember hr:RealEstateAcquisitionsMember 2019-08-01 2019-08-01 0000899749 hr:MedicalOfficeBuildingMember stpr:OK hr:RealEstateAcquisitionsMember 2019-09-30 0000899749 hr:MedicalOfficeBuildingMember hr:HoustonTexasMember hr:RealEstateAcquisitionsMember 2019-08-01 0000899749 hr:MedicalOfficeBuildingMember stpr:WA hr:RealEstateAcquisitionsMember 2019-06-14 0000899749 hr:MedicalOfficeBuildingMember stpr:CA hr:RealEstateAcquisitionsMember 2019-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:WA hr:RealEstateAcquisitionsMember 2019-06-26 0000899749 hr:MedicalOfficeBuildingMember stpr:WA hr:RealEstateAcquisitionsMember 2019-06-11 0000899749 hr:MedicalOfficeBuildingMember stpr:GA hr:RealEstateAcquisitionsMember 2019-04-02 0000899749 srt:WeightedAverageMember 2018-12-31 0000899749 srt:MaximumMember 2018-01-01 2018-12-31 0000899749 2018-01-01 2018-12-31 0000899749 srt:MinimumMember 2018-12-31 0000899749 srt:MaximumMember 2018-12-31 0000899749 srt:MinimumMember 2018-01-01 2018-12-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2019-09-30 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2018-12-31 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2018-12-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2019-09-30 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2019-09-30 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2019-09-30 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-09-30 0000899749 hr:UnsecuredCreditFacilityMember us-gaap:LineOfCreditMember 2018-12-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2018-12-31 0000899749 hr:UnsecuredCreditFacilityMember us-gaap:LineOfCreditMember 2019-09-30 0000899749 srt:MinimumMember hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember 2019-05-31 2019-05-31 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-07-01 2019-09-30 0000899749 hr:TermLoanAgreementMember us-gaap:MediumTermNotesMember 2019-04-01 2019-06-30 0000899749 hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-07-01 2019-09-30 0000899749 srt:MinimumMember hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-05-31 2019-05-31 0000899749 srt:MaximumMember hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-05-31 2019-05-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2019-04-10 0000899749 hr:TermLoandue2024Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2019-09-30 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-05-31 2019-05-31 0000899749 hr:TermLoanAgreementMember us-gaap:MediumTermNotesMember 2019-05-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2019-01-01 2019-09-30 0000899749 hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember 2019-05-31 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-05-31 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-07-01 2019-09-30 0000899749 srt:MaximumMember hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-05-31 2019-05-31 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-09-30 0000899749 hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-11-04 2019-11-04 0000899749 srt:MaximumMember hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-05-31 2019-05-31 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2019-05-31 0000899749 srt:MinimumMember hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-05-31 2019-05-31 0000899749 srt:MaximumMember hr:AmendedandRestatedUnsecuredCreditFacilityDue2023Member us-gaap:LineOfCreditMember 2019-05-31 2019-05-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2019-04-10 2019-04-10 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-05-31 0000899749 srt:MinimumMember hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-05-31 2019-05-31 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember 2018-07-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2018-07-01 2018-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2018-07-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateContractMember 2018-07-01 2018-09-30 0000899749 us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestExpenseMember 2018-07-01 2018-09-30 0000899749 us-gaap:InterestRateContractMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000899749 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000899749 hr:ActiveInterestRateSwapsMember 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-05-15 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-04-12 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateContractMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateContractMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:NC 2019-09-30 0000899749 hr:MedicalOfficeBuildingExpansionMember stpr:NC 2019-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:WA 2019-09-30 0000899749 hr:EquityOfferingMember 2019-03-19 2019-03-19 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-03-31 0000899749 us-gaap:SubsequentEventMember hr:AtTheMarketEquityOfferingProgramMember 2019-10-01 2019-10-31 0000899749 hr:FormerExecutiveChairmanMember 2019-07-01 2019-09-30 0000899749 srt:MaximumMember us-gaap:SubsequentEventMember hr:AtTheMarketEquityOfferingProgramMember 2019-10-01 2019-10-31 0000899749 us-gaap:SubsequentEventMember hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-10-31 0000899749 hr:EquityOfferingMember 2019-03-19 0000899749 srt:MaximumMember hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-03-31 0000899749 us-gaap:SubsequentEventMember hr:AtTheMarketEquityOfferingProgramMember 2019-10-31 0000899749 srt:MinimumMember hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-03-31 0000899749 srt:MinimumMember us-gaap:SubsequentEventMember hr:AtTheMarketEquityOfferingProgramMember 2019-10-01 2019-10-31 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2019-01-01 2019-09-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2019-07-01 2019-09-30 0000899749 srt:MaximumMember hr:AtTheMarketEquityOfferingProgramMember 2019-07-01 2019-09-30 0000899749 srt:MinimumMember hr:AtTheMarketEquityOfferingProgramMember 2019-07-01 2019-09-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2019-04-01 2019-06-30 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2018-01-01 2018-09-30 0000899749 srt:MinimumMember us-gaap:SubsequentEventMember hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-10-31 0000899749 us-gaap:SubsequentEventMember 2019-10-29 2019-10-29 0000899749 srt:MaximumMember us-gaap:SubsequentEventMember hr:AtTheMarketEquityOfferingProgramMember 2019-01-01 2019-10-31 0000899749 hr:StockIncentivePlanMember 2018-09-30 0000899749 hr:StockIncentivePlanMember 2019-01-01 2019-09-30 0000899749 hr:StockIncentivePlanMember 2018-07-01 2018-09-30 0000899749 hr:StockIncentivePlanMember 2018-01-01 2018-09-30 0000899749 hr:StockIncentivePlanMember 2018-12-31 0000899749 hr:StockIncentivePlanMember 2019-07-01 2019-09-30 0000899749 hr:StockIncentivePlanMember 2017-12-31 0000899749 hr:StockIncentivePlanMember 2019-09-30 0000899749 hr:StockIncentivePlanMember 2018-06-30 0000899749 hr:StockIncentivePlanMember 2019-06-30 0000899749 us-gaap:EmployeeStockMember 2018-07-01 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2019-07-01 2019-09-30 0000899749 us-gaap:EmployeeStockMember 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2018-01-01 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2019-01-01 2019-09-30 0000899749 us-gaap:EmployeeStockMember 2019-09-30 0000899749 us-gaap:EmployeeStockMember 2017-12-31 0000899749 us-gaap:EmployeeStockMember 2018-12-31 0000899749 us-gaap:EmployeeStockMember 2018-06-30 0000899749 us-gaap:EmployeeStockMember 2019-06-30 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-09-30 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-09-30 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 pure iso4217:USD shares hr:revenue_type shares hr:swap_agreement iso4217:USD utreg:sqft hr:state hr:property hr:Lease false --12-31 Q3 2019 0000899749 400000 0.30 0.90 0.30 0.90 0.01 0.01 300000000 300000000 125279000 131368000 125279000 131368000 0.0100 P7Y 0.01 0.01 50000000 50000000 0 0 0 0 10-Q true 2019-09-30 false 001-11852 HEALTHCARE REALTY TRUST INCORPORATED MD 62-1507028 3310 West End Avenue, Suite 700 Nashville TN 37203 615 269-8175 Common stock, $0.01 par value per share HR NYSE Yes Yes Large Accelerated Filer false false false 133736079 267803000 230206000 3915308000 3675415000 10899000 10696000 44041000 33107000 24647000 24647000 4262698000 3974071000 1106387000 1015174000 3156311000 2958897000 11809000 8381000 5289000 9272000 126711000 0 9063000 0 181975000 214697000 3491158000 3191247000 1443919000 1345984000 75094000 80411000 300000 587000 91356000 14305000 61023000 47623000 1685997000 1474605000 0 0 1314000 1253000 3379572000 3180284000 8470000 902000 1100094000 1088119000 2667349000 2552112000 1805161000 1716642000 3491158000 3191247000 117740000 111452000 342787000 331247000 2059000 2010000 5987000 5973000 119799000 113462000 348774000 337220000 46777000 44135000 133790000 127691000 10802000 8504000 27157000 25977000 501000 141000 1227000 538000 45137000 42061000 131725000 121764000 -62000 42000 103217000 94779000 293899000 276012000 200000 1288000 5065000 30879000 14181000 13464000 41619000 39202000 0 5610000 0 41000 -736000 571000 -13981000 -12135000 -42900000 -7752000 2601000 6548000 11975000 53456000 0.02 0.05 0.08 0.42 0.02 0.05 0.08 0.42 128090000 123300000 126571000 123281000 128169000 123352000 126657000 123336000 0.30 0.30 0.90 0.90 2601000 6548000 11975000 53456000 -60000 -95000 -74000 -369000 -2341000 374000 -7642000 1403000 -2281000 469000 -7568000 1772000 320000 7017000 4407000 55228000 1292000 3305344000 -6189000 1097493000 -2628497000 1769443000 22000 71792000 71814000 2695000 2695000 5131000 5131000 2601000 2601000 -60000 -60000 -2341000 -2341000 38852000 38852000 1314000 3379572000 -8470000 1100094000 -2667349000 1805161000 1253000 3180284000 -902000 1088119000 -2552112000 1716642000 61000 192414000 192475000 1000 3266000 3267000 1000 10140000 10141000 11975000 11975000 -74000 -74000 -7642000 -7642000 115237000 115237000 1314000 3379572000 -8470000 1100094000 -2667349000 1805161000 1252000 3178514000 4000 1065256000 -2476971000 1768055000 113000 113000 39000 39000 0 2675000 2675000 6548000 6548000 -95000 -95000 374000 374000 37569000 37569000 1252000 3181263000 473000 1071804000 -2514540000 1740252000 1251000 3173429000 -1299000 1018348000 -2401846000 1789883000 464000 464000 719000 719000 1000 8089000 8090000 53456000 53456000 -369000 -369000 1403000 1403000 112694000 112694000 1252000 3181263000 473000 1071804000 -2514540000 1740252000 11975000 53456000 131725000 121764000 2279000 2113000 10141000 8090000 1833000 3599000 1159000 1147000 5065000 30879000 5610000 -16000 15000 277000 182000 42000 6740000 6891000 3220000 5908000 5709000 -638000 158473000 150680000 271575000 67445000 19152000 21059000 45902000 59802000 14151000 64271000 8000 -322478000 -84027000 60000000 56000000 50000000 12663000 3808000 115237000 112694000 192514000 459000 2343000 2673000 4589000 125000 249000 167433000 -62841000 3428000 3812000 8381000 6215000 11809000 10027000 37946000 30463000 10702000 5680000 7995000 999000 684000 <div style="line-height:174%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had gross investments of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;"><span>204</span></span><span style="font-family:inherit;font-size:10pt;"> real estate properties located in </span><span style="font-family:inherit;font-size:10pt;"><span>26</span></span><span style="font-family:inherit;font-size:10pt;"> states totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet. The Company provided leasing and property management services to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>11.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet nationwide.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Use of Estimates in the Condensed Consolidated Financial Statements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Revenue from Contracts with Customers (Topic 606)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type of Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,935</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,538</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,197</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental lease guaranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management fee income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Miscellaneous</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,059</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,987</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle. </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, "Leases." In January 2018, FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," in July 2018, FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements," and in December 2018, FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These accounting standard updates are collectively referred to as "Topic 842." </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Topic 842 provides several practical expedients that the Company elected. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, (b) the lessor practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately and (c) the lessee practical expedient not to separate certain non-lease components from the associated lease component.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. The Company's ground leases executed or assumed prior to the adoption of Topic 842 continue to be accounted for as operating leases and will not result in a materially different ground lease expense. However, each ground lease executed by the Company after the adoption of Topic 842 will be evaluated to determine if it is an operating or finance lease. If the lease is to be accounted for as a finance lease, ground lease expense would be accounted for using the effective interest method instead of the straight-line method over the term of the lease, which would result in higher ground lease expense in the earlier years of a ground lease when compared to the straight-line method. Leases in which the Company is the lessee are primarily ground leases, but also includes management office leases in third party buildings and certain copier and postage machine leases. The terms of the ground leases generally range from </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>99</span></span><span style="font-family:inherit;font-size:10pt;"> years with a weighted average lease term remaining of </span><span style="font-family:inherit;font-size:10pt;"><span>52.5 years</span></span><span style="font-family:inherit;font-size:10pt;">, excluding renewal options. The Company's discount rates, which approximates the Company's incremental borrowing rate, ranged from </span><span style="font-family:inherit;font-size:10pt;"><span>3.4%</span></span><span style="font-family:inherit;font-size:10pt;"> for leases expiring in 2019 to </span><span style="font-family:inherit;font-size:10pt;"><span>6.2%</span></span><span style="font-family:inherit;font-size:10pt;"> for leases expiring in 2115. The Company utilized a third party to assist in determining the discount rates for its ground leases. The discount rates consider the general economic environment and factor in various financing and asset specific adjustments so that the discount rate is appropriate for the intended use of the underlying lease. As of January 1, 2019, the Company recognized the present value of its lease payments and a corresponding lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$91.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, the Company reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of prepaid ground leases and below-market lease intangibles from the Other assets line item, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of above-market lease intangibles from the Other liabilities line and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of straight-line rent from the Accounts payable and accrued liabilities line item to the Operating lease right-of-use assets line item on the Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, are generally accounted for under Topic 606 and separated from the lease payments. However, the Company elected the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The combined component is accounted for under Topic 842. Lease related receivables, which include accounts receivable and accrued straight-line rent receivables, are reduced for revenue reserves and are recognized as a reduction to rental income. The adoption of Topic 842, where the Company is the lessor, did not have a material impact on the Company's Condensed Consolidated Financial Statements for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard was effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company elected to choose the prospective optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 was adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. See Note 3 to the Company's Condensed Consolidated Financial Statements for additional disclosures. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-13 and No. 2018-19</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of this topic. Instead, impairment of these receivables should be accounted for in accordance with Topic 842, Leases. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is evaluating the impact from the adoption of this new standard on the Condensed Consolidated Financial Statements and related notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2017-04</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Condensed Consolidated Financial Statements and related notes from the adoption of this standard.</span></div> <div style="line-height:174%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had gross investments of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;"><span>204</span></span><span style="font-family:inherit;font-size:10pt;"> real estate properties located in </span><span style="font-family:inherit;font-size:10pt;"><span>26</span></span><span style="font-family:inherit;font-size:10pt;"> states totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet. The Company provided leasing and property management services to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>11.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet nationwide.</span></div> 4200000000 204 26 15400000 11200000 <div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.</span></div> <div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Use of Estimates in the Condensed Consolidated Financial Statements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.</span></div> <div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Revenue from Contracts with Customers (Topic 606)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type of Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,935</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,538</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,197</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental lease guaranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management fee income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Miscellaneous</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,059</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,987</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle. </span></div> Below is a detail of the amounts by category:<div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type of Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,935</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,538</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,197</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental lease guaranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management fee income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Miscellaneous</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,059</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,987</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1935000 1752000 5538000 5197000 0 168000 128000 488000 69000 68000 201000 205000 55000 22000 120000 83000 2059000 2010000 5987000 5973000 3 <div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, "Leases." In January 2018, FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," in July 2018, FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements," and in December 2018, FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These accounting standard updates are collectively referred to as "Topic 842." </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Topic 842 provides several practical expedients that the Company elected. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, (b) the lessor practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately and (c) the lessee practical expedient not to separate certain non-lease components from the associated lease component.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. The Company's ground leases executed or assumed prior to the adoption of Topic 842 continue to be accounted for as operating leases and will not result in a materially different ground lease expense. However, each ground lease executed by the Company after the adoption of Topic 842 will be evaluated to determine if it is an operating or finance lease. If the lease is to be accounted for as a finance lease, ground lease expense would be accounted for using the effective interest method instead of the straight-line method over the term of the lease, which would result in higher ground lease expense in the earlier years of a ground lease when compared to the straight-line method. Leases in which the Company is the lessee are primarily ground leases, but also includes management office leases in third party buildings and certain copier and postage machine leases. The terms of the ground leases generally range from </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>99</span></span><span style="font-family:inherit;font-size:10pt;"> years with a weighted average lease term remaining of </span><span style="font-family:inherit;font-size:10pt;"><span>52.5 years</span></span><span style="font-family:inherit;font-size:10pt;">, excluding renewal options. The Company's discount rates, which approximates the Company's incremental borrowing rate, ranged from </span><span style="font-family:inherit;font-size:10pt;"><span>3.4%</span></span><span style="font-family:inherit;font-size:10pt;"> for leases expiring in 2019 to </span><span style="font-family:inherit;font-size:10pt;"><span>6.2%</span></span><span style="font-family:inherit;font-size:10pt;"> for leases expiring in 2115. The Company utilized a third party to assist in determining the discount rates for its ground leases. The discount rates consider the general economic environment and factor in various financing and asset specific adjustments so that the discount rate is appropriate for the intended use of the underlying lease. As of January 1, 2019, the Company recognized the present value of its lease payments and a corresponding lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$91.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, the Company reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of prepaid ground leases and below-market lease intangibles from the Other assets line item, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of above-market lease intangibles from the Other liabilities line and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of straight-line rent from the Accounts payable and accrued liabilities line item to the Operating lease right-of-use assets line item on the Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, are generally accounted for under Topic 606 and separated from the lease payments. However, the Company elected the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The combined component is accounted for under Topic 842. Lease related receivables, which include accounts receivable and accrued straight-line rent receivables, are reduced for revenue reserves and are recognized as a reduction to rental income. The adoption of Topic 842, where the Company is the lessor, did not have a material impact on the Company's Condensed Consolidated Financial Statements for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard was effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company elected to choose the prospective optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 was adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. See Note 3 to the Company's Condensed Consolidated Financial Statements for additional disclosures. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-13 and No. 2018-19</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of this topic. Instead, impairment of these receivables should be accounted for in accordance with Topic 842, Leases. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is evaluating the impact from the adoption of this new standard on the Condensed Consolidated Financial Statements and related notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2017-04</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Condensed Consolidated Financial Statements and related notes from the adoption of this standard.</span></div> P40Y P99Y P52Y6M 0.034 0.062 91700000 45000000.0 1900000 8400000 Real Estate Investments<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">2019 Acquisitions</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table details the Company's acquisitions for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:26%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Date<br/>Acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Purchase Price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Cash<br/>Consideration</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Real<br/>Estate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Square<br/>Footage<br/></span><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Unaudited)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Washington, D.C. </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>50.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>158,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indianapolis, IN </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Atlanta, GA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4/2/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47,963</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dallas, TX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/10/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89,990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seattle, WA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/11/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29,870</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seattle, WA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/14/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47,255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seattle, WA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Houston, TX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8/1/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29,903</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oklahoma City, OK</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9/26/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Los Angeles, CA </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(6)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9/30/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>115,634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>273.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>271.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>276.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>769,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">MOB = medical office building.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> properties. The Company assumed </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> ground leases in connection with this acquisition that are classified as financing leases. The present value of future lease payments totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$14.3 million</span></span><span style="font-family:inherit;font-size:9pt;"> was recorded on the Company's Condensed Consolidated Balance Sheets under the caption Finance lease liabilities. In addition, the right-of-use assets were partially offset by </span><span style="font-family:inherit;font-size:9pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:9pt;"> of above-market lease intangibles included in Other.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The Company assumed a prepaid ground lease totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:9pt;"> and recorded a below-market lease intangible totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:9pt;"> in connection with this acquisition that is classified as an operating lease that is included in Other.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(6)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> properties.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Subsequent Acquisitions</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 31, 2019, the Company acquired a </span><span style="font-family:inherit;font-size:10pt;"><span>57,730</span></span><span style="font-family:inherit;font-size:10pt;"> square foot medical office building in Raleigh, North Carolina for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$21.6 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 31, 2019, the Company acquired a </span><span style="font-family:inherit;font-size:10pt;"><span>48,192</span></span><span style="font-family:inherit;font-size:10pt;"> square foot medical office building in Dallas, Texas for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$20.1 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">2019 Real Estate Asset Dispositions</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table details the Company's dispositions for the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="31"/></tr><tr><td style="width:16%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Date<br/>Disposed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Sales Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Closing Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Net<br/>Proceeds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Net Real<br/>Estate<br/>Investment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other<br/>(including<br/>receivables)</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Gain/<br/>(Impairment)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Square<br/>Footage<br/>(</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Unaudited</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tucson, AZ </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4/9/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67,345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Virginia Beach, VA </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8/1/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">San Antonio, TX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total dispositions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>87,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">MOB = medical office building.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes straight-line rent receivables, leasing commissions and lease inducements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes four properties sold to a single purchaser.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The Company reclassified this property to held for sale during the second quarter of 2019 and recorded an impairment charge of </span><span style="font-family:inherit;font-size:9pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:9pt;"> based on the sales price less estimated costs to sell.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Subsequent Disposition</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 25, 2019, the Company disposed of a </span><span style="font-family:inherit;font-size:10pt;"><span>90,123</span></span><span style="font-family:inherit;font-size:10pt;"> square foot inpatient rehabilitation facility located in Erie, Pennsylvania following the ground lessor's exercise of a purchase option. The purchase price, determined by an appraisal process, was </span><span style="font-family:inherit;font-size:10pt;"><span>$14.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the Company's net investment in the building as of September 30, 2019 was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Assets Held for Sale</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> properties and </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> property, respectively, classified as held for sale. The following is a description of the two properties held for sale as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, the Company reclassified an inpatient rehabilitation facility to held for sale upon notification that the ground lessor exercised a purchase option. The purchase price, determined by an appraisal process, was </span><span style="font-family:inherit;font-size:10pt;"><span>$14.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the current net investment is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. This property was sold on October 25, 2019.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company accepted an offer from a third party to purchase a former long-term acute care facility located in Pittsburgh, Pennsylvania and recorded an impairment charge totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the sales price less estimated costs to sell. This property was reclassified to held for sale in 2017.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below reflects the assets and liabilities of the properties classified as held for sale as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet data:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Buildings, improvements and lease intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35,551</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,356</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(30,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Real estate assets held for sale, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>444</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>573</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Assets held for sale, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Liabilities of properties held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>587</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table details the Company's acquisitions for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:26%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Date<br/>Acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Purchase Price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Cash<br/>Consideration</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Real<br/>Estate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Square<br/>Footage<br/></span><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Unaudited)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Washington, D.C. </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>50.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>158,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indianapolis, IN </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Atlanta, GA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4/2/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47,963</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dallas, TX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/10/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89,990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seattle, WA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/11/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29,870</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seattle, WA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/14/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47,255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seattle, WA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Houston, TX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8/1/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29,903</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oklahoma City, OK</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9/26/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Los Angeles, CA </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(6)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9/30/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>115,634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>273.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>271.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>276.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>769,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">MOB = medical office building.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> properties. The Company assumed </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> ground leases in connection with this acquisition that are classified as financing leases. The present value of future lease payments totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$14.3 million</span></span><span style="font-family:inherit;font-size:9pt;"> was recorded on the Company's Condensed Consolidated Balance Sheets under the caption Finance lease liabilities. In addition, the right-of-use assets were partially offset by </span><span style="font-family:inherit;font-size:9pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:9pt;"> of above-market lease intangibles included in Other.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The Company assumed a prepaid ground lease totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:9pt;"> and recorded a below-market lease intangible totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:9pt;"> in connection with this acquisition that is classified as an operating lease that is included in Other.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(6)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> properties.</span></div> 2019-03-28 46000000.0 45900000 50200000 -4300000 158338 2019-03-28 47000000.0 44800000 43700000 1100000 143499 2019-04-02 28000000.0 28000000.0 28000000.0 0 47963 2019-06-10 17000000.0 16700000 17000000.0 -300000 89990 2019-06-11 7700000 7800000 7800000 0 29870 2019-06-14 19000000.0 19100000 19500000 -400000 47255 2019-06-28 30500000 30400000 30600000 -200000 78288 2019-08-01 13500000 13500000 13500000 0 29903 2019-09-26 4100000 4100000 4100000 0 28542 2019-09-30 61100000 60900000 61800000 -900000 115634 273900000 271200000 276200000 -5000000.0 769282 2 2 14300000 5200000 800000 900000 2 57730 21600000 48192 20100000 <div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table details the Company's dispositions for the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="31"/></tr><tr><td style="width:16%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Date<br/>Disposed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Sales Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Closing Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Net<br/>Proceeds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Net Real<br/>Estate<br/>Investment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other<br/>(including<br/>receivables)</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Gain/<br/>(Impairment)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Square<br/>Footage<br/>(</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Unaudited</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tucson, AZ </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4/9/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67,345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Virginia Beach, VA </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8/1/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">San Antonio, TX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8/28/19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total dispositions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>87,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">MOB = medical office building.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes straight-line rent receivables, leasing commissions and lease inducements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes four properties sold to a single purchaser.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(4)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The Company reclassified this property to held for sale during the second quarter of 2019 and recorded an impairment charge of </span><span style="font-family:inherit;font-size:9pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:9pt;"> based on the sales price less estimated costs to sell.</span></div> 2019-04-09 13000000.0 900000 12100000 6900000 400000 4800000 67345 2019-08-01 1300000 100000 1200000 1200000 0 0 10000 2019-08-28 900000 100000 800000 600000 0 200000 10138 15200000 1100000 14100000 8700000 400000 5000000.0 87483 400000 90123 14000000.0 1300000 2 1 14000000.0 1300000 5200000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below reflects the assets and liabilities of the properties classified as held for sale as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet data:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Buildings, improvements and lease intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35,551</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,356</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(30,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Real estate assets held for sale, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>444</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>573</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Assets held for sale, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Liabilities of properties held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>587</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1125000 1125000 34426000 18231000 35551000 19356000 30706000 10657000 4845000 8699000 444000 573000 5289000 9272000 93000 450000 207000 137000 300000 587000 Leases<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessor Accounting Under ASC 842</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components such as reimbursement of operating expenses as additional rent or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> ground lease that is associated with a property under construction where rent has not yet commenced. Lease income for the Company's operating leases recognized for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$117.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$342.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:38.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>91,501</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>340,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>292,541</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>252,315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>210,559</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>572,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,760,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessor Accounting Under ASC 840</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through </span><span style="font-family:inherit;font-size:10pt;">2036</span><span style="font-family:inherit;font-size:10pt;">. Some leases and financial arrangements provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease and for a short period thereafter, with an option or a right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 were as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:38.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>326,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>279,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201,072</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,683,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessee Accounting Under ASC 842</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>108</span></span><span style="font-family:inherit;font-size:10pt;"> properties, excluding </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> property classified as held for sale, totaling </span><span style="font-family:inherit;font-size:10pt;"><span>9.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet that were held under ground leases. Some of the ground leases renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>99</span></span><span style="font-family:inherit;font-size:10pt;"> years with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index. The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>46</span></span><span style="font-family:inherit;font-size:10pt;"> prepaid ground leases as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The amortization of the prepaid rent, included in the operating lease right-of-use asset represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s rental expense for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s future lease payments (primarily for its </span><span style="font-family:inherit;font-size:10pt;"><span>62</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>999</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,816</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,877</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>312,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>333,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,369</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(241,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(63,064</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>91,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides details of the Company's total lease expense for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,169</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Variable lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest on lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,261</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,321</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating cash flows outflows related to operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,461</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing cash flows outflows related to financing leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Right-of-use assets obtained in exchange for new finance lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,294</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average remaining lease term (excluding renewal options) - operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49.7</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average remaining lease term (excluding renewal options) -finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70.1</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average discount rate - operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.7%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average discount rate - finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.5%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessee Accounting Under ASC 840</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company was obligated under operating lease agreements consisting primarily of the Company’s ground leases. At December 31, 2018, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>107</span></span><span style="font-family:inherit;font-size:10pt;"> properties totaling </span><span style="font-family:inherit;font-size:10pt;"><span>8.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet that were held under ground leases with a remaining weighted average term of </span><span style="font-family:inherit;font-size:10pt;"><span>53.9</span></span><span style="font-family:inherit;font-size:10pt;"> years, excluding renewal options. These ground leases typically have initial terms of </span><span style="font-family:inherit;font-size:10pt;"><span>50</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>75</span></span><span style="font-family:inherit;font-size:10pt;"> years with one or more renewal options extending the terms to </span><span style="font-family:inherit;font-size:10pt;"><span>75</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>100</span></span><span style="font-family:inherit;font-size:10pt;"> years, with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s future minimum lease payments (primarily for its </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:28.515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:34%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>349,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> Leases<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessor Accounting Under ASC 842</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components such as reimbursement of operating expenses as additional rent or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> ground lease that is associated with a property under construction where rent has not yet commenced. Lease income for the Company's operating leases recognized for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$117.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$342.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:38.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>91,501</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>340,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>292,541</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>252,315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>210,559</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>572,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,760,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessor Accounting Under ASC 840</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through </span><span style="font-family:inherit;font-size:10pt;">2036</span><span style="font-family:inherit;font-size:10pt;">. Some leases and financial arrangements provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease and for a short period thereafter, with an option or a right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 were as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:38.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>326,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>279,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201,072</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,683,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessee Accounting Under ASC 842</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>108</span></span><span style="font-family:inherit;font-size:10pt;"> properties, excluding </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> property classified as held for sale, totaling </span><span style="font-family:inherit;font-size:10pt;"><span>9.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet that were held under ground leases. Some of the ground leases renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>99</span></span><span style="font-family:inherit;font-size:10pt;"> years with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index. The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>46</span></span><span style="font-family:inherit;font-size:10pt;"> prepaid ground leases as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The amortization of the prepaid rent, included in the operating lease right-of-use asset represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s rental expense for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s future lease payments (primarily for its </span><span style="font-family:inherit;font-size:10pt;"><span>62</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>999</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,816</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,877</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>312,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>333,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,369</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(241,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(63,064</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>91,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides details of the Company's total lease expense for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,169</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Variable lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest on lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,261</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,321</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating cash flows outflows related to operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,461</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing cash flows outflows related to financing leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Right-of-use assets obtained in exchange for new finance lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,294</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average remaining lease term (excluding renewal options) - operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49.7</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average remaining lease term (excluding renewal options) -finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70.1</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average discount rate - operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.7%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average discount rate - finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.5%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Lessee Accounting Under ASC 840</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company was obligated under operating lease agreements consisting primarily of the Company’s ground leases. At December 31, 2018, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>107</span></span><span style="font-family:inherit;font-size:10pt;"> properties totaling </span><span style="font-family:inherit;font-size:10pt;"><span>8.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet that were held under ground leases with a remaining weighted average term of </span><span style="font-family:inherit;font-size:10pt;"><span>53.9</span></span><span style="font-family:inherit;font-size:10pt;"> years, excluding renewal options. These ground leases typically have initial terms of </span><span style="font-family:inherit;font-size:10pt;"><span>50</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>75</span></span><span style="font-family:inherit;font-size:10pt;"> years with one or more renewal options extending the terms to </span><span style="font-family:inherit;font-size:10pt;"><span>75</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>100</span></span><span style="font-family:inherit;font-size:10pt;"> years, with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s future minimum lease payments (primarily for its </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:28.515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:34%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>349,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1 117700000 342800000 <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:38.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>91,501</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>340,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>292,541</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>252,315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>210,559</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>572,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,760,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 91501000 340549000 292541000 252315000 210559000 572767000 1760232000 <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 were as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:38.0859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>326,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>279,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201,072</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>476,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,683,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 326441000 279211000 235660000 201072000 163978000 476673000 1683035000 108 1 9000000.0 P40Y P99Y 46 200000 100000 400000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s future lease payments (primarily for its </span><span style="font-family:inherit;font-size:10pt;"><span>62</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>999</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,816</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,877</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>312,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>333,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,369</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(241,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(63,064</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>91,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s future lease payments (primarily for its </span><span style="font-family:inherit;font-size:10pt;"><span>62</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>999</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,816</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,877</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>312,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>333,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,369</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(241,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(63,064</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>91,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 62 999000 107000 4816000 611000 4846000 619000 4877000 628000 4915000 637000 312712000 74767000 333165000 77369000 241809000 63064000 91356000 14305000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides details of the Company's total lease expense for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,169</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Variable lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finance lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest on lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,261</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,321</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating cash flows outflows related to operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,461</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing cash flows outflows related to financing leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Right-of-use assets obtained in exchange for new finance lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,294</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average remaining lease term (excluding renewal options) - operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49.7</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average remaining lease term (excluding renewal options) -finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70.1</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average discount rate - operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.7%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average discount rate - finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.5%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1169000 3448000 845000 2380000 51000 101000 196000 392000 2261000 6321000 1313000 5461000 107000 249000 0 14294000 P49Y8M12D P70Y1M6D 0.057 0.055 107 8800000 P53Y10M24D P50Y P75Y P75Y P100Y <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s future minimum lease payments (primarily for its </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands): </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:28.515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:34%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>349,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 60 5288000 5260000 5238000 5207000 5224000 323533000 349750000 Notes and Bonds Payable<div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below details the Company’s notes and bonds payable.</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:38%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Maturity</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Dates</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance as of</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Interest Rate as of </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$700 million Unsecured Credit Facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5/23</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>322,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>262,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.92</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$200 million Unsecured Term Loan Facility, net of issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5/24</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>198,957</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>149,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$150 million Unsecured Term Loan due 2026 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">6/26</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">N/A</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2023, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4/23</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.95</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2025, net of discount and issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5/25</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,460</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2028, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1/28</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>295,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>295,198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage notes payable, net of discounts and issuance costs and including premiums</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">7/20-5/40</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>130,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.81</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,443,919</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,345,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of interest rate swaps on $</span><span style="font-family:inherit;font-size:8pt;"><span>175.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> at a weighted average rate of </span><span style="font-family:inherit;font-size:8pt;"><span>2.29%</span></span><span style="font-family:inherit;font-size:8pt;"> (plus the applicable margin rate, currently 100 basis points).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of September 30, 2019, there were </span><span style="font-family:inherit;font-size:8pt;"><span>no</span></span><span style="font-family:inherit;font-size:8pt;"> outstanding loans under the </span><span style="font-family:inherit;font-size:8pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> unsecured term loan due June 2026. This term loan has a delayed draw feature that allows the Company until February 2020 to draw against the commitments.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of the </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:8pt;"> settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets. </span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Changes in Debt Structure</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 10, 2019, the Company repaid in full a mortgage note payable bearing interest at a rate of </span><span style="font-family:inherit;font-size:10pt;"><span>5.00%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum with an outstanding principal of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. The mortgage note encumbered a </span><span style="font-family:inherit;font-size:10pt;"><span>52,813</span></span><span style="font-family:inherit;font-size:10pt;"> square foot property in Washington.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 31, 2019, the Company amended and restated its </span><span style="font-family:inherit;font-size:10pt;"><span>$700.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> unsecured credit facility due 2020 (the "Unsecured Credit Facility") to extend the maturity date from July 2020 to May 2023. Amounts outstanding under the Unsecured Credit Facility bear interest at LIBOR plus an applicable margin, which depends on the Company's credit ratings, ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>0.775%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>1.45%</span></span><span style="font-family:inherit;font-size:10pt;"> (currently </span><span style="font-family:inherit;font-size:10pt;"><span>0.90%</span></span><span style="font-family:inherit;font-size:10pt;">). In addition, the Company pays a facility fee per annum on the aggregate amount of commitments ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>0.125%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>0.30%</span></span><span style="font-family:inherit;font-size:10pt;"> (currently </span><span style="font-family:inherit;font-size:10pt;"><span>0.20%</span></span><span style="font-family:inherit;font-size:10pt;">). In connection with the amendment, the Company paid up front fees to the lenders and other costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, which were capitalized and are being amortized over the term of the Unsecured Credit Facility. </span></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Also, on May 31, 2019, the Company amended and restated its term loan agreement (the "Term Loan") with a syndicate of lenders. The amended agreement extended the maturity date of the Company's unsecured term loan due 2022 to May 2024 (the "Term Loan due 2024") and increased the loan amount from </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, the amended agreement added a </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> seven-year term loan facility (the "Term Loan due 2026"). The Term Loan due 2024 bears interest at LIBOR plus an applicable margin ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>0.85%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>1.65%</span></span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span><span style="font-family:inherit;font-size:10pt;"> at September 30, 2019) based upon the Company's unsecured debt ratings. The Term Loan due 2026 has a delayed draw feature that allows the Company up to </span><span style="font-family:inherit;font-size:10pt;"><span>nine months</span></span><span style="font-family:inherit;font-size:10pt;"> to draw against the commitments. As of September 30, 2019, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> loans were outstanding under the Term Loan due 2026. Loans outstanding under the Term Loan due 2026 will bear interest at a rate equal to LIBOR plus a margin ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>1.45%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>2.40%</span></span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;"><span>1.60%</span></span><span style="font-family:inherit;font-size:10pt;"> at September 30, 2019). Committed amounts that remain undrawn are subject to a ticking fee ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>0.125%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>0.30%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum (</span><span style="font-family:inherit;font-size:10pt;"><span>0.20%</span></span><span style="font-family:inherit;font-size:10pt;"> at September 30, 2019). In connection with the amendment, the Company paid up front fees to the lenders of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> were capitalized and are being amortized over the respective term of the term loans and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span> were expensed during the second quarter of 2019. <div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below details the Company’s notes and bonds payable.</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:38%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Maturity</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Dates</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance as of</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Interest Rate as of </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$700 million Unsecured Credit Facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5/23</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>322,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>262,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.92</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$200 million Unsecured Term Loan Facility, net of issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5/24</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>198,957</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>149,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$150 million Unsecured Term Loan due 2026 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">6/26</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">N/A</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2023, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4/23</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.95</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2025, net of discount and issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5/25</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,460</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2028, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1/28</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>295,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>295,198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage notes payable, net of discounts and issuance costs and including premiums</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">7/20-5/40</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>130,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>143,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.81</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,443,919</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,345,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of interest rate swaps on $</span><span style="font-family:inherit;font-size:8pt;"><span>175.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> at a weighted average rate of </span><span style="font-family:inherit;font-size:8pt;"><span>2.29%</span></span><span style="font-family:inherit;font-size:8pt;"> (plus the applicable margin rate, currently 100 basis points).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of September 30, 2019, there were </span><span style="font-family:inherit;font-size:8pt;"><span>no</span></span><span style="font-family:inherit;font-size:8pt;"> outstanding loans under the </span><span style="font-family:inherit;font-size:8pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> unsecured term loan due June 2026. This term loan has a delayed draw feature that allows the Company until February 2020 to draw against the commitments.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of the </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:8pt;"> settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets. </span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 322000000 262000000 0.0292 198957000 149183000 0.0329 248434000 248117000 0.0395 248460000 248278000 0.0408 295536000 295198000 0.0384 130532000 143208000 0.0481 1443919000 1345984000 175000000.0 0.0229 0 150000000.0 -1700000 0.0500 8900000 52813 700000000.0 0.00775 0.0145 0.0090 0.00125 0.0030 0.0020 3500000 150000000.0 200000000.0 150000000.0 0.0085 0.0165 0.0100 P9M 0 0.0145 0.0240 0.0160 0.00125 0.0030 0.0020 1800000 1000000.0 800000 Derivative Financial Instruments<div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Risk Management Objective of Using Derivatives</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Cash Flow Hedges of Interest Rate Risk</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) ("AOCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 12, 2019, the Company entered into </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> interest rate swaps totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to fix the one-month LIBOR portion of the cost of borrowing to a rate of </span><span style="font-family:inherit;font-size:10pt;"><span>2.33%</span></span><span style="font-family:inherit;font-size:10pt;">. These derivatives are being used to hedge variable cash flows associated with variable-rate debt.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 15, 2019, the Company entered into </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> interest rate swaps totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to fix the one-month LIBOR portion of the cost of borrowing to a rate of </span><span style="font-family:inherit;font-size:10pt;"><span>2.13%</span></span><span style="font-family:inherit;font-size:10pt;">. These derivatives are being used to hedge variable cash flows associated with variable-rate debt.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>eight</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Derivative Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Notional Amount</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$175.0</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:59%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance at September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,533</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the effect of cash flow hedge accounting on AOCI during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> related to the Company's outstanding interest rate swaps.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Gain (Loss) Recognized in AOCI on Derivative</span></div></td><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Loss Reclassified from AOCI into Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,341</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>374</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Settled interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>374</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Gain (Loss) Recognized in AOCI on Derivative</span></div></td><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Gain) Loss Reclassified from AOCI into Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7,642</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Settled interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7,642</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>369</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Credit-risk-related Contingent Features</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company estimates that </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> will be reclassified from AOCI to interest expense over the next 12 months.</span></div> 2 50000000.0 0.0233 2 50000000.0 0.0213 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>eight</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Derivative Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Notional Amount</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$175.0</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8 8 175000000.0 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:59%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance at September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,533</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 7533000 7533000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the effect of cash flow hedge accounting on AOCI during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> related to the Company's outstanding interest rate swaps.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Gain (Loss) Recognized in AOCI on Derivative</span></div></td><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Loss Reclassified from AOCI into Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,341</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>374</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Settled interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>374</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Gain (Loss) Recognized in AOCI on Derivative</span></div></td><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Gain) Loss Reclassified from AOCI into Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7,642</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Settled interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7,642</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>369</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -2341000 374000 18000 53000 0 0 42000 42000 -2341000 374000 60000 95000 -7642000 1403000 -52000 243000 0 0 126000 126000 -7642000 1403000 74000 369000 1300000 Commitments and Contingencies<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Redevelopment Activity</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company redeveloped a medical office building in Charlotte, North Carolina, which includes a </span><span style="font-family:inherit;font-size:10pt;"><span>40,278</span></span><span style="font-family:inherit;font-size:10pt;"> square foot vertical expansion. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had funded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$9.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> towards the redevelopment of this property. The Company expects to fund approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for additional tenant improvements associated with this project. The first tenant took occupancy during the second quarter of 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Development Activity</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company began the development of a </span><span style="font-family:inherit;font-size:10pt;"><span>151,000</span></span><span style="font-family:inherit;font-size:10pt;"> square foot medical office building in Seattle, Washington during 2017. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had funded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$44.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> towards the development. The Company expects to fund an additional amount of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to complete this project. The Company expects the first tenant to take occupancy in the first quarter of 2020.</span></div> 40278 9800000 2200000 151000 44300000 19800000 Stockholders' Equity<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Common Stock    </span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,279,455</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,131,593</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,099,012</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26,203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested share-based awards, net of withheld shares </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>121,659</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>131,368,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,279,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in </span><span style="font-family:inherit;font-size:9pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:9pt;"> of expenses associated with the acceleration of his outstanding nonvested share-based awards. In connection with the vesting, </span><span style="font-family:inherit;font-size:9pt;"><span>80,490</span></span><span style="font-family:inherit;font-size:9pt;"> shares were withheld to pay employee federal income taxes. </span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Equity Offering</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 19, 2019, the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>3,737,500</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share, at </span><span style="font-family:inherit;font-size:10pt;"><span>$31.40</span></span><span style="font-family:inherit;font-size:10pt;"> per share in an underwritten public offering pursuant to the Company's existing effective registration statement. The net proceeds of the offering, after underwriting discounts and offering expenses, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$115.8 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">At-The-Market Equity Offering Program</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>4,694,624</span></span><span style="font-family:inherit;font-size:10pt;"> shares under the Company's at-the-market equity offering program from January 1, 2019 through October 31, 2019. The sales generated </span><span style="font-family:inherit;font-size:10pt;"><span>$153.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net proceeds at prices to the public ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>$32.01</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$33.77</span></span><span style="font-family:inherit;font-size:10pt;"> per share (weighted average of </span><span style="font-family:inherit;font-size:10pt;"><span>$33.31</span></span><span style="font-family:inherit;font-size:10pt;"> per share). The sales occurred during the following time periods:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first quarter of 2019, the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>135,265</span></span><span style="font-family:inherit;font-size:10pt;"> shares generating </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net proceeds at prices to the public ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>$32.01</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$32.86</span></span><span style="font-family:inherit;font-size:10pt;"> per share (weighted average of </span><span style="font-family:inherit;font-size:10pt;"><span>$32.36</span></span><span style="font-family:inherit;font-size:10pt;"> per share).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> shares were sold in the second quarter of 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the third quarter of 2019, the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>2,191,522</span></span><span style="font-family:inherit;font-size:10pt;"> shares generating </span><span style="font-family:inherit;font-size:10pt;"><span>$71.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net proceeds at prices to the public ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>$32.62</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$33.77</span></span><span style="font-family:inherit;font-size:10pt;"> per share (weighted average of </span><span style="font-family:inherit;font-size:10pt;"><span>$33.15</span></span><span style="font-family:inherit;font-size:10pt;"> per share).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During October 2019, the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>2,367,837</span></span><span style="font-family:inherit;font-size:10pt;"> shares generating </span><span style="font-family:inherit;font-size:10pt;"><span>$78.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net proceeds at prices to the public ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>$33.17</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$33.74</span></span><span style="font-family:inherit;font-size:10pt;"> per share (weighted average of </span><span style="font-family:inherit;font-size:10pt;"><span>$33.52</span></span><span style="font-family:inherit;font-size:10pt;"> per share).</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>1,174,073</span></span><span style="font-family:inherit;font-size:10pt;"> authorized shares remaining available to be sold under the current sales agreements as of </span><span style="font-family:inherit;font-size:10pt;">October 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Common Stock Dividends</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company declared and paid common stock dividends totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$0.90</span></span><span style="font-family:inherit;font-size:10pt;"> per share. On </span><span style="font-family:inherit;font-size:10pt;">October 29, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company declared a quarterly common stock dividend in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.30</span></span><span style="font-family:inherit;font-size:10pt;"> per share payable on </span><span style="font-family:inherit;font-size:10pt;">November 29, 2019</span><span style="font-family:inherit;font-size:10pt;"> to stockholders of record on</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">November 14, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Earnings Per Common Share</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands, except per share data)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted average Common Shares outstanding</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>129,865,985</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,233,462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,348,638</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,206,342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,775,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,933,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,777,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,925,589</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,090,074</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,299,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126,570,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,280,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,090,074</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,299,809</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126,570,895</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,280,753</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dilutive effect of employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>54,763</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,168,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,351,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126,656,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,335,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,601</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,548</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,975</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53,456</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dividends paid on nonvested share-based awards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(534</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(580</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income applicable to common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,968</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,372</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51,716</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Incentive Plans</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the activity under the Company's share-based incentive plans for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.7734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:37%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,778,134</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,938,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,769,863</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,907,645</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89,767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107,751</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(204,548</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5,051</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(286,044</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(82,347</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,573,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,933,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,573,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,933,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in the accelerated vesting of </span><span style="font-family:inherit;font-size:9pt;"><span>204,548</span></span><span style="font-family:inherit;font-size:9pt;"> outstanding nonvested share-based awards. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company withheld </span><span style="font-family:inherit;font-size:10pt;"><span>100,036</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>22,555</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:37%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>363,218</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>350,535</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>328,533</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>318,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,572</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>203,836</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9,927</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,531</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(28,943</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13,236</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11,762</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9,583</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(51,559</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(34,489</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(142,074</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(135,790</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>341,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>338,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>341,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>338,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,279,455</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,131,593</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,099,012</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26,203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested share-based awards, net of withheld shares </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>121,659</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>131,368,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,279,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in </span><span style="font-family:inherit;font-size:9pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:9pt;"> of expenses associated with the acceleration of his outstanding nonvested share-based awards. In connection with the vesting, </span><span style="font-family:inherit;font-size:9pt;"><span>80,490</span></span><span style="font-family:inherit;font-size:9pt;"> shares were withheld to pay employee federal income taxes. </span></div> 125279455 125131593 6099012 26203 -10269 121659 131368198 125279455 2900000 80490 3737500 0.01 31.40 115800000 4694624 153700000 32.01 33.77 33.31 135265 4300000 32.01 32.86 32.36 0 2191522 71600000 32.62 33.77 33.15 2367837 78200000 33.17 33.74 33.52 1174073 0.90 0.30 The following table sets forth the computation of basic and diluted earnings per common share for the <span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands, except per share data)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted average Common Shares outstanding</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>129,865,985</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,233,462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,348,638</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,206,342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,775,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,933,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,777,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,925,589</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,090,074</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,299,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126,570,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,280,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,090,074</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,299,809</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126,570,895</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,280,753</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dilutive effect of employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>54,763</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,168,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,351,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126,656,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,335,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,601</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,548</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,975</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53,456</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dividends paid on nonvested share-based awards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(534</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(580</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income applicable to common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,968</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,372</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51,716</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 129865985 125233462 128348638 125206342 1775911 1933653 1777743 1925589 128090074 123299809 126570895 123280753 128090074 123299809 126570895 123280753 78610 52147 85690 54763 128168684 123351956 126656585 123335516 2601000 6548000 11975000 53456000 534000 580000 1603000 1740000 2067000 5968000 10372000 51716000 0.02 0.05 0.08 0.42 0.02 0.05 0.08 0.42 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the activity under the Company's share-based incentive plans for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.7734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:37%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,778,134</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,938,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,769,863</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,907,645</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89,767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107,751</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(204,548</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5,051</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(286,044</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(82,347</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,573,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,933,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,573,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,933,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in the accelerated vesting of </span><span style="font-family:inherit;font-size:9pt;"><span>204,548</span></span><span style="font-family:inherit;font-size:9pt;"> outstanding nonvested share-based awards. </span></div> 1778134 1938100 1769863 1907645 0 0 89767 107751 204548 5051 286044 82347 1573586 1933049 1573586 1933049 204548 100036 22555 A summary of the activity under the Purchase Plan for the <span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:37%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>363,218</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>350,535</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>328,533</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>318,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,572</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>203,836</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9,927</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,531</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(28,943</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13,236</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11,762</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9,583</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(51,559</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(34,489</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(142,074</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(135,790</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>341,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>338,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>341,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>338,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 363218 350535 328533 318100 0 0 235572 203836 9927 2531 28943 13236 11762 9583 51559 34489 0 0 142074 135790 341529 338421 341529 338421 Fair Value of Financial Instruments<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and cash equivalents - </span><span style="font-family:inherit;font-size:10pt;">The carrying amount approximates fair value due to the short term maturity of these investments. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Borrowings under the Unsecured Credit Facility and the Term Loan Due 2024 - </span><span style="font-family:inherit;font-size:10pt;">The carrying amount approximates fair value because the borrowings are based on variable market interest rates.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Notes and Mortgage Notes payable - </span><span style="font-family:inherit;font-size:10pt;">The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate swap agreements - </span><span style="font-family:inherit;font-size:10pt;">Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below details the fair values and carrying values for notes and bonds payable at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Notes and bonds payable </span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,443.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,468.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,346.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,326.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.</span></div> <div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below details the fair values and carrying values for notes and bonds payable at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Notes and bonds payable </span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,443.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,468.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,346.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,326.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.</span></div> 1443900000 1468500000 1346000000.0 1326500000 XML 54 R27.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) - USD ($)
$ in Thousands
Jan. 01, 2019
Sep. 30, 2019
Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Operating lease liabilities   $ 91,356  
Minimum      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term     50 years
Maximum      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term     75 years
Weighted Average Remaining Term      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term     53 years 10 months 24 days
Accounting Standards Update 2016-02      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Operating lease liabilities     $ 91,700
Accounting Standards Update 2016-02 | Minimum      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term   40 years  
Ground lease, discount rate     3.40%
Accounting Standards Update 2016-02 | Maximum      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term   99 years  
Ground lease, discount rate     6.20%
Accounting Standards Update 2016-02 | Weighted Average Remaining Term      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Ground lease, initial term   52 years 6 months  
Other Assets      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Transfers to operating lease, right-of-use assets $ 45,000    
Other liabilities      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Transfers to operating lease, right-of-use assets 1,900    
Accounts Payable and Accrued Liabilities      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Transfers to operating lease, right-of-use assets $ 8,400    
XML 55 R23.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Reconciliation of beginning and ending common stock outstanding
The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2019 and the year ended December 31, 2018:
 
September 30, 2019
 
December 31, 2018
Balance, beginning of period
125,279,455

 
125,131,593

Issuance of common stock
6,099,012

 
26,203

Nonvested share-based awards, net of withheld shares (1)
(10,269
)
 
121,659

Balance, end of period
131,368,198

 
125,279,455


______
(1)
The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in $2.9 million of expenses associated with the acceleration of his outstanding nonvested share-based awards. In connection with the vesting, 80,490 shares were withheld to pay employee federal income taxes.
Earnings (loss) per share The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2019 and 2018.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(Dollars in thousands, except per share data)
2019
 
2018
 
2019
 
2018
Weighted average Common Shares outstanding
 
 
 
 
 
 
 
Weighted average Common Shares outstanding
129,865,985

 
125,233,462

 
128,348,638

 
125,206,342

Nonvested shares
(1,775,911
)
 
(1,933,653
)
 
(1,777,743
)
 
(1,925,589
)
Weighted average Common Shares outstanding—Basic
128,090,074

 
123,299,809

 
126,570,895

 
123,280,753

Weighted average Common Shares outstanding—Basic
128,090,074

 
123,299,809

 
126,570,895

 
123,280,753

Dilutive effect of employee stock purchase plan
78,610

 
52,147

 
85,690

 
54,763

Weighted average Common Shares outstanding—Diluted
128,168,684

 
123,351,956

 
126,656,585

 
123,335,516

Net Income
$
2,601

 
$
6,548

 
$
11,975

 
$
53,456

Dividends paid on nonvested share-based awards
(534
)
 
(580
)
 
(1,603
)
 
(1,740
)
Net income applicable to common stockholders
$
2,067

 
$
5,968

 
$
10,372

 
$
51,716

Basic earnings per common share - Net income
$
0.02

 
$
0.05

 
$
0.08

 
$
0.42

Diluted earnings per common share - Net income
$
0.02

 
$
0.05

 
$
0.08

 
$
0.42



Summary of the activity under the Incentive Plan
A summary of the activity under the Company's share-based incentive plans for the three and nine months ended September 30, 2019 and 2018 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Share-based awards, beginning of period
1,778,134

 
1,938,100

 
1,769,863

 
1,907,645

Granted

 

 
89,767

 
107,751

Vested (1)
(204,548
)
 
(5,051
)
 
(286,044
)
 
(82,347
)
Share-based awards, end of period
1,573,586

 
1,933,049

 
1,573,586

 
1,933,049


______
(1)
The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in the accelerated vesting of 204,548 outstanding nonvested share-based awards.
Summary of employee stock purchase plan activity A summary of the activity under the Purchase Plan for the three and nine months ended September 30, 2019 and 2018 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Outstanding and exercisable, beginning of period
363,218

 
350,535

 
328,533

 
318,100

Granted

 

 
235,572

 
203,836

Exercised
(9,927
)
 
(2,531
)
 
(28,943
)
 
(13,236
)
Forfeited
(11,762
)
 
(9,583
)
 
(51,559
)
 
(34,489
)
Expired

 

 
(142,074
)
 
(135,790
)
Outstanding and exercisable, end of period
341,529

 
338,421

 
341,529

 
338,421


XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 R42.htm IDEA: XBRL DOCUMENT v3.19.3
Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Derivative [Line Items]        
Gain (Loss) Recognized in OCI on Derivative $ (2,341) $ 374 $ (7,642) $ 1,403
(Gain) Loss Reclassified from Accumulated OCI into Income (60) (95) (74) (369)
Interest Rate Swaps        
Derivative [Line Items]        
Gain (Loss) Recognized in OCI on Derivative (2,341) 374 (7,642) 1,403
Settled Interest Rate Swaps        
Derivative [Line Items]        
Gain (Loss) Recognized in OCI on Derivative 0 0 0 0
Interest Expense        
Derivative [Line Items]        
(Gain) Loss Reclassified from Accumulated OCI into Income 60 95 74 369
Interest Expense | Interest Rate Swaps        
Derivative [Line Items]        
(Gain) Loss Reclassified from Accumulated OCI into Income 18 53 (52) 243
Interest Expense | Settled Interest Rate Swaps        
Derivative [Line Items]        
(Gain) Loss Reclassified from Accumulated OCI into Income $ 42 $ 42 $ 126 $ 126
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Weighted average Common Shares outstanding        
Weighted average Common Shares outstanding 129,865,985 125,233,462 128,348,638 125,206,342
Nonvested shares (1,775,911) (1,933,653) (1,777,743) (1,925,589)
Weighted average Common Shares—Basic 128,090,074 123,299,809 126,570,895 123,280,753
Dilutive effect of employee stock purchase plan 78,610 52,147 85,690 54,763
Weighted average Common Shares outstanding—Diluted 128,168,684 123,351,956 126,656,585 123,335,516
Net Income $ 2,601 $ 6,548 $ 11,975 $ 53,456
Dividends paid on nonvested share-based awards (534) (580) (1,603) (1,740)
Net income applicable to common stockholders $ 2,067 $ 5,968 $ 10,372 $ 51,716
Basic earnings per common share (in dollars per share) $ 0.02 $ 0.05 $ 0.08 $ 0.42
Diluted earnings per common share (in dollars per share) $ 0.02 $ 0.05 $ 0.08 $ 0.42
XML 60 R6.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Equity (Unaudited) Statement - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Cumulative Net Income
Cumulative Dividends
Beginning balance at Dec. 31, 2017 $ 1,789,883 $ 1,251 $ 3,173,429 $ (1,299) $ 1,018,348 $ (2,401,846)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock, net of issuance costs 464   464      
Common stock redemptions (719)   (719)      
Share-based compensation 8,090 1 8,089      
Net income 53,456       53,456  
Reclassification adjustments for losses included in net income (interest expense) 369     369    
Losses arising during the period on interest rate swaps 1,403     1,403    
Dividends to common stockholders (112,694)         (112,694)
Ending balance at Sep. 30, 2018 1,740,252 1,252 3,181,263 473 1,071,804 (2,514,540)
Beginning balance at Jun. 30, 2018 1,768,055 1,252 3,178,514 4 1,065,256 (2,476,971)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock, net of issuance costs 113   113      
Common stock redemptions (39)   (39)      
Share-based compensation 2,675 0 2,675      
Net income 6,548       6,548  
Reclassification adjustments for losses included in net income (interest expense) 95     95    
Losses arising during the period on interest rate swaps 374     374    
Dividends to common stockholders (37,569)         (37,569)
Ending balance at Sep. 30, 2018 1,740,252 1,252 3,181,263 473 1,071,804 (2,514,540)
Beginning balance at Dec. 31, 2018 1,716,642 1,253 3,180,284 (902) 1,088,119 (2,552,112)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock, net of issuance costs 192,475 $ 61 192,414      
Stock Repurchased and Retired During Period, Shares   (1)        
Common stock redemptions (3,267)   (3,266)      
Share-based compensation 10,141 $ 1 10,140      
Net income 11,975       11,975  
Reclassification adjustments for losses included in net income (interest expense) 74     74    
Losses arising during the period on interest rate swaps (7,642)     (7,642)    
Dividends to common stockholders (115,237)         (115,237)
Ending balance at Sep. 30, 2019 1,805,161 1,314 3,379,572 (8,470) 1,100,094 (2,667,349)
Beginning balance at Jun. 30, 2019 1,769,443 1,292 3,305,344 (6,189) 1,097,493 (2,628,497)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock, net of issuance costs 71,814 22 71,792      
Common stock redemptions (2,695)   (2,695)      
Share-based compensation 5,131   5,131      
Net income 2,601       2,601  
Reclassification adjustments for losses included in net income (interest expense) 60     60    
Losses arising during the period on interest rate swaps (2,341)     (2,341)    
Dividends to common stockholders (38,852)         (38,852)
Ending balance at Sep. 30, 2019 $ 1,805,161 $ 1,314 $ 3,379,572 $ (8,470) $ 1,100,094 $ (2,667,349)
XML 61 R2.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Real estate properties:    
Land $ 267,803 $ 230,206
Buildings, improvements and lease intangibles 3,915,308 3,675,415
Personal property 10,899 10,696
Construction in progress 44,041 33,107
Land held for development 24,647 24,647
Real estate properties, Total 4,262,698 3,974,071
Less accumulated depreciation and amortization (1,106,387) (1,015,174)
Total real estate properties, net 3,156,311 2,958,897
Cash and cash equivalents 11,809 8,381
Assets held for sale, net 5,289 9,272
Operating lease right-of-use assets 126,711 0
Financing lease right-of-use assets 9,063 0
Other assets, net 181,975 214,697
Total assets 3,491,158 3,191,247
Liabilities:    
Notes and bonds payable 1,443,919 1,345,984
Accounts payable and accrued liabilities 75,094 80,411
Liabilities of properties held for sale 300 587
Operating lease liabilities 91,356  
Financing lease liabilities 14,305  
Other liabilities 61,023 47,623
Total liabilities 1,685,997 1,474,605
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding 0 0
Common stock, $.01 par value per share; 300,000 shares authorized; 131,368 and 125,279 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively 1,314 1,253
Additional paid-in capital 3,379,572 3,180,284
Accumulated other comprehensive loss (8,470) (902)
Cumulative net income attributable to common stockholders 1,100,094 1,088,119
Cumulative dividends (2,667,349) (2,552,112)
Total stockholders' equity 1,805,161 1,716,642
Total liabilities and stockholders' equity $ 3,491,158 $ 3,191,247
XML 63 R15.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity
9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity

Common Stock    
The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2019 and the year ended December 31, 2018:
 
September 30, 2019
 
December 31, 2018
Balance, beginning of period
125,279,455

 
125,131,593

Issuance of common stock
6,099,012

 
26,203

Nonvested share-based awards, net of withheld shares (1)
(10,269
)
 
121,659

Balance, end of period
131,368,198

 
125,279,455


______
(1)
The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in $2.9 million of expenses associated with the acceleration of his outstanding nonvested share-based awards. In connection with the vesting, 80,490 shares were withheld to pay employee federal income taxes.

Equity Offering
On March 19, 2019, the Company issued 3,737,500 shares of common stock, par value $0.01 per share, at $31.40 per share in an underwritten public offering pursuant to the Company's existing effective registration statement. The net proceeds of the offering, after underwriting discounts and offering expenses, were approximately $115.8 million.

At-The-Market Equity Offering Program
The Company sold 4,694,624 shares under the Company's at-the-market equity offering program from January 1, 2019 through October 31, 2019. The sales generated $153.7 million in net proceeds at prices to the public ranging from $32.01 to $33.77 per share (weighted average of $33.31 per share). The sales occurred during the following time periods:

During the first quarter of 2019, the Company sold 135,265 shares generating $4.3 million in net proceeds at prices to the public ranging from $32.01 to $32.86 per share (weighted average of $32.36 per share).
No shares were sold in the second quarter of 2019.
During the third quarter of 2019, the Company sold 2,191,522 shares generating $71.6 million in net proceeds at prices to the public ranging from $32.62 to $33.77 per share (weighted average of $33.15 per share).
During October 2019, the Company sold 2,367,837 shares generating $78.2 million in net proceeds at prices to the public ranging from $33.17 to $33.74 per share (weighted average of $33.52 per share).

The Company had 1,174,073 authorized shares remaining available to be sold under the current sales agreements as of October 31, 2019.

Common Stock Dividends
During the nine months ended September 30, 2019, the Company declared and paid common stock dividends totaling $0.90 per share. On October 29, 2019, the Company declared a quarterly common stock dividend in the amount of $0.30 per share payable on November 29, 2019 to stockholders of record on November 14, 2019.

Earnings Per Common Share
The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2019 and 2018.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(Dollars in thousands, except per share data)
2019
 
2018
 
2019
 
2018
Weighted average Common Shares outstanding
 
 
 
 
 
 
 
Weighted average Common Shares outstanding
129,865,985

 
125,233,462

 
128,348,638

 
125,206,342

Nonvested shares
(1,775,911
)
 
(1,933,653
)
 
(1,777,743
)
 
(1,925,589
)
Weighted average Common Shares outstanding—Basic
128,090,074

 
123,299,809

 
126,570,895

 
123,280,753

Weighted average Common Shares outstanding—Basic
128,090,074

 
123,299,809

 
126,570,895

 
123,280,753

Dilutive effect of employee stock purchase plan
78,610

 
52,147

 
85,690

 
54,763

Weighted average Common Shares outstanding—Diluted
128,168,684

 
123,351,956

 
126,656,585

 
123,335,516

Net Income
$
2,601

 
$
6,548

 
$
11,975

 
$
53,456

Dividends paid on nonvested share-based awards
(534
)
 
(580
)
 
(1,603
)
 
(1,740
)
Net income applicable to common stockholders
$
2,067

 
$
5,968

 
$
10,372

 
$
51,716

Basic earnings per common share - Net income
$
0.02

 
$
0.05

 
$
0.08

 
$
0.42

Diluted earnings per common share - Net income
$
0.02

 
$
0.05

 
$
0.08

 
$
0.42



Incentive Plans
A summary of the activity under the Company's share-based incentive plans for the three and nine months ended September 30, 2019 and 2018 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Share-based awards, beginning of period
1,778,134

 
1,938,100

 
1,769,863

 
1,907,645

Granted

 

 
89,767

 
107,751

Vested (1)
(204,548
)
 
(5,051
)
 
(286,044
)
 
(82,347
)
Share-based awards, end of period
1,573,586

 
1,933,049

 
1,573,586

 
1,933,049


______
(1)
The Company's former Executive Chairman, David R. Emery, died on September 30, 2019 resulting in the accelerated vesting of 204,548 outstanding nonvested share-based awards.

During the nine months ended September 30, 2019 and 2018, the Company withheld 100,036 and 22,555 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.

In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three and nine months ended September 30, 2019 and 2018 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Outstanding and exercisable, beginning of period
363,218

 
350,535

 
328,533

 
318,100

Granted

 

 
235,572

 
203,836

Exercised
(9,927
)
 
(2,531
)
 
(28,943
)
 
(13,236
)
Forfeited
(11,762
)
 
(9,583
)
 
(51,559
)
 
(34,489
)
Expired

 

 
(142,074
)
 
(135,790
)
Outstanding and exercisable, end of period
341,529

 
338,421

 
341,529

 
338,421


XML 64 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Leases
9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Leases Leases
Lessor Accounting Under ASC 842
The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.

The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components such as reimbursement of operating expenses as additional rent or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. As of September 30, 2019, the Company had one ground lease that is associated with a property under construction where rent has not yet commenced. Lease income for the Company's operating leases recognized for the three and nine months ended September 30, 2019 was $117.7 million and $342.8 million, respectively.

Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of September 30, 2019 were as follows (in thousands):
2019
$
91,501

2020
340,549

2021
292,541

2022
252,315

2023
210,559

2024 and thereafter
572,767

 
$
1,760,232



Lessor Accounting Under ASC 840
The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases and financial arrangements provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease and for a short period thereafter, with an option or a right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.
Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 were as follows (in thousands):
2019
$
326,441

2020
279,211

2021
235,660

2022
201,072

2023
163,978

2024 and thereafter
476,673

 
$
1,683,035



Lessee Accounting Under ASC 842
As of September 30, 2019, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of September 30, 2019, the Company had 108 properties, excluding one property classified as held for sale, totaling 9.0 million square feet that were held under ground leases. Some of the ground leases renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index. The Company had 46 prepaid ground leases as of September 30, 2019. The amortization of the prepaid rent, included in the operating lease right-of-use asset represented approximately $0.2 million and $0.1 million of the Company’s rental expense for the three months ended September 30, 2019 and 2018, respectively and $0.4 million for the nine months ended September 30, 2019 and 2018, respectively.

The Company’s future lease payments (primarily for its 62 non-prepaid ground leases) as of September 30, 2019 were as follows (in thousands):

 
 
Operating

 
Financing

2019
$
999

 
$
107

2020
4,816

 
611

2021
4,846

 
619

2022
4,877

 
628

2023
4,915

 
637

2024 and thereafter
312,712

 
74,767

Total undiscounted lease payments
333,165

 
77,369

Discount
(241,809
)
 
(63,064
)
Lease liabilities
$
91,356

 
$
14,305



The following table provides details of the Company's total lease expense for the three and nine months ended September 30, 2019 (in thousands):
 
 
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2019
 
Operating lease cost
 
 
 
 
 
Operating lease expense
 
$
1,169

 
$
3,448

 
Variable lease expense
 
845

 
2,380

 
Finance lease cost
 
 
 
 
 
Amortization of right-of-use assets
 
51

 
101

 
Interest on lease liabilities
 
196

 
392

 
Total lease expense
 
$
2,261

 
$
6,321

 
 
 
 
 
 
 
Other information
 
 
 
 
 
Operating cash flows outflows related to operating leases
 
$
1,313

 
$
5,461

 
Financing cash flows outflows related to financing leases
 
$
107

 
$
249

 
Right-of-use assets obtained in exchange for new finance lease liabilities
 
$

 
$
14,294

 
 
 
 
 
 
 
Weighted-average remaining lease term (excluding renewal options) - operating leases
 
49.7
 
 
 
Weighted-average remaining lease term (excluding renewal options) -finance leases
 
70.1
 
 
 
Weighted-average discount rate - operating leases
 
5.7%
 
 
 
Weighted-average discount rate - finance leases
 
5.5%
 
 
 


Lessee Accounting Under ASC 840
As of December 31, 2018, the Company was obligated under operating lease agreements consisting primarily of the Company’s ground leases. At December 31, 2018, the Company had 107 properties totaling 8.8 million square feet that were held under ground leases with a remaining weighted average term of 53.9 years, excluding renewal options. These ground leases typically have initial terms of 50 to 75 years with one or more renewal options extending the terms to 75 to 100 years, with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index.

The Company’s future minimum lease payments (primarily for its 60 non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands):
 
2019
$
5,288

2020
5,260

2021
5,238

2022
5,207

2023
5,224

2024 and thereafter
323,533

 
$
349,750


Leases Leases
Lessor Accounting Under ASC 842
The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.

The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components such as reimbursement of operating expenses as additional rent or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. As of September 30, 2019, the Company had one ground lease that is associated with a property under construction where rent has not yet commenced. Lease income for the Company's operating leases recognized for the three and nine months ended September 30, 2019 was $117.7 million and $342.8 million, respectively.

Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of September 30, 2019 were as follows (in thousands):
2019
$
91,501

2020
340,549

2021
292,541

2022
252,315

2023
210,559

2024 and thereafter
572,767

 
$
1,760,232



Lessor Accounting Under ASC 840
The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2036. Some leases and financial arrangements provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease and for a short period thereafter, with an option or a right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.
Future minimum lease payments under the non-cancelable operating leases, excluding any reimbursements, as of December 31, 2018 were as follows (in thousands):
2019
$
326,441

2020
279,211

2021
235,660

2022
201,072

2023
163,978

2024 and thereafter
476,673

 
$
1,683,035



Lessee Accounting Under ASC 842
As of September 30, 2019, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of September 30, 2019, the Company had 108 properties, excluding one property classified as held for sale, totaling 9.0 million square feet that were held under ground leases. Some of the ground leases renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index. The Company had 46 prepaid ground leases as of September 30, 2019. The amortization of the prepaid rent, included in the operating lease right-of-use asset represented approximately $0.2 million and $0.1 million of the Company’s rental expense for the three months ended September 30, 2019 and 2018, respectively and $0.4 million for the nine months ended September 30, 2019 and 2018, respectively.

The Company’s future lease payments (primarily for its 62 non-prepaid ground leases) as of September 30, 2019 were as follows (in thousands):

 
 
Operating

 
Financing

2019
$
999

 
$
107

2020
4,816

 
611

2021
4,846

 
619

2022
4,877

 
628

2023
4,915

 
637

2024 and thereafter
312,712

 
74,767

Total undiscounted lease payments
333,165

 
77,369

Discount
(241,809
)
 
(63,064
)
Lease liabilities
$
91,356

 
$
14,305



The following table provides details of the Company's total lease expense for the three and nine months ended September 30, 2019 (in thousands):
 
 
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2019
 
Operating lease cost
 
 
 
 
 
Operating lease expense
 
$
1,169

 
$
3,448

 
Variable lease expense
 
845

 
2,380

 
Finance lease cost
 
 
 
 
 
Amortization of right-of-use assets
 
51

 
101

 
Interest on lease liabilities
 
196

 
392

 
Total lease expense
 
$
2,261

 
$
6,321

 
 
 
 
 
 
 
Other information
 
 
 
 
 
Operating cash flows outflows related to operating leases
 
$
1,313

 
$
5,461

 
Financing cash flows outflows related to financing leases
 
$
107

 
$
249

 
Right-of-use assets obtained in exchange for new finance lease liabilities
 
$

 
$
14,294

 
 
 
 
 
 
 
Weighted-average remaining lease term (excluding renewal options) - operating leases
 
49.7
 
 
 
Weighted-average remaining lease term (excluding renewal options) -finance leases
 
70.1
 
 
 
Weighted-average discount rate - operating leases
 
5.7%
 
 
 
Weighted-average discount rate - finance leases
 
5.5%
 
 
 


Lessee Accounting Under ASC 840
As of December 31, 2018, the Company was obligated under operating lease agreements consisting primarily of the Company’s ground leases. At December 31, 2018, the Company had 107 properties totaling 8.8 million square feet that were held under ground leases with a remaining weighted average term of 53.9 years, excluding renewal options. These ground leases typically have initial terms of 50 to 75 years with one or more renewal options extending the terms to 75 to 100 years, with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the Consumer Price Index.

The Company’s future minimum lease payments (primarily for its 60 non-prepaid ground leases) as of December 31, 2018 were as follows (in thousands):
 
2019
$
5,288

2020
5,260

2021
5,238

2022
5,207

2023
5,224

2024 and thereafter
323,533

 
$
349,750


XML 65 R19.htm IDEA: XBRL DOCUMENT v3.19.3
Real Estate Investments (Tables)
9 Months Ended
Sep. 30, 2019
Business Combinations [Abstract]  
Summary of acquisitions
The following table details the Company's acquisitions for the nine months ended September 30, 2019:
(Dollars in millions)
Type (1)
 
Date
Acquired
 
Purchase Price

 
Cash
Consideration
(2)

 
Real
Estate

 
Other (3)

 
Square
Footage
(Unaudited)

Washington, D.C. (4)
MOB
 
3/28/19
 
$
46.0

 
$
45.9

 
$
50.2

 
$
(4.3
)
 
158,338

Indianapolis, IN (5)
MOB
 
3/28/19
 
47.0

 
44.8

 
43.7

 
1.1

 
143,499

Atlanta, GA
MOB
 
4/2/19
 
28.0

 
28.0

 
28.0

 

 
47,963

Dallas, TX
MOB
 
6/10/19
 
17.0

 
16.7

 
17.0

 
(0.3
)
 
89,990

Seattle, WA
MOB
 
6/11/19
 
7.7

 
7.8

 
7.8

 

 
29,870

Seattle, WA
MOB
 
6/14/19
 
19.0

 
19.1

 
19.5

 
(0.4
)
 
47,255

Seattle, WA
MOB
 
6/28/19
 
30.5

 
30.4

 
30.6

 
(0.2
)
 
78,288

Houston, TX
MOB
 
8/1/19
 
13.5

 
13.5

 
13.5

 

 
29,903

Oklahoma City, OK
MOB
 
9/26/19
 
4.1

 
4.1

 
4.1

 

 
28,542

Los Angeles, CA (6)
MOB
 
9/30/19
 
61.1

 
60.9

 
61.8

 
(0.9
)
 
115,634

 
 
 
 
 
$
273.9

 
$
271.2

 
$
276.2

 
$
(5.0
)
 
769,282

______
(1)
MOB = medical office building.
(2)
Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
(3)
Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.
(4)
Includes two properties. The Company assumed two ground leases in connection with this acquisition that are classified as financing leases. The present value of future lease payments totaling $14.3 million was recorded on the Company's Condensed Consolidated Balance Sheets under the caption Finance lease liabilities. In addition, the right-of-use assets were partially offset by $5.2 million of above-market lease intangibles included in Other.
(5)
The Company assumed a prepaid ground lease totaling $0.8 million and recorded a below-market lease intangible totaling $0.9 million in connection with this acquisition that is classified as an operating lease that is included in Other.
(6)
Includes two properties.
Summary of dispositions
The following table details the Company's dispositions for the nine months ended September 30, 2019:
(Dollars in millions)
Type (1)
 
Date
Disposed
 
Sales Price
 
Closing Adjustments
 
Net
Proceeds
 
Net Real
Estate
Investment
 
Other
(including
receivables)
 (2)
 
Gain/
(Impairment)
 
Square
Footage
(
Unaudited)
Tucson, AZ (3)
MOB
 
4/9/19
 
$
13.0

 
$
(0.9
)
 
$
12.1

 
$
6.9

 
$
0.4

 
$
4.8

 
67,345

Virginia Beach, VA (4)
MOB
 
8/1/19
 
1.3

 
(0.1
)
 
1.2

 
1.2

 

 

 
10,000

San Antonio, TX
MOB
 
8/28/19
 
0.9

 
(0.1
)
 
0.8

 
0.6

 

 
0.2

 
10,138

Total dispositions
 
$
15.2

 
$
(1.1
)
 
$
14.1

 
$
8.7

 
$
0.4

 
$
5.0

 
87,483

______
(1)
MOB = medical office building.
(2)
Includes straight-line rent receivables, leasing commissions and lease inducements.
(3)
Includes four properties sold to a single purchaser.
(4)
The Company reclassified this property to held for sale during the second quarter of 2019 and recorded an impairment charge of $0.4 million based on the sales price less estimated costs to sell.
Assets held for sale
The table below reflects the assets and liabilities of the properties classified as held for sale as of September 30, 2019 and December 31, 2018:
(Dollars in thousands)
September 30,
2019
 
December 31,
2018
Balance Sheet data:
 
 
 
Land
$
1,125

 
$
1,125

Buildings, improvements and lease intangibles
34,426

 
18,231

 
35,551

 
19,356

Accumulated depreciation
(30,706
)
 
(10,657
)
Real estate assets held for sale, net
4,845

 
8,699

Other assets, net
444

 
573

Assets held for sale, net
$
5,289

 
$
9,272

 
 
 
 
Accounts payable and accrued liabilities
$
93

 
$
450

Other liabilities
207

 
137

Liabilities of properties held for sale
$
300

 
$
587


XML 66 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Lease Income (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
Lease
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Lease
Sep. 30, 2018
USD ($)
Leases [Abstract]        
Ground leases not yet commenced | Lease 1   1  
Rental income | $ $ 117,740,000 $ 111,452,000 $ 342,787,000 $ 331,247,000
XML 67 R36.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Future Minimum Lease Payments (Details)
$ in Thousands
Sep. 30, 2019
USD ($)
Operating  
2019 $ 999
2020 4,816
2021 4,846
2022 4,877
2023 4,915
2024 and thereafter 312,712
Total undiscounted lease payments 333,165
Discount (241,809)
Lease liabilities 91,356
Financing  
2019 107
2020 611
2021 619
2022 628
2023 637
2024 and thereafter 74,767
Total undiscounted lease payments 77,369
Discount (63,064)
Lease liabilities $ 14,305